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ABSTRACT 
	  
Extending the release of therapeutic proteins is an area of study that has received a lot of 
attention of late due to the increasing use of antibodies in treating cancer, autoimmune diseases, viral 
infections, and even asthma.  In many cases, long-term, local delivery systems are preferred over 
parenteral routes in order to reduce systemic exposure and avoid frequent injections. Hydrogels offer 
a promising potential for many drug delivery applications because they can be formed into a variety 
of shapes and sizes using biocompatible materials, while at the same time exhibiting a wide range of 
permeabilities. However, one of the challenges of developing an effective hydrogel delivery device is 
in controlling the diffusion of proteins within the hydrogel in order to provide the correct release rate 
and profile.  The objective of this dissertation, therefore, was to investigate the permeability of 
therapeutic proteins in hydrogels to aid the development of long-term drug delivery vehicles. The 
work presented in this dissertation includes the study of protein partitioning in hydrogels, the 
development and modeling of a prototype release system, and the advancement of a hydrogel 
crosslinking method in an effort to expand the use of hydrogels for extended release applications. 
One particular area in which a long-term delivery system is needed is ocular drug delivery, 
where retinal diseases such as age related macular degeneration and diabetic macular edema require 
frequent injections into the vitreous in order to deliver drugs to the retina and prevent major vision 
loss.  These diseases affect an estimated 16 million Americans and are the leading cause of blindness 
and vision loss in people over the age of 50. A hydrogel implant that could deliver sustained release 
to the retina would offer a number of advantages including convenience, safety, and financial 
benefits when compared to the current intravitreal dosing regimen.  
 One of the difficulties in developing a hydrogel delivery device is achieving a significant 
protein concentration within the hydrogel. A method for loading proteins into monolithic hydrogels 
using the thermodynamic principles of aqueous two-phase extraction was investigated. By using a 
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variety of polymers and partitioning salts, significant increases were seen in the partitioning of 
ovalbumin and IgG in PEG and dextran hydrogels.  The results demonstrate the versatility of a 
method to overcome size exclusion of proteins, even as large as monoclonal antibodies, into many 
types of hydrogels, thus opening the door to new delivery strategies for therapeutic proteins using 
hydrogels. 
A successful hydrogel delivery device must be small enough to be implanted in the eye, yet 
carry a large enough drug load to achieve long-term release. Therefore, hollow mini cylinders were 
chosen as the structure for the intravitreal implants instead of a monolithic device.  Achieving these 
goals requires a hydrogel with a very low diffusion coefficient (values below 10-10 cm2/s), an area of 
study that has received little attention in the literature yet has major implications in situations where 
long term, local delivery systems are needed to deliver therapeutic proteins such as ocular delivery. 
The swelling degrees required to achieve this target diffusion coefficient in a hydrogel were 
predicted using a free volume theory for protein diffusion in hydrogels, and were estimated to be in 
the range of 4-6 (g/g).   In order to achieve such low swelling degrees, the cylinders were made from 
HA hydrogels that were highly crosslinked using a base-catalyzed Michael addition and the 
difunctional crosslinker divinyl sulfone (DVS). HA-DVS hydrogels with swelling degrees as low as 
2.7 were achieved using HA concentrations that ranged from 15-30% (w/w) and HA:DVS ratios that 
ranged from 3:1–1:1.  Using a custom mold, prototype cylinders were developed and proved capable 
of successfully releasing an antigen-binding fragment (Fab) for over 4 months in vitro with a 
maximum release rate of 4 micrograms a day. The results showed that a hollow cylinder made from 
hydrogels can achieve 3-6 months release of anti-vascular endothelial growth factors to the retina.  
In an effort to determine the target diffusion coefficients and cylinder dimensions required 
for ocular delivery the release of proteins from hollow cylinders was modeled using the physics 
software COMSOL. The largest size cylinders that were studied (1mm outer diameter) were able to 
load the largest amount of drug and provide the longest release. These cylinders were capable of 
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delivering over 1 mg of drug while achieving a release rate of 2.5 micrograms a day for over 4.5 
months. Moving to smaller cylinders makes the insertion process faster, safer, and less painful, yet it 
comes at the expense of smaller drug loading and shorter release times. The results indicated that the 
small dimensions required for an intravitreal implant leads to a narrow range of diffusion coefficients 
(1-3 x 10-11 cm2/s) that are capable of producing an effective delivery device, highlighting the 
importance of being able to tune the diffusion coefficient of hydrogels.  
Being able to control the network structure and the diffusion coefficient of a hydrogel was 
the main motivation for modifying HA with pentenoic anhydride and crosslinking it into hydrogels 
using the dithiol crosslinker dithiothreitol via a photoinitiated thiol-ene reaction. This crosslinking 
reaction is hypothesized to allow for greater control of the hydrogel network structure, while at the 
same time providing a way to quickly and efficiently tune the mechanical properties of the hydrogel. 
Evidence of a more uniform network included gelation at lower polymer concentrations and higher 
fracture strains (>85%) when compared with hydrogels crosslinked via the chain polymerization of 
methacrylated HA.  The hydrogel network can also be controlled simply by varying the ratio of 
thiols:ene, which can increase the crosslinking and reduce the swelling degree.  Additionally, in most 
cases the photoinitiated reaction was completed after only 60 seconds of irradiation with UV light 
using initiator concentrations of only 0.1 mM, indicating a more efficient crosslinking reaction when 
compared to HA-DVS and methacrylated HA.  The reaction can also occur under physiological 
conditions, a necessary requirement for the encapsulation of cells and proteins.  
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CHAPTER 1: INTRODUCTION 
 
The primary objective of this dissertation was to investigate the permeability of therapeutic 
proteins in hydrogels to aid the development of effective long-term drug delivery devices. 
Hydrogels have long been used as drug delivery vehicles as they can be designed to exhibit a 
wide range of permeabilities using a number of biocompatible materials and crosslinking 
methods. In these drug delivery systems, controlling the diffusion of proteins within a hydrogel 
is crucial for providing the correct release rate and profile required to be therapeutically effective.  
Because of its importance, the diffusion of solutes in hydrogels is a subject that has been well-
studied in the literature and has led to an increased understanding of how the diffusion 
coefficient is affected by key parameters of a hydrogel and solute size.  However, one area that 
has received little attention in the literature is when the diffusion coefficient in hydrogels is very 
small (100 times lower than in solution), which occurs as the polymer volume fraction of the gel 
increases, or as the size of the solute increases. Despite the limited amount of work in literature, 
the diffusion of solutes in hydrogels with low diffusion coefficients is an important area of study 
that has major implications in situations where long term, local delivery systems are needed to 
deliver these therapeutic proteins. 
One of the motivations for this work was a specific area in which the long term, local 
delivery of therapeutic proteins is required: ocular drug delivery. Specifically, the need to deliver 
high molecular weight drugs to the vitreous humor to treat retinal diseases such as age related 
macular degeneration and diabetic macular edema, two of the leading causes of blindness and 
vision loss in the elderly. While recent treatments have allowed patients to successfully manage 
the symptoms and vision loss of retinal diseases, these treatments consist of intravitreal 
injections that are administered to the patient every 4-8 weeks. A hydrogel implant that could 
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offer long term, sustained delivery would offer a number of advantages when compared to the 
current intravitreal dosing regimen. The difficulty in developing a successful ocular implant is 
that the device must be small enough to be implanted in the eye, yet carry a large enough drug 
load to achieve long-term release at the desired level. Accomplishing this requires a highly 
crosslinked hydrogel that has a low swelling degree in order to produce the diffusion coefficients 
required to achieve extended release. 
Therefore, the work presented in this thesis addresses two major aims: 1) to develop a 
better understanding of the partitioning and diffusion of solutes in hydrogels with low diffusion 
coefficients and 2) to examine the feasibility of developing a hydrogel delivery device that can 
be implanted in the vitreous and is capable of delivering therapeutic proteins for 3-6 months. The 
two aims are closely related and are explored together throughout many of the chapters in this 
dissertation. 
Chapter 2 contains the essential background material on hydrogels, which introduces the 
reader to the key concepts and terminology that will be used throughout this dissertation.  The 
chapter begins with a brief description of the materials that are used to form hydrogels, including 
both biological polymers such as hyaluronic acid which is used in Chapters 5 and 7, as well as 
the synthetic polymer poly(ethylene glycol) which is used in Chapter 4.  The chapter continues 
with a concise description of the synthesis methods that are used throughout this dissertation to 
form hydrogels: the copolymerization/crosslinking of monomers, and the crosslinking of linear 
polymers. Next, a description of the characterization methods that were used to define the 
network structures of the hydrogels in this dissertation is presented.  This section includes an 
overview of the swelling theory, mechanical properties, and mesh size of hydrogels as well as 
the partition coefficient. The chapter concludes with a brief review of the use of hydrogels as 
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drug delivery vehicles and the different mechanisms that are often used to control the release rate 
of drugs in a variety of biomedical applications. 
Chapter 3 continues with an in depth review of the current state of the art on the diffusion 
of solutes in hydrogels, an important area of study that is directly relevant to a number of 
research fields, including drug delivery, tissue engineering, and separation processes. The first 
goal of the chapter is to introduce the reader to the theoretical models that have been developed 
that attempt to relate the diffusion coefficient to the key parameters of a hydrogel. The models 
are separated into three separate categories that each uses a different phenomenon to describe the 
hindered diffusion of solutes through hydrogels:  
1) Free volume theories that suggest the solutes only diffuse by jumping into the voids, or 
free volume, within the solvent. 
2) Obstruction models that suggest diffusion is restricted due to the polymer chains acting 
as physical obstructions that increase the length the drug has to travel. 
3) Hydrodynamic models which suggest that both the solvent and the polymer chains 
within the hydrogel increases the hydrodynamic drag on the molecule and slows the diffusion.   
 
While these three models use different approaches for modeling the diffusion of solutes 
through hydrogels, they all depend primarily on water content and solute size, which leads to 
similar predictions for hydrogels with high water contents.  Where the models differ, however, is 
in the ways in which the network structure is represented using various parameters. Therefore, 
the second goal of the chapter is to examine how well these models perform under conditions 
where the diffusion coefficient in hydrogels is projected to be very small, where the effect of 
network structure increases. Throughout this dissertation, a central theme is being able to control 
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and predict the diffusion of large solutes in hydrogels with low swelling degrees. Developing 
models for hydrogels that accurately describe the diffusion in this region is important not only 
for making predictions, but also in developing an understanding of how the key parameters such 
as swelling degree, solute size, and the various parameters that represent the hydrogel network 
structure play a role in diffusion. 
Chapter 4 is the first chapter in this dissertation in which hydrogels are examined for their 
use as a drug delivery system.  The chapter builds on previous work that was performed by 
Gehrke’s research group in which a method for loading proteins into hydrogels was developed 
using the thermodynamic principles of aqueous two-phase extraction (ATPE) to overcome size 
exclusion.  They developed the method and showed that proteins such as ovalbumin, bovine 
serum albumin (BSA), and α-amylase could be loaded into dextran hydrogels at significantly 
higher concentrations when compared with normal equilibration techniques with the addition of 
poly(ethylene glycol) and salts to the loading solution.  It had been hypothesized to be 
thermodynamically general, but this had not been demonstrated. Therefore, the main goal of 
Chapter 4 was to test the hypothesis that the thermodynamic principles of this method could be 
generalized to any type of hydrogel and loading system, including proteins as large as 
monoclonal antibodies. The results showed that multiple hydrogels and loading systems follow 
the ATPE heuristics, including both polymer/polymer systems and polymer/salt systems. 
Additionally, substantial increases in the partitioning of IgG in dextran hydrogels with the 
addition of PEG in the loading solution were observed, while IgG was completely excluded from 
the gel in buffer alone.  The results provide a much needed and useful way to load antibodies 
into hydrogels and enables loading systems and drugs that have been successfully demonstrated 
in literature to be quickly extended to hydrogel drug delivery devices.  
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While Chapter 4 focuses on the general question of how to increase the partitioning of 
proteins into preformed gels, Chapter 5 examines a more specific problem and investigates the 
use of hyaluronic acid (HA) hydrogels for the sustained release of therapeutic proteins to the eye. 
Hyaluronic acid is natural component of the eye, and a HA hydrogel delivery system would 
make an excellent device that could be implanted in the eye for long periods of time, where low 
toxicity is necessary for success. The goal for the chapter was to develop an actual prototype 
implant that is capable of delivering proteins of similar size to the treatments currently on the 
market proteins for 3-6 months release at rates that would be therapeutically effective if the 
device were to be injected or surgically implanted in the back of the eye. Achieving this goal 
required first investigating whether or not an implantable device of this size and shape (hollow 
cylinder) could be fabricated using HA hydrogels as well as determining if these hydrogels could 
be made with a swelling degree low enough to produce the diffusion coefficients required to 
achieve extended release. HA-DVS hydrogels were made using HA concentrations that ranged 
from 15-30% (w/w) and HA:DVS ratios that ranged from 3:1–1:1.  Using a custom mold, 
prototype cylinders were developed and loaded with both bovine serum albumin (BSA) and an 
antigen-binding fragment (Fab). The results showed that a hollow cylinder made from hydrogels 
can achieve 3-6 months release of anti-vascular endothelial growth factors to the retina. 
Having successfully developed a prototype that was able to achieve over 3 months release, 
Chapter 6 directly follows up the work presented in Chapter 5 by using the physics software 
COMSOL to model the release of therapeutic proteins from hollow cylinders.  The main goal of 
the chapter was to understand how the diffusion coefficient and cylinder dimensions affect the 
release rate and profile. The chapter focused on hydrogel implants with three different outer 
diameters: a 1mm implant that would have to be implanted and had similar dimensions to the 
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prototypes in Chapter 5, a 0.45 mm implant that could be injected using a 22-gauge 
microinjector, and a 0.21 mm implant that could be injected using a 27-gauge needle. By 
modeling the release rate and profile of each implant size, a better idea of the range of the 
diffusion coefficients and dimensions required for a successful hollow cylinder intravitreal 
implant were determined. 
 The results from Chapter 6 revealed that precise control over the diffusion coefficient is 
required. Therefore, Chapter 7 introduces an alternative way to crosslink HA hydrogels using the 
thiol-ene reaction, which is hypothesized to allow for greater control of the hydrogel network, an 
important feature that would be useful for controlling the diffusion in hydrogels while also 
improving the mechanical properties of the hydrogel. The chemistry of the thiol-ene reaction is 
also hypothesized to provide many advantages when compared to traditional crosslinking 
reaction such as the Michael-type addition used in Chapter 5.  These advantages include higher 
selectivity and reactivity, an increase in reaction rate, and milder reaction conditions that will 
lead to benefits in both drug delivery and tissue engineering.  The results showed that the 
crosslinking reaction occurs within seconds of irradiation, using very little initiator. The network 
structure of the hydrogel was shown to be easily controlled by varying the ratios of thiol:ene 
groups, providing a simple way to tune the crosslink density and swelling degree.  The hydrogels 
can be synthesized using physiological conditions, which allowed for the encapsulation and 
release of the model proteins ovalbumin and BSA. 
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CHAPTER 2: AN INTRODUCTION TO HYDROGELS 
 
 
2.1  INTRODUCTION 
 
The purpose of this chapter is to introduce the reader to the key concepts and terminology 
that will be used throughout this dissertation. In Section 2.2, a brief description of the materials 
that are used to form hydrogels is given, and includes biological polymers such as hyaluronic 
acid and dextran, as well as the synthetic polymer poly(ethylene glycol).  Section 2.3 provides a 
concise description of the synthesis methods that are used throughout this dissertation to form 
hydrogels.  The chapter finishes up with a description of the characterization methods that were 
used to define the network structures of the hydrogels in Section 2.4.  This section includes an 
overview of the swelling theory, mechanical properties, and mesh size of hydrogels as well as 
the partition coefficient. Excellent articles that contain more information on the materials, 
synthesis methods, mechanical properties, and uses of hydrogels in biomedical applications are 
available for a more detailed review.1-5 
 
 
2.2  HYDROGEL MATERIALS 
Hydrogels are hydrophilic polymer networks that are crosslinked into a permanent three-
dimensional network.  These networks are capable of absorbing many times their weight of 
water, and often contain more than 90% water by weight.  They can be made from any 
hydrophilic polymers, both biological and synthetic, and can be formed using a variety of 
crosslinking methods.  Hydrogels can be made into any size or shape and can even be made to 
respond to a number of external stimuli, including light, temperature, and pH.6   
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The large number of hydrogel materials and synthesis methods available allow for gels to 
be made that exhibit a wide range of swelling degrees, mechanical properties, and permeabilities.  
Of these properties, the most important is the water content of the gel, or the swelling degree 
(explained in Section 2.4.1).  The swelling degree of a hydrogel has a direct influence on the 
other properties of the hydrogel, as changes in water content can lead to changes in the 
mechanical properties of the hydrogel such as moduli and crosslink density.7  The swelling 
degree can also play a role in determining the rate at which a gel degrades and can influence the 
permeability of the hydrogel to both water and larger solutes such as proteins and antibodies. 
The ability to produce a wide range of properties has led to the use of hydrogels in a 
number of industries and applications.  Hydrogels are used as additives in the food and cosmetic 
industry, as superabsorbents in the hygiene and agriculture industries, and have even been used 
to improve oil recovery. However, due to their ability to absorb water and their potential to be 
biocompatible, a lot of the research in hydrogels has been in the fields of biology and medicine.  
In fact, some of the earliest work on hydrogels was done in the 1950’s when Lim and Wichterle 
were investigating the use of poly(2-hydroxyethyl methacrylate) hydrogels as contact lenses.8  
Since that time, a large amount of research has been done on the preparation, structure, and 
properties of hydrogels for use in biomedical applications.9  Hydrogels have been used as 
coatings for both pills and catheters, as wound adhesives, burn dressings, and implants. Certain 
hydrogels also have the ability to safely encapsulate cells, which has led to the extensive use of 
hydrogels in repairing and regenerating tissues and organs in the rapidly expanding field of tissue 
engineering.10  
The widely adjustable properties of hydrogels make them ideal for drug delivery 
applications.  The high water content allows for the safe encapsulation of bioactive molecules 
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such as proteins, carbohydrates, DNA and antibodies.11  The loading and release of small 
molecules and macromolecules through the network structure can be tuned by controlling the 
swelling degree and crosslink density of the hydrogels.4 They also have the advantage of being 
synthesized under relatively mild conditions, as the most common hydrogels are formed in water 
at ambient temperatures.12  Because of these many advantages, the use of hydrogels in drug 
delivery systems has increased over the past few decades and hydrogels are being used as drug 
delivery systems in ocular, oral, nasal, buccal, rectal, vaginal, nasal and parenteral applications. 
One of the key requirements of a hydrogel in drug delivery and biomedical applications is 
biocompatibility.  While this word is often used within the field of biomaterials, there is still a 
degree of uncertainty as to how biocompatibility is actually defined as well as the assumptions 
that come along with it.13  Early work was focused on long term implants, where the goal of the 
material was to have as little interaction with the cells and tissue as possible.  Under these 
circumstances, a biocompatible material was one that was non-immunogenic, non-toxic, non-
carcinogenic, non-irritant, and so on.  However, the development of degradable implants along 
with the rise of tissue engineering presented a need to revisit the definition of biocompatibility.13 
A material could no longer be described as biocompatible by simply being bioinert, but had to 
take into account how the host area responded to the biodegradation process.  Furthermore, in 
tissue engineering, the biomaterial that is used as a scaffold or matrix is often selected because it 
can interact with encapsulated cells via molecular or mechanical signals.  Biocompatibility is 
therefore dependent on both the absence of undesirable local or systemic effects as well as the 
ability to support the desired cellular activity.13  Hydrogels can be made to exhibit a high degree 
of biocompatibility, not only because of their high water content, but also because they can be 
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synthesized so that they have a mechanical and compositional similarity to the extracellular 
matrix.1  
There are a number of materials that can be used to form hydrogels for drug delivery and 
biomedical applications, and these materials play a large role in determining the biocompatibility 
and mechanical properties of the hydrogel.  They are often classified based on where the material 
is derived, such as biological (e.g. alginic acid, dextran, hyaluronic acid (HA)), synthetic (e.g. 
poly(ethylene glycol), poly(vinyl alcohol)), and even modified biological or semisynthetic (e.g. 
cellulose ether, methacrylated HA (MHA)) polymers.7  Hydrogels formed from biopolymers 
have a number of advantages, including the inherent ability to be biocompatible and 
biodegradable. They can also contain biologically recognizable moieties that can participate in 
cell signaling and other cellular activities.12 Biopolymers often need to be modified in order to 
crosslink and form hydrogels, which can lead to a reduction in biocompatibility and cellular 
interaction.  While synthetic materials may not have the same cell signaling capabilities that 
biological hydrogels have, the enormous amount of monomers and polymers that are available to 
polymerize or crosslink provide an endless amount of hydrogels with a wide range of physical 
properties.  Hydrogels formed from synthetic materials can produce well-defined and 
controllable structures, and the degradation rate can be tuned to fit the given application.12 Many 
of these synthetic hydrogels have been shown to have very few undesirable local and systemic 
effects, and have proved to be very useful in drug delivery applications.  
Choosing the right material and properties of a hydrogel often depends on the application 
and the administration site.  In some cases, the chemical composition is the key factor for 
choosing a certain hydrogel material. For example, in Chapters 5 and 6 we investigate the use of 
hydrogel implants that are implanted into the vitreous humor of the eye in order to deliver drugs 
	   11 
to the retina for 3-6 months.  An ideal implant would have a chemical composition that is similar 
to the vitreous of the eye (hyaluronic acid) in order to decrease the potential for any cellular or 
inflammatory responses. In other cases, the way the hydrogel material interacts with tissue is the 
most important criteria. 
An example of this is the development of drug delivery systems to remove fungal 
infections in the oral cavity.  The biggest challenge is the fast elimination of any topically 
applied drugs due to the movement of saliva in the mouth. To overcome this challenge, 
bioadhesive polymers like chitosan and poly(methyl methacrylate) are used in gel form to extend 
the residence time in the mouth and increase the amount of drug that can be delivered14,15.  In 
other cases, the mechanical properties of the hydrogel are critical for achieving clinical success.  
For example, in tissue engineering, the hydrogels often fill a void that was once occupied by 
natural tissue and will be exposed to mechanical loads.  In order to maintain stability, the 
hydrogel must have adequate mechanical properties such as compressibility, elasticity, tensile 
strength, and failure strain.16 Selecting the right material and physical properties is often the first 
step in developing a successful hydrogel drug delivery system. 
This dissertation is focused on the synthesis of both biologically and synthetically based 
hydrogels. The goal is to understand how the synthesis conditions affect the diffusion and 
partitioning of solutes within the hydrogel. In Chapter 4 both dextran and poly(ethylene glycol) 
are used to synthesize gels. Chapters 5 and 7 are dedicated to studying the use of hyaluronic acid 
as a drug delivery vehicle using two different crosslinking methods.  In the next section, these 
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2.2.1 Poly(ethylene glycol) (PEG) 
 
 Poly(ethylene glycol) (PEG) is one of the most widely used polymers for biomedical 
applications.  PEG is a polymer made up of repeating units of (CH2CH2O) and can range in size 
from 400 Da to over 100 kDa.  At low molecular weights, PEG appears as a colorless liquid and 
at higher molecular weights PEG becomes a solid that is waxy and white in color.17  PEG is 
soluble in both water and organic solvents.  While the ability to dissolve in water is crucial for 
biological applications, the fact that it also dissolves in organic solvents allows for easy 
modification to the end groups of PEG.  This, coupled with the commercial significance of PEG, 
has led to an abundance of PEGs including monofuctional, homobifunctional, heterobifunctional, 





Figure 2.1 The chemical structure of poly(ethylene glycol) and examples of several of the modifications 
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One of the advantages of PEG is that it is one of the most bioinert polymers available and 
has been approved by the FDA for use in pharmaceutical, cosmetic and even food applications. 
PEG is eliminated from the body by either the kidney or in the feces (depending on the 
molecular weight of the PEG), and is considered non-toxic.19  This has led to widespread use in 
biomedical applications. One of the most popular uses of PEG in the pharmaceutical industry is 
to conjugate PEG with proteins and peptides, also known as PEGylation.  PEGylation increases 
the molecular mass of the conjugated drug and reduces renal clearance, which prolongs the 
circulation in the blood.  PEGylation also increases the water solubility of the drug and shields 
the drug from proteolytic degradation and adverse immunological effects.20  This leads to a 
longer half-life and increases the probability that the drug will reach its intended target.21  The 
shielding effect of PEG is useful for applications beyond PEGylation, as PEG is used as a 
coating on implant surfaces, medical devices, and even poly(vinylchloride) bags to prevent 
interactions with components in the surrounding blood and tissue and to reduce protein 
adsorption.22-24  PEG is used as a common excipient in many pharmaceutical applications and is 
also the main ingredient in a number of commercially available laxatives.21,25  PEG has also been 
used extensively in drug delivery to produce liposomes, micelles, and polymersomes and extend 
the circulation times of these drug delivery vehicles.26-29   
 PEG has also been used to make hydrogels that are well suited for biomedical 
applications. The many sizes, shapes, and functionalities of PEG that are available can create 
hydrogels with a wide range of physical and chemical properties.  There are a number of 
methods that can be used to form hydrogels from PEG.  Linear or branched PEG polymers can 
be crosslinked directly by gamma irradiation.30,31  The end groups of PEG can also be modified 
with acrylates or methacrylates, which allow it to be polymerized via a number of reaction 
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mechanisms including free radical polymerization and thiol-ene reactions.  Free radical 
polymerization can be initiated by radiation, however chemical initiators are used more often to 
generate free radicals. These chemical initiators provide versatility as they can be activated by 
light, heat, and in some cases even by certain solvents.  
This versatility can lead to a number of useful applications.  For example, the 
commercially available Focalseal is a solution containing modified PEG that is used as a surgical 
sealant to prevent air leaks in lungs after chest surgeries and the removal of lung tumors.32  
Focalseal is applied to the target tissue area as a liquid and is then photoinitiated, forming a 
hydrogel network that is waterproof.  Over time, segments of the gel degrade, leading to eventual 
dissolution and clearance through the kidneys.  Another method to crosslink PEG is through 
Michael-type addition reactions, and this method has been used in tissue engineering to crosslink 
four and eight arm PEG molecules into hydrogels that were successfully used to culture 
chondrocytes for cartilage repair.33,34 In this dissertation functionalized PEG is used to form 
hydrogels for use as drug delivery vehicles in Chapter 4.  Linear, unmodified PEG is also used in 
Chapter 4 to create an aqueous two-phase system that is used for loading proteins and antibodies 
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2.2.2 Dextran 
 
Dextran is another material that can be easily crosslinked into hydrogels and is used in a 
number of biomedical applications due to its high solubility and biocompatibility. Dextran is a 
naturally occurring polysaccharide that is made up of D-glucose molecules that are connected 
through α(1,6)-linkages.  This naturally occurring polysaccharide is synthesized from sucrose by 
a number of bacteria, including Leuconostoc, Streptococcus, and Lactobacillus.35,36 The amount 
of branching, the weight average molecular weight (MW), and the MW distribution can change 
depending on the species.   
These key factors play a large role in determining the properties of dextran and can have a 
direct influence on the way dextran is used in clinical applications.  For example, one of the most 
important uses of dextran is as a blood flow enhancer and plasma volume expander.  Dextran 
solutions are injected and used as a blood plasma substitute in times when plasma is scarce due 
to their high water solubility and low antigenicity.37  The dextran provides osmotic pressure and 
can pull fluid from the interstitial space into the plasma, acting as a substitute for blood 
proteins.38 Natural dextran is known to have a very high MW that generally ranges from 9 x 106 – 
5 x 108 Da, with a large MW distribution.39  When dextran with this high of MW is injected into 
the bloodstream it can disrupt the coagulation process of the blood.40  At the same time, dextran 
with a very low molecular weight is quickly cleared by the kidneys, losing its therapeutic 
effect.41 Therefore, dextran with a MW between 40-80 kDa is used clinically, and is produced by 
partial hydrolysis and fractionation of native dextran in order to produce the MW and MW 
distributions that are needed.42 
  Although the majority of the links occur through α(1,6)-linkages, dextran can also contain 
a large number of side chains or branches that can stem from α(1,2)-, α(1,3)-, and α(1,4)-
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linkages.  The amount of branching can range from between 0.5-50% of the total gylcosidic 
bonds, and plays a large role in the properties of dextran. Dextran that contains a high number of 
α(1,6)-linkages tend to have both increased chain flexibility and water solubility. Alternatively, if 
the amount of branching exceeds a certain percentage ( > 43%), dextran can become insoluble in 
water.  The amount of branching also affects the pharmacokinetic properties of dextran, as 
α(1,4)-linkages are broken down in the body much faster than α(1,6)-linkages, and dextran with 
higher proportions of non α(1,6)-linkages often lead to more occurrences of allergic reactions. 
 
Figure 2.2 The chemical structure of dextran. The main chain consists of D-glucose molecules connected 
with α(1,6)-linkages.  Branching is shown in the α(1,2)-, α(1,3)-, and α(1,4)-positions38. 
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Dextran is used in a number of biomedical applications.  As mentioned earlier, the high 
water solubility and low antigenicity of dextran allows it to provide osmotic pressure in 
physiological environments.  These advantages of dextran are also utilized in ophthalmic 
formulations of eye drops and artificial tears.43  Dextran has also been used as macromolecular 
carriers of proteins and drugs, similar to PEGylation, to increase the half-lives of these 
therapeutic agents in the blood and reduce immunogenicity.44 Dextran is also used in 
combination with PEG to create aqueous two-phase systems that are capable of purifying and 
separating a wide range of biomolecules including cells, proteins, nucleic acids, and viruses.45  
 Dextran hydrogels have received a lot of attention in drug delivery and tissue engineering 
due to their biocompatibility and their ability to biodegrade.  There are a number of ways that 
dextran can be formed into hydrogels, by both physical and chemical crosslinks. A commonly 
used chemical crosslinker is epichlorhydrin, which can crosslink dextran in alkaline aqueous 
solutions to form hydrogels.  These hydrogels, known commercially as Sephadex®, are used in 
separation and purification membranes and act as molecular sieves for important biochemical 
molecules such as polysaccharides, proteins, and nucleic acids.39  Another commercially known 
hydrogel product, Debrisan®, is made using the same crosslinking method and is used as a 
wound healing agent to speed up the recovery time.46  Dextran can also be crosslinked from a 
number of bifunctional reagents including phosphorous oxychloride, diisocyanates, and divinyl 
sulfone.47,48  Additionally, dextran can be modified with acrylate or methacrylate groups and 
polymerized via free radical polymerization.  These gels have been used as protein releasing 
matrices and as scaffolding for tissue engineering and show biocompatibility with native 
tissue.49,50   
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 In this dissertation dextran hydrogels are formed under alkaline conditions using the 
crosslinker divinyl sulfone. This is done in Chapter 4 and is used to investigate the partitioning 
of proteins and antibodies in dextran under various loading conditions.  Linear, unmodified 
dextran is also used in Chapter 4 to create an aqueous two-phase system that is used for loading 




2.2.3 Hyaluronic Acid 
 
Hyaluronic acid (HA) is another naturally occurring polysaccharide that is used 
extensively in biomedical applications.  Hyaluronic acid is a linear, unbranched polysaccharide 
that is composed of repeating units of the disaccharide glucoronic acid and N-acetylglucosamine. 
Unlike dextran, HA is found in all living organisms.  It plays a key role in the extracellular 
matrix of tissues, acting as a scaffold and providing mechanical properties to tissues.51 HA 
participates in a number of important biological functions, including the manipulation of cell 
differentiation and proliferation, and the regulation of cell motility and cell adhesion.52 HA is 
negatively charged under physiological conditions due to the presence of the carboxyl group, and 
electrostatic interactions can have large effects on the rheological and hydrodynamic properties.  
Under physiological conditions HA forms a stiff twisted ribbon structure due to distinct charged 
and hydrophobic faces that are formed from the hydrogen atoms and the carboxyl groups of 
glucoronic acid. This structure, along with the association of counter ions with ionized groups on 
the HA, causes it to occupy a large volume and leads to a large amount of water trapped inside 
the structure.53,54 The structure also provides viscoelasticity to biological fluids and tissue such as 
synovial fluid and the vitreous humor of the eye.53   
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Figure 2.3 The chemical structure of hyaluronic acid. The axial hydrogen atoms are shown in red and 
form a relatively hydrophobic face.  The equatorial hydroxyl groups are shown in blue and, along with the 
carboxyl group, form a charged hydrophilic face.  These two faces are responsible for the stiff backbone 
in solution and HA’s viscoelastic properties54. 
 
 
The unique combination of properties of HA, including its biocompatibility, 
viscoelasticity, and non-immunogenicity has made it a useful material for use in biomedical 
applications. Unmodified HA has been used as a vitreous replacement during eye surgeries, as a 
viscosupplementation in arthritis treatments, and in the regeneration and healing of surgical 
wounds.53  Despite the many intrinsic benefits of unmodified HA, it has a high turnover and 
elimination rate in vivo.55,56 To overcome these disadvantages HA is often crosslinked and 
formed into hydrogels. HA hydrogels can be synthesized by two routes. The first route is to 
crosslink unmodified HA directly using bifunctional crosslinkers such as divinyl sulfone or bis-
epoxides.57  The second route is to modify HA with any number of chemical groups including 
bromoacetate,58 hydrazides,59 tyramines,60 thiols,61 and methacrylates.62  These HA derivatives 
can then be formed into hydrogels by addition reactions, condensation reactions, and radical 
polymerizations. 
 HA hydrogels have been used in a number of biomedical and drug delivery 
applications.57  HA hydrogels have been studied for their use in tissue applications as scaffolding 
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for cells.52,63,64 They have also been used to deliver a wider range of drugs including peptides for 
chronic wound therapy,65 anti-inflammatory drugs for coatings of implants,66and proteins such as 
erythropoietin and human growth hormone.67,68  
 In this dissertation, HA was used to synthesize drug delivery vehicles that were capable of 
providing extended release of proteins and antibodies.  HA hydrogels were formed using divinyl 
sulfone (DVS) as a crosslinker in Chapter 5, and in Chapter 6 the gels were synthesized using the 
thiol-ene reaction, which will be discussed in Section 2.3.3. 
 
 
2.3  HYDROGEL SYNTHESIS 
 
 In this section, the synthesis methods that are used throughout this dissertation to create 
hydrogels are reviewed. One of the many advantages of hydrogels is that they can be formed 
using a wide variety of synthesis methods.  By definition, a hydrogel is a hydrophilic polymer 
network that is held in place by crosslinks that support the network’s three-dimensional structure.  
These crosslinks can be formed by any number of methods, including chemical reactions, 
electrostatic interactions, and even physical entanglements.  The synthesis method plays a large 
role in determining the hydrogel’s network structure, which is believed to play a critical factor in 
drug delivery devices that control the rate at which drugs can be released from the device. The 
synthesis method is also crucial in deciding whether or not a drug can be incorporated into the 
network during hydrogel formation.  Therefore, because of its importance in the field of drug 
delivery, a number of synthesis methods have been developed throughout the years to produce 
hydrogels.  
 In this dissertation, two types of synthesis methods are used to create hydrogels: the 
copolymerization/crosslinking of monomers, and the crosslinking of linear polymers. In the 
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copolymerization/crosslinking of monomers, smaller monofunctional and multifunctional 
monomers are linked together, usually via free radical polymerization to form a complex 
network of connected polymer chains. Alternatively, the crosslinking of linear polymers takes 
long, polymer chains and links them together with multifunctional crosslinks. These methods are 
described in more detail in the following sections. 
 
 
2.3.1 Free Radical Polymerization 
Free radical chain polymerization is a well-established technique that is used to produce 
gels from hydrophilic monomers that can be used for pharmaceutical and biomedical 
applications.7 The reaction can occur with any monomer that contains double bonds, including 
vinyl, divinyl, and even 1,3-diene molecules.  All free radical chain polymerizations begin with 
an initiation step that produces a radical species.  The radical species can come from a number of 
sources, including light sensitive, temperature sensitive, or solvent sensitive chemical initiators.  
These radical species associate with the vinyl groups of the monomer and the reaction continues 
as more and more vinyl groups are attached to the growing chain.  The chain will continue to 
propagate until the radical species of the chain is terminated by a number of routes including 
combination, disproportionation, etc.  Free radical chain polymerization produces high molecular 
weight chains that grow quickly and eventually crosslink with other chains to form the hydrogel 
network.69 However, even as the reaction is completed, there can still be a number of monomers 
and even polymer chains that have not incorporated into the network. 
Free radical polymerization was used in Chapter 4 to synthesize poly(ethylene glycol) 
diacrylate (PEGDA) hydrogels.  The reaction can be seen in Figure 2.4 in which, following 
initiation, the acrylate of one PEGDA reacts with the acrylate group of an additional PEGDA. 
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The reaction produces polyacrylate kinetic chains (zig-zag lines) that link the molecules together. 
While PEGDA is itself a polymer that has a molecular weight of 700 g/mol, the reaction still 
undergoes the initiation, propagation, and termination steps that characterize a free radical 
polymerization. 
 
Figure 2.4 The free radical polymerization of poly(ethylene glycol) diacrylate that was used in this 
dissertation to create hydrogels.   
 
 
2.3.2 Crosslinking of Linear Polymers 
 
 Another way of forming hydrogels is through the crosslinking of linear hydrophilic 
polymers.  These crosslinks can be formed through chemical reactions, physical entanglements, 
and via ionizing radiation.2  There are a large number of linear polymers that can be chemically 
crosslinked into hydrogels and the synthesis method often depends on the chemical groups on the 
polymers that are available to react.70  Many hydrophilic polymers contain hydroxyl, carboxyl, or 
amine groups that can serve as reactive sites for chemical crosslinkers.7 There are a number of 
chemical crosslinkers that can be used to react with linear polymers including aldehydes 
(acetaldehyde, formaldehyde, gluteraldehyde), diepoxides, divinyl sulfone, epichlorohydrin, and 
diisocyanates to name a few.70,71  In order to effectively crosslink polymers, these crosslinkers 
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 In this dissertation, the naturally occurring polysaccharides dextran and hyaluronic acid 
are crosslinked chemically to form hydrogels.  In Chapters 4 and 6, both dextran and hyaluronic 
acid are crosslinked under basic conditions using the chemical crosslinker divinyl sulfone (DVS) 
(Figure 2.4).  This reaction has been used previously in literature to create hydrogels for 
biomedical applications due to its ease of use and high degree of crosslinking.72  They have been 
investigated for use in tissue engineering, and gels with high molecular weight HA crosslinked 
with DVS were shown to be bioinert.73  Further investigation of the hydrogels discovered that by 
inserting smaller molecular weight HA into the network, cells were able to attach, spread, and 





Figure 2.5 The reaction for chemically crosslinking hyaluronic acid (HA) and dextran that was used 
throughout this dissertation.  The reaction occurs through the hydroxyl groups that are present on both 










Hyaluronic Acid Hydrogel 
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2.3.3 Click Chemistry 
 
In 2001 KB Sharpless introduced an approach for a new set of reactions termed “click 
chemistry” that allowed for the synthesis of new and useful compounds using simple reaction 
conditions.77  These reactions were to use materials and reagents that were widely available, 
proceed to very high yields, be able to be carried out in water and in the presence of oxygen, and 
give products that are easy to collect and purify.  Sharpless realized that in order to achieve these 
qualities in a reaction, a high thermodynamic driving force would be needed.  It is this 
thermodynamic driving force that causes the reaction to be “spring-loaded” and leads to 
reactions that proceed rapidly and with high selectivity.  Click chemistry is not a single specific 
reaction, but rather a concept that encompasses a number of possible reactions and mechanisms.  
Several of the reactions that fit the “click” reaction requirements are seen below in Figure 2.6.78 
Of these reactions, the Cu(I) mediated 1,3-Dipolarcycloaddition of alkynes and azides has been 
utilized extensively in the literature for drug discovery and material and polymer science due to 
its orthogonality and near quantitative yields.78-82  It has become so synonymous with click 
chemistry that it is often called “the click reaction”. While this reaction has been used to create 
polysaccharide hydrogels of hyaluronic acid83 and dextran,84 the toxicity of the copper catalyst 
prevents it from seeing widespread use in tissue engineering and in vivo applications.85 
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Figure 2.6 Some of the most widely used chemical reactions which fit the requirements of click 






 In Chapter 7 of this dissertation, a relatively new synthesis method called the thiol-ene 
reaction was developed for crosslinking HA hydrogels.  The thiol-ene reaction was studied due 
to the fact that some of the chemical crosslinking methods used in the earlier chapters were not 
suitable for the encapsulation of proteins and left behind reactive groups that interacted with 
proteins and impeded the release from the resulting hydrogels.  The thiol-ene reaction, while able 
to safely encapsulate cells and proteins, is also hypothesized to produce a more homogeneous 
network structure.  A more homogeneous hydrogel network would lead to improved mechanical 
properties and could also play a role in the diffusion of solutes within the hydrogel. This section 
will introduce the thiol-ene reaction and give a brief review of the ways in which the reaction has 
been used previously in literature to form HA hydrogels. 
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The thiol-ene reaction has been used since the early 1900’s, and is, at its core, the 
hydrothiolation of a carbon-carbon double bond.86 The reaction is carried out in one of two ways 
and can be seen below in Figure 2.7.87  The first is a free radical mechanism that is termed the 
“thiol-ene” reaction.  It involves the addition of a thiyl radical (RS•) to a carbon-carbon bond that 
can be either electron rich or poor. The second is an anionic mechanism that is termed the “thiol 
Michael addition”.  It involves the addition of a thiolate (RS-) to an electron deficient carbon-
carbon bond.  While the reactions produce the same product, the thiol Michael addition is more 
restrictive, and requires an electron deficient carbon-carbon bond such as an acrylate or a 
methacrylate group.   
 
 
Figure 2.7 The addition of a thiol to an “ene” group by a.) the thiol-ene reaction and b.) the thiol Michael 




The mechanism of the reaction was first proposed in 193876 and can be seen below in 
Figure 2.8.88,89 A thiol is first initiated, either with heat or light, to give a thiyl radical.  This thiyl 
radical then propagates across a carbon-carbon double bond, resulting in an intermediate carbon-
centered radical.  This radical is then able to pull a hydrogen radical off of a second thiol, which 
gives the final thiol-ene product and in turn generates a new thiyl radical that is able to react with 
another vinyl group.  The termination step has not been systematically studied, however it is 
assumed that the termination occurs via the quenching of two radical species.  It should be noted 
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that the mechanism in Figure 2.8 is for an ideal thiol-ene reaction.  When an activated carbon-
carbon double bond is used, it is possible for the carbon centered radical to homopolymerize with 
another carbon centered radical, essentialy starting a competing chain reaction. However, the 




Figure 2.8	  The mechanism of the Thiol-Ene reaction including: initiation, propagation, and chain 




The thiol-ene reaction has many advantages: it is incredibly fast, proceeds to high yields, 
can be performed in water over a wide range of concentrations, and is insensitive to oxygen.89-91 
The reaction can take place with virtually any carbon-carbon double bond, including terminal, 
internal, conjugated, substituted, and even cyclic alkenes.92 At the same time, there are a wide 
range of thiols that can be used, as any thiol is able to participate in the thiol-ene reaction. 
It wasn’t until 2012 that a true thiol-ene reaction using a free radical as an initiator was 
performed using HA.  The work was done by Auzély-Velty et al. and it involved attaching a 
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pentenoate group onto the backbone of HA and dextran by esterification of the hydroxyl 
groups.93 The motivation behind the work was mostly to functionalize the polysaccharides with 
hydrophobic groups, peptides, and oligosaccharides, yet they were also able to form hydrogels 
using the pentenoate modified dextran and a PEG-dithiol.  Similar work was done in 2013 by 
Burdick who modified HA with a norbornene group.94 The modified HA was crosslinked using a 
small disulfide molecule (dithiothreitol), and the compressive moduli was varied with the 
irradiation time, the ratio of thiols to norbornene, and the weight percent of HA in solution.  The 
focus was on photopatterning the hydrogels to either modify the crosslink density or to couple 
chemical ligands.  This was done by selecting conditions in which after gelation there still 
existed pendent norbornenes that could undergo further reactions with a variety of thiol 
containing molecules. 
While the use of thiol-ene reactions to create hydrogels is a more recent advance in 
literature, a number of HA hydrogels have been made using the thiol-Michael addition 
reaction.52,95-97 Although the thiol-Michael addition reactions (the addition of a thiolate (RS-) to 
an electron deficient carbon-carbon bond) are similar to the thiol-ene reaction they lack one of 
the key advantages of the thiol-ene reaction: the ability to be initiated by a radical species. The 
ability to be initiated by a radical species enables the thiol-ene reaction to be controlled spatially 
and temporally via photoinitiation, or by temperature using a thermal initiator. On the other 
hand, the thiol-michael addition reaction begins immediately when the reactants are mixed 
together.  Not only are thiol-Michael addition reactions spontaneous but they also occur under 
slightly alkaline conditions that can often lead to disulfide formation and off-stoichiometric 
reactions of monomers as the hydrogel is being formed. 
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2.4  PROPERTIES OF HYDROGELS 
   
 The swelling degree and mechanical properties of a hydrogel play a large role in 
determining its usefulness and application as a drug delivery device.  In this section, an overview 
of the equilibrium swelling theory is provided along with the theory for determining the 
mechanical properties of a hydrogel such as the compressive moduli (Young’s and elastic), and 
crosslink density. 
 
2.4.1 Swelling Theory 
 
One of the most important properties of a hydrogel is the equilibrium swelling degree, as 
it has a direct influence on the other properties of the hydrogel.7  The swelling degree is typically 
expressed as either the mass degree of swelling, q, or the volume degree of swelling, Q, and are 
defined as: 
q = mass of swollen gel/mass of dry polymer     (2.1) 
Q = volume of swollen gel/volume of dry polymer     (2.2) 
 
Unlike polymer chains in solution, the polymer chains of a hydrogel are constrained by 
crosslinks that serve as elastic junctions. As the chains begin to absorb solvent and swell they 
become elongated, creating a retractive force that opposes the thermodynamic force of dilution.  
When these two forces are equal, a state of equilibrium is reached. The physical situation can be 
described in terms of the Gibbs free energy: 
 
∆Gtotal  = ∆Gmixing    +  ∆Gelastic     (2.3)  
 
where ∆Gmixing is the change in free energy due to polymer mixing between the solvent and the 
polymer chains, and ∆Gelastic is the change in free energy due to elastically effective crosslinks in 
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the hydrogel network.   Equation 2.3 can also be described in terms of the osmotic swelling 
pressure, giving: 




Pext = the externally applied pressure 
 
Πmixing = the swelling pressure due to the tendency of the polymer to dissolve in the solvent 
Πelastic  = the elastic response of the network due to crosslinking 
 
 The model that is used most often used to describe the polymer-solvent mixing term is 





ln(1- ϕ2)+ ϕ2 + χ1ϕ2
2         (2.5)  
 
in which: 
R = gas constant 
T = Temperature 
V1= solvent molar volume 
ϕ2 = polymer volume fraction 
χ1 =  polymer solvent interaction parameter  
The last term in Equation 2.5 represents the enthalpy of mixing using the polymer solvent 
interaction parameter, and takes into account both the solvent and the material.  This interaction 
parameter is often referred to as the Flory Huggins solubility parameter, and is generally between 
0 and 1.  Higher values (χ > ½) indicate that polymer-polymer interactions are more prevalent 
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than polymer-solvent interactions and discourages dissolution.  Lower values (χ < ½) indicate 
that polymer-solvent interactions are more prevalent than polymer-polymer interactions and 
supports dissolution. Values of χ equal to 1/2 signify that polymers and solvents that have no net 
interactions. 
 The elastic contributions in Equation 2.4 can be written as: 
 
∆Πelastic=  -RTveV0    ϕ2
1/3 − 1
2
ϕ2 = − RTρx ϕ2
1/3 − 1
2
ϕ2          (2.6)  
 
where: 
ve = the number of elastically effective chains in the network 
V0 = volume of the undeformed polymer network (network before swelling) 
ρx = ve/V0 = effective crosslink density of the hydrogel 
 For networks made in solution (as is the case for many common hydrogels),  










        (2.7)  
 
in which 𝜙!,! is the polymer volume fraction at network formation.98  By combining Equations 
2.4, 2.5 and 2.7, the free swelling of a nonionic gel in equilibrium can be defined as: 
 
0 =  ln 1-ϕ2   +    ϕ2  +    χ1ϕ2







   (2.8)  
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If the gels have ionizable groups, two more terms are added to the equation to take into 
account the electrostatic and ionic effects that can affect the swelling of the gel, giving: 
 
Pext  = Πmixing  +  Πelastic   +  Πion+  Πelectrostatic       (2.9)  
 
 
where  ∆Gion  represents the change in free energy due to concentration differences of ions 
between the hydrogel and solvent, and ∆Gelectrostatic   represents the change in free energy due to 
electrostatic interactions between the polymer and the solvent.  The ionic term can be 
represented as: 
∆Πion=  RT c− c*      (2.10)  
 
 
where c is the molar concentration of mobile ions in the solution inside the gel and c* is the 
molar concentration of mobile ions in the solution outside the gel. In general, the effects of 
electrostatics are often much smaller than the osmotic effects in a polyelectrolyte hydrogel, and 
large changes in the swelling degree of polyelectrolyte gels can be seen as the degree of 
ionization is altered. 
 
 
2.4.2 Mechanical Properties 
 
 While a number of important properties of the hydrogel network can be determined from 
the swelling degree, a more complete picture of the hydrogel network is achieved when the 
mechanical properties of the gel are tested.  In this dissertation, all of the gels were tested under 
compression and a representative stress-strain curve can be seen in Figure 2.9. By using a 
Gaussian model to describe the chain extensions within the network combined with statistical 
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Figure 2.9 A representative sample of the stress-strain curves that were obtained from compression 
testing of the hydrogels in this dissertation. The curves were used to calculate both the compressive 
modulus (E) and the shear modulus (G).  
 
 When a hydrogel is compressed the work required to deform the network or elastically 
store a given amount of free energy per unit volume is expressed as: 
W = -TΔS     (2.11)  
When under compression, assuming a uniaxial force and no volume changes, the change in 
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ΔS = - 12NkT λ
2  +   2λ   -  3      (2.12)  
 
 
where N is the number of crosslinked chains present in the network, k is Boltzmann’s constant, 
and T is the temperature in Kelvin.   λ is the extension ratio, and is defined as: 
λ = LL0      (2.13)  
 
When the shear modulus (G) of the network is included in Equation 2.12 and inserted into 
Equation 2.11, the resulting equation is: 
 
W =  12  G λ
2 + 2λ  - 3       (2.14)  
 
 
and, σ, the nominal stress can be expressed as:  
 
 
σ =  dW
dλ
 = G λ  - 1
λ2
    (2.15)  
 
 
The shear moduli of the hydrogels in this dissertation were calculated using Equation 2.15 and 
the stress strain data collected.  When the stress is plotted against the strain function λ  - 1
λ2
, a 
hydrogel that is considered an ideal elastomer and follows neo-Hookean behavior will have a 
linear slope. The shear modulus can also be expressed in terms of the number average molecular 
weight between crosslinks (Mc),  
 
G  =   𝜌𝑅𝑇𝑀𝑐
     (2.16)  
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Where ρ is the density of the polymer and R is the gas constant per mole.  From this equation we 
see that the shear modulus is directly related to the number of crosslinks per unit volume, as 
larger number of crosslinks result in lower values of Mc.  The shear modulus can also be used to 






2/3     (2.17)  
 
in which v2r is the polymer volume fraction during hydrogel formation. There are other models 
that exist other than the affine model. One of these models, the phantom model, is also 
commonly used for hydrogels and can be used to calculate the crosslink density as well. The 
crosslink density calculated from the phantom model is twice the value of the crosslink density 
calculated from the affine model.  The crosslink density and the number average molecular 
weight between crosslinks are important properties of the hydrogel network and are often used in 
drug delivery applications to compare network properties between different gels and to calculate 
the average mesh size, which will be shown in Section 2.4.3. 
The compressive modulus, E, can be calculated directly from the stress-strain curve. At 
low strain percent, the curve follows Hooke’s law: 
 
σ   =  Eε  =  E  (λ− 1)     (2.18)  
 
 
The compressive modulus was calculated by using the data up to strains of 10%.  The 
relationship between the compressive modulus and shear modulus can be written by: 
E = 2G (1+ υ)     (2.19)  
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in which v is known as Poisson’s ratio.  For an ideal elastomer, the value of v = 0.5 and 
therefore, if the ratio of E/G = 3 it is often a good indication that the hydrogel is following the 
Gaussian statistics and is an ideal elastomer.99,100  Certain hydrogels do not exhibit a Gaussian 
chain distribution, which can lead to errors in the calculation of meaningful structural parameters 
of the gel. For these hydrogels, a different model (such as the Gent model101) might more 
accurately account for the non-Gaussian chain effects.102 
 
2.4.3 Hydrogel Mesh Size 
 
 One network parameter that is frequently used in drug delivery literature is the hydrogel 
mesh size.  The mesh size is the space between the molecular chains in a hydrogel network.  
Characterizing these spaces is difficult in a hydrogel due to their heterogeneous nature of 
hydrogels and the fact that most of the relevant structural features in a hydrogel range from 1-
100 nm.103  The most accurate method in determining the average mesh size in a hydrogel is 
small-angle X-ray scattering (SAXS), however this method is time consuming and generally 
requires a synchrotron radiation source.103,104  Two alternative methods have been developed to 
estimate the average mesh size within a hydrogel. 
 The first method was introduced by Peppas105 and was developed from Flory’s classical 
derivation. The mesh size is based on the swelling and mechanical properties of the hydrogel and 
is normally represented as the distance between two adjacent crosslinks (ξ). This distance, also 
known as the correlation length, is calculated using the equation:105 
ξ  =  α r02
1/2
          (2.20)  
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where α is the elongation ratio of the polymer chains in any direction and r02 is the root-mean-




Figure 2.10 Graphical representation of an idealized hydrogel network.  The arrow represents the 




For hydrogels that swell isotropically, the elongation ratio of the polymer chains is related to the 
swollen polymer volume fraction (v2s) as follows: 
 
α  =    v2s








=l CnN 1/2     (2.22)  
 
ξ 
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in which l is the length of the bond along the polymer backbone, Cn is the Flory characteristic 
ratio, and N is the number of links between two crosslinks calculated as: 
N  =  
2Mc
Mr




Mc = the molecular weight between crosslinks 
 
Mr = the molecular weight of the repeating units from which the chain is composed 
 
 
By combining Equations 2.20 through 2.23, a final equation is produced that allows for the 
calculation of the distance between two adjacent crosslinks: 
 




l                                                                                                                          (2.24) 
 
 While this method for calculating the average mesh size of a hydrogel is much simpler 
and faster when compared to SAXS, it does have limitations.  The theory is highly dependent on 
an accurate value of Mc, which is based off of elastic models and can vary in value depending on 
the model used (affine vs. phantom).  Additionally, these models are developed under the 
assumption that the hydrogel exhibits a Gaussian chain distribution, and there are situations 
where this assumption is not valid.2 
 The second model for determining the average mesh size of a hydrogel is based on the De 
Gennes’ scaling theory.  This model is often known as the “blob” model and calculates the mesh 
size based on the precursor polymer solution.  This model assumes that for polymers in the 
semidilute state, there are certain entanglement points on the polymer chains where the polymers 
can interact with each other.  The rest of the chain is contained within a region known as a blob, 
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and is free to move and does not interact with other chains.107,108  Therefore, crosslinking is 
assumed to occur at the entanglement points where the polymer chains interact.  The blob size, 
ξb,, can then be estimated by the concentration of the precursor polymer solution:
109,110 
 




     (2.25)  
 
where Rg is the radius of gyration, c is the concentration of the polymer, c* is the overlapping 
concentration of the polymer, and ν is Flory’s exponent.  As the hydrogel swells, the mesh size 
of the gel will increase and can be calculated from the blob size by: 
 








    (2.26)  
 
in which Qr is the volumetric swelling ratio of the gel from the relaxed state to its equilibrium 
swollen state.  In gels that undergo very little swelling from the relaxed state to the equilibrium 





Figure 2.11 Schematic showing the blob size in a semidilute solution and how it is related to the mesh 
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One of the advantages of the blob model is that values of Rg, c*, and ν can be found in 
literature for most polymers, making it very easy to calculate the mesh size a priori.  However, 
the model is rather simple and assumes that polymer chains can only be crosslinked at the 
entanglement points.  The model assumes that increasing the degree of modification of the 
polymers does not affect the mesh size and only increases the density of the polymer chains 
between entanglement points. The blob model is also only valid when hydrogels are synthesized 
via the crosslinking of linear polymers and not via the polymerization of multifunctional 




2.4.4 Partition Coefficients of Solutes in Hydrogels 
 
One of the most important properties of a hydrogel is the ability to control the movement 
of solutes within the hydrogel network and to provide a wide range of permeabilities.  This 
ability to control or restrict the movement of solutes is crucial in many applications including 
biosensors, chromatography for separation processes, the encapsulation of cells, and especially 
drug delivery.112-118 The permeability is highly dependent on the hydrogel network and is 
influenced by the crosslink density and mesh size of the network, the swelling degree, the size of 
the solute molecule, and interactions that may occur between the solute and the polymer chains.10  
The permeability is often defined as the product of the diffusion coefficient (Dg), a kinetic term, 
and the partition coefficient (K), a thermodynamic term.119  In this section, the focus will be on 
the partition coefficient, while the diffusion coefficient is discussed in greater detail in Chapter 3.  
When a hydrogel is placed in a solution containing a solute, the chemical potential of the 
solute must be equal in both phases (the gel and the external solution), and results in the solute 
being distributed between the external solution and the hydrogel.119 The partition coefficient is 
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used to describe this distribution that occurs, and is defined as the ratio of the solute 





      (2.27)  
 
 
The partitioning of a solute within a hydrogel will vary depending on a number of factors, 
including physical parameters such as the size and shape of the solute molecule, but also any 
chemical interactions that may occur between the hydrogel and the solute such as electrostatic, 
hydrophobic, and even biospecific interactions.  These factors all contribute to the overall 
partition coefficient, and can be separated into individual partition coefficients as follows: 
 
ln K = ln K0    + ln Ksize  +  ln Kconf  +  ln Khphob+  ln Kelectr  +  ln Kbiosp  (2.28)  
 
where the subscripts size, conf, hphob, electr and biosp indicate size and conformational effects, 
hydrophobic interactions, electrostatic interactions, and biospecific interactions, 
respectively.119,120 K0 is often used to describe any other interactions that may occur including 
hydrogen bonding, van der Waals forces, and even the effects of polymer concentration. The 
value of K can range from zero (meaning the solute is completely excluded from the hydrogel) to 
values well over 100. Large values of K are often a result of favorable interactions between the 
hydrogel and the solute, such as charged solutes that are attracted to an oppositely charged 
hydrogel network or solutes that are designed to interact with ligands built into the hydrogel 
network. When K =1, the solute concentration is equal in both of the phases. 
 One simple case of solute partitioning that is of particular interest in this dissertation is 
when there are no interactions between the gel and the solute and the partitioning is determined 
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based only on the size of the molecule.  When this situation occurs it is often referred to as ideal 
size exclusion.119  Size exclusion occurs due to entropic effects.  As the size of the solutes 
increase or the pores between the polymer chains become smaller, a solute within the gel 
becomes more restricted and has fewer orientations available relative to free solution.121  
Because of this, solutes that might be small enough to enter into the hydrogel network may no 
longer partition into the hydrogel.   Therefore, in ideal size exclusion, the partitioning is always 
between 0 and 1, and the value will depend on the size of the solute and the size of the pores in 
the network.   
While the concept of size exclusion is relatively straightforward, it is often wrongly 
interpreted in drug delivery literature.   Authors often make the assumption that because a large 
molecule is unable to partition into a hydrogel, the mesh size of the hydrogel must be smaller 
than the diameter or cross sectional area of the solute.  In reality, the solute may actually be able 
to enter the pores of the hydrogel but does not only because of the reduction in orientational 
freedom that it would experience.  At the same time, a hydrogel that has a calculated mesh size 
that is smaller than a given solute does not mean that the solute will be completely excluded 
from the hydrogel.  Hydrogels are inherently heterogeneous and will have regions of higher and 
lower crosslink densities and mesh sizes.  Additionally, under certain conditions the chemical 
potential of the solution outside of the hydrogel may change and affect the partitioning of the 
solute within the hydrogel. The partitioning and size exclusion of solutes in hydrogels is studied 
in Chapter 4, where the partitioning of ovalbumin and IgG is investigated in dextran and PEGDA 
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2.5 HYDROGELS AS DRUG DELIVERY VEHICLES 
 
One of the most important applications of hydrogels is their use as drug delivery vehicles. 
Their high water content and mechanical properties are similar to that of the extracellular matrix, 
which provides a high degree of biocompatibility while at the same time allowing for the safe 
encapsulation of bioactive molecules.1,11 They can be synthesized using a wide range of synthetic 
or biological materials and can be formed under mild conditions. Because of these many 
advantages, hydrogel based delivery devices have become a major area of research and have 
seen commercial success in ocular,122,123 vaginal,124-126 buccal,127 and subcutaneous128 
applications.129,130 
Controlling the rate of drug release from the gel is essential for a successful delivery 
device. The release of drugs from hydrogels can be controlled by a number of mechanisms that 






Drug delivery devices that are made up of chemically-controlled hydrogels release drugs 
at a rate that is dependent on the enzymatic or hydrolytic degradation of the hydrogel network. 
While this often involves bulk erosion of the hydrogel, it can also include a change of the 
binding equilibrium between the drug and drug-binding moiety of the hydrogel.131  Hydrogels 
consisting of varying formulations of the polymers PEG and poly(lactic acid) have degradation 
rates that allow them to be used in several biomedical applications including the prevention of 
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postsurgical adhesion, and the controlled release of a number of proteins and 
oligonucleotides.132,133 
 
Figure 2.12. Chemically-controlled hydrogels can release drug through A) the bulk erosion of the 




In swelling-controlled delivery devices, the release is controlled by the rate at which 
solvent molecules can penetrate the polymer matrix.3  As the solvent penetrates the hydrogel, the 
network begins to swell which allows the drug to diffuse out of the hydrogel. Since the drug 
diffusion rate occurs at a faster rate than the rate of hydrogel swelling, a broad range of delivery 
times can be achieved by tuning the swelling rate of the hydrogel matrix. Swelling-controlled 
hydrogels have been used in a number of biomedical applications.  Methocel®, a commercially 
available hydrogel that consists of hydroxypropyl methylcellulose and methylcelluluse, has been 
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controlled drug delivery system is Cervidil®, a hydrogel vaginal insert that releases the labor 
inducing drug dinoprostone.124-126  The moist environment causes the hydrogel to swell and 
triggers the release.130 
 
Figure 2.13 Schematic of a swelling-controlled hydrogel delivery device that releases drug as solvent 
molecules penetrate the gel and swell the network. 
 
  
In diffusion-controlled devices, the release occurs due to the diffusion of drug through the 
hydrogel matrix. This movement of drug molecules can be described by Fick’s law of diffusion: 
 
j = -D dCdx      (2.29)   
 
where j is the flux, or rate of transfer per unit area of section, dC/dx is the concentration gradient 
of the diffusing drug, and D is the diffusion coefficient.  The diffusion coefficient is a parameter 
that represents the transport of drug through the hydrogel network, and takes into account the 
size of the drug and the physical properties of the system through which it is diffusing. For a 
drug in solution, diffusion occurs as a result of the random motion of molecules (Brownian 
motion) in the absence of an external driving force.119  This is often referred to as D0, the 
diffusion coefficient of a drug in solution at infinite dilution. Values of D0 for solutes in solution 
Dried State Swollen State 
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can range from as high as 1.8 x 10-5 cm2/s for smaller solutes like urea to as low as 4.0 x 10-7 
cm2/s for larger drugs like antibodies.134,135  
In a hydrogel, the diffusive movement of drugs is restricted.  There are several factors 
that affect the movement of drugs in a hydrogel network including the size of the solute, the 
amount of water in the network, the polymer concentration, and the polymer chain mobility.  In 
certain cases, the existence of charged groups in the gel may also interact with the drug and 
reduce the mobility.  In some cases, the diffusion coefficient within the hydrogel, Dg, will be so 
low that drugs are effectively trapped inside the hydrogel network.  On the other hand, in highly 
swollen hydrogels the values of Dg will often approach values of D0. 
 Out of the three mechanisms, the one that is most often applicable in hydrogel drug 
delivery devices is diffusion-controlled release.131  Diffusion is almost always involved in 
controlling the release of drug from hydrogel delivery vehicles.  In many hydrogels, drug 
diffusion is the only mechanism in which drug is released from the device.  In other cases, 
diffusion plays a major role in combination with either polymer swelling or the 
degradation/erosion of the hydrogel network.129,131,136-140  Much of the work in this dissertation 
focuses on hydrogel delivery vehicles where the release is controlled predominantly by diffusion.  
The diffusion of solutes in hydrogels is the primary focus of next chapter, where it discussed in 
greater detail. 
  
	   47 
REFERENCES 
 
1. Hoare TR, Kohane DS 2008. Hydrogels in drug delivery: progress and challenges. 
Polymer  49(8):1993-2007. 
2. Peppas NA. 1987. Hydrogels in medicine and pharmacy. ed.: CRC press Boca Raton, FL. 
3. Peppas NA, Bures P, Leobandung W, Ichikawa H 2000. Hydrogels in pharmaceutical 
formulations. European Journal of Pharmaceutics and Biopharmaceutics  50(1):27-46. 
4. Gupta P, Vermani K, Garg S 2002. Hydrogels: from controlled release to pH-responsive 
drug delivery. Drug Discovery Today  7(10):569-579. 
5. Anseth KS, Bowman CN, BrannonPeppas L 1996. Mechanical properties of hydrogels 
and their experimental determination. Biomaterials  17(17):1647-1657. 
6. Qiu Y, Park K 2001. Environment-sensitive hydrogels for drug delivery. Adv Drug Deliv 
Rev  53(3):321-339. 
7. Gehrke SH. 2000. Synthesis and properties of hydrogels used for drug delivery. ed.: 
Marcel Dekker: New York. 
8. Wichterle O, Lim D 1960. HYDROPHILIC GELS FOR BIOLOGICAL USE. Nature  
185(4706):117-118. 
9. Peppas NA, Hilt JZ, Khademhosseini A, Langer R 2006. Hydrogels in biology and 
medicine: From molecular principles to bionanotechnology. Advanced Materials  18(11):1345-
1360. 
10. Hoffman AS 2002. Hydrogels for biomedical applications. Adv Drug Deliv Rev  54(1):3-
12. 
11. Oh JK, Drumright R, Siegwart DJ, Matyjaszewski K 2008. The development of 
microgels/nanogels for drug delivery applications. Progress in Polymer Science  33(4):448-477. 
12. Lin C-C, Metters AT 2006. Hydrogels in controlled release formulations: Network design 
and mathematical modeling. Adv Drug Deliv Rev  58(12-13):1379-1408. 
13. Williams DF 2008. On the mechanisms of biocompatibility. Biomaterials  29(20):2941-
2953. 
14. Remunan-Lopez C, Portero A, Vila-Jato JL, Alonso MJ 1998. Design and evaluation of 
chitosan/ethylcellulose mucoadhesive bilayered devices for buccal drug delivery. Journal of 
Controlled Release  55(2-3):143-152. 
	   48 
15. Senel S, Ikinci G, Kas S, Yousefi-Rad A, Sargon MF, Hincal AA 2000. Chitosan films 
and hydrogels of chlorhexidine gluconate for oral mucosal delivery. International Journal of 
Pharmaceutics  193(2):197-203. 
16. Drury JL, Mooney DJ 2003. Hydrogels for tissue engineering: scaffold design variables 
and applications. Biomaterials  24(24):4337-4351. 
17. Bailey FJ. 2012. Poly (ethylene oxide). ed.: Elsevier. 
18. Sedlak M 2005. Recent advances in chemistry and applications of substituted 
poly(ethylene glycol)s. Collect Czech Chem Commun  70(3):269-291. 
19. Yamaoka T, Tabata Y, Ikada Y 1994. DISTRIBUTION AND TISSUE UPTAKE OF 
POLY(ETHYLENE GLYCOL) WITH DIFFERENT MOLECULAR-WEIGHTS AFTER 
INTRAVENOUS ADMINISTRATION TO MICE. Journal of Pharmaceutical Sciences  
83(4):601-606. 
20. Harris JM, Chess RB 2003. Effect of pegylation on pharmaceuticals. Nature Reviews 
Drug Discovery  2(3):214-221. 
21. Knop K, Hoogenboom R, Fischer D, Schubert US 2010. Poly(ethylene glycol) in Drug 
Delivery: Pros and Cons as Well as Potential Alternatives. Angewandte Chemie-International 
Edition  49(36):6288-6308. 
22. Tosatti S, De Paul SM, Askendal A, VandeVondele S, Hubbell JA, Tengvall P, Textor M 
2003. Peptide functionalized poly(L-lysine)-g-poly(ethylene glycol) on titanium: resistance to 
protein adsorption in full heparinized human blood plasma. Biomaterials  24(27):4949-4958. 
23. Balakrishnan B, Kumar DS, Yoshida Y, Jayakrishnan A 2005. Chemical modification of 
poly(vinyl chloride) resin using poly(ethylene glycol) to improve blood compatibility. 
Biomaterials  26(17):3495-3502. 
24. Suggs LJ, West JL, Mikos AG 1999. Platelet adhesion on a bioresorbable poly(propylene 
fumarate-co-ethylene glycol) copolymer. Biomaterials  20(7):683-690. 
25. Zurad EG, Johanson JF 2011. Over-the-counter laxative polyethylene glycol 3350: an 
evidence-based appraisal. Current Medical Research and Opinion  27(7):1439-1452. 
26. Blume G, Cevc G 1990. LIPOSOMES FOR THE SUSTAINED DRUG RELEASE 
INVIVO. Biochimica Et Biophysica Acta  1029(1):91-97. 
27. Kabanov AV, Chekhonin VP, Alakhov VY, Batrakova EV, Lebedev AS, Meliknubarov 
NS, Arzhakov SA, Levashov AV, Morozov GV, Severin ES, Kabanov VA 1989. THE 
	   49 
NEUROLEPTIC ACTIVITY OF HALOPERIDOL INCREASES AFTER ITS 
SOLUBILIZATION IN SURFACTANT MICELLES - MICELLES AS MICROCONTAINERS 
FOR DRUG TARGETING. Febs Letters  258(2):343-345. 
28. Klibanov AL, Maruyama K, Torchilin VP, Huang L 1990. AMPHIPATHIC 
POLYETHYLENEGLYCOLS EFFECTIVELY PROLONG THE CIRCULATION TIME OF 
LIPOSOMES. Febs Letters  268(1):235-237. 
29. Kwon GS, Kataoka K 1995. BLOCK-COPOLYMER MICELLES AS LONG-
CIRCULATING DRUG VEHICLES. Adv Drug Deliv Rev  16(2-3):295-309. 
30. Keys KB, Andreopoulos FM, Peppas NA 1998. Poly(ethylene glycol) star polymer 
hydrogels. Macromolecules  31(23):8149-8156. 
31. Peppas NA, Keys KB, Torres-Lugo M, Lowman AM 1999. Poly(ethylene glycol)-
containing hydrogels in drug delivery. Journal of Controlled Release  62(1-2):81-87. 
32. Gillinov AM, Lytle BW 2001. A novel synthetic sealant to treat air leaks at cardiac 
reoperation. Journal of Cardiac Surgery  16(3):255-257. 
33. Park Y, Lutolf MP, Hubbell JA, Hunziker EB, Wong M 2004. Bovine primary 
chondrocyte culture in synthetic matrix metalloproteinase-sensitive poly(ethylene glycol)-based 
hydrogels as a scaffold for cartilage repair. Tissue Eng  10(3-4):515-522. 
34. Metters A, Hubbell J 2005. Network formation and degradation behavior of hydrogels 
formed by Michael-type addition reactions. Biomacromolecules  6(1):290-301. 
35. Chludzin.Am, Germaine GR, Schachte.Cf 1974. PURIFICATION AND PROPERTIES 
OF DEXTRANSUCRASE FROM STREPTOCOCCUS-MUTANS. Journal of Bacteriology  
118(1):1-7. 
36. Leathers TD 2002. Dextran. Biopolymers Online. 
37. Long DM, Sanchez L, Varco RL, Lillehei CW 1961. THE USE OF LOW MOLECULAR 
WEIGHT DEXTRAN AND SERUM ALBUMIN AS PLASMA EXPANDERS IN 
EXTRACORPOREAL CIRCULATION. Surgery  50(1):12-&. 
38. Heinze T, Liebert T, Heublein B, Hornig S. 2006. Functional polymers based on dextran.  
Polysaccharides II, ed.: Springer. p 199-291. 
39. Naessens M, Cerdobbel A, Soetaert W, Vandamme EJ 2005. Leuconostoc dextransucrase 
and dextran: production, properties and applications. Journal of Chemical Technology and 
Biotechnology  80(8):845-860. 
	   50 
40. de Belder D 1996. Medical application of dextran and its derivatives. Polysaccharides in 
Medicinal Applications New York, NY: Marcel Dekker:505-524. 
41. Guggenheim B, Schroeder H 1967. Biochemical and morphological aspects of 
extracellular polysaccharides produced by cariogenic streptococci. Helvetica odontologica acta  
11(2):131. 
42. Zief M, Brunner G, Metzendor J 1956. Fractionation of partially hydrolyzed dextran. 
Industrial & Engineering Chemistry  48(1):119-121. 
43. Holly FJ, Esquivel ED 1985. Colloid osmotic pressure of artificial tears. Journal of ocular 
pharmacology  1(4):327-336. 
44. Mehvar R 2000. Dextrans for targeted and sustained delivery of therapeutic and imaging 
agents. Journal of controlled release  69(1):1-25. 
45. Hatti-Kaul R 2001. Aqueous two-phase systems. Molecular biotechnology  19(3):269-
277. 
46. Jacobsson S, Jonsson L, Rank F, Rothman U 1976. Studies on healing of Debrisan-
treated wounds. Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery  
10(2):97-101. 
47. Denizli BK, Can HK, Rzaev ZM, Guner A 2004. Preparation conditions and swelling 
equilibria of dextran hydrogels prepared by some crosslinking agents. Polymer  45(19):6431-
6435. 
48. Can HK, Denizli BK, Güner A, Rzaev ZM 2005. Effect of functional crosslinking agents 
on preparation and swelling properties of dextran hydrogels. Carbohydrate polymers  59(1):51-
56. 
49. Cadee JA, van Luyn MJA, Brouwer LA, Plantinga JA, van Wachem PB, de Groot CJ, 
den Otter W, Hennink WE 2000. In vivo biocompatibility of dextran-based hydrogels. Journal of 
Biomedical Materials Research  50(3):397-404. 
50. Franssen O, van Ooijen RD, de Boer D, Maes RAA, Hennink WE 1999. Enzymatic 
degradation of cross-linked dextrans. Macromolecules  32(9):2896-2902. 
51. Garg HG, Hales CA. 2004. Chemistry and biology of hyaluronan. ed.: Elsevier. 
52. Shu XZ, Liu Y, Palumbo FS, Luo Y, Prestwich GD 2004. In situ crosslinkable 
hyaluronan hydrogels for tissue engineering. Biomaterials  25(7):1339-1348. 
	   51 
53. Necas J, Bartosikova L, Brauner P, Kolar J 2008. Hyaluronic acid (hyaluronan): a review. 
Veterinarni medicina  53(8):397-411. 
54. Toole BP 2004. Hyaluronan: from extracellular glue to pericellular cue. Nature Reviews 
Cancer  4(7):528-539. 
55. Fraser J, Laurent T, Laurent U 1997. Hyaluronan: its nature, distribution, functions and 
turnover. Journal of internal medicine  242(1):27-33. 
56. Laurent TC, Fraser J 1992. Hyaluronan. The FASEB Journal  6(7):2397-2404. 
57. Burdick JA, Prestwich GD 2011. Hyaluronic acid hydrogels for biomedical applications. 
Advanced materials  23(12):H41-H56. 
58. Serban MA, Prestwich GD 2007. Synthesis of hyaluronan haloacetates and biology of 
novel cross-linker-free synthetic extracellular matrix hydrogels. Biomacromolecules  8(9):2821-
2828. 
59. Prestwich GD, Marecak DM, Marecek JF, Vercruysse KP, Ziebell MR 1998. Controlled 
chemical modification of hyaluronic acid: synthesis, applications, and biodegradation of 
hydrazide derivatives. J Control Release  53(1-3):93-103. 
60. Darr A, Calabro A 2009. Synthesis and characterization of tyramine-based hyaluronan 
hydrogels. J Mater Sci-Mater Med  20(1):33-44. 
61. Shu XZ, Liu YC, Luo Y, Roberts MC, Prestwich GD 2002. Disulfide cross-linked 
hyaluronan hydrogels. Biomacromolecules  3(6):1304-1311. 
62. Burdick JA, Chung C, Jia XQ, Randolph MA, Langer R 2005. Controlled degradation 
and mechanical behavior of photopolymerized hyaluronic acid networks. Biomacromolecules  
6(1):386-391. 
63. Park KM, Yang JA, Jung H, Yeom J, Park JS, Park KH, Hoffman AS, Hahn SK, Kim K 
2012. In Situ Supramolecular Assembly and Modular Modification of Hyaluronic Acid 
Hydrogels for 3D Cellular Engineering. ACS Nano  6(4):2960-2968. 
64. Leach JB, Bivens KA, Patrick CW, Schmidt CE 2003. Photocrosslinked hyaluronic acid 
hydrogels: natural, biodegradable tissue engineering scaffolds. Biotechnology and 
bioengineering  82(5):578-589. 
65. Barros SC, Martins JA, Marcos JC, Cavaco-Paulo A 2012. Influence of secretory 
leukocyte protease inhibitor-based peptides on elastase activity and their incorporation in 
hyaluronic acid hydrogels for chronic wound therapy. Biopolymers  98(6):576-590. 
	   52 
66. Hahn SK, Jelacic S, Maier RV, Stayton PS, Hoffman AS 2004. Anti-inflammatory drug 
delivery from hyaluronic acid hydrogels. J Biomater Sci-Polym Ed  15(9):1111-1119. 
67. Motokawa K, Hahn SK, Nakamura T, Miyamoto H, Shimoboji T 2006. Selectively 
crosslinked hyaluronic acid hydrogels for sustained release formulation of erythropoietin. 
Journal of Biomedical Materials Research Part A  78A(3):459-465. 
68. Kim MR, Park TG 2002. Temperature-responsive and degradable hyaluronic 
acid/Pluronic composite hydrogels for controlled release of human growth hormone. Journal of 
Controlled Release  80(1-3):69-77. 
69. Colombani D 1997. Chain-growth control in free radical polymerization. Progress in 
Polymer Science  22(8):1649-1720. 
70. Finch CA. 2013. Chemistry and technology of water-soluble polymers. ed.: Springer 
Science & Business Media. 
71. Kulicke W, Nottelmann H 1989. Structure and swelling of some synthetic, semisynthetic, 
and biopolymer hydrogels. Adv Chem Ser  223:15-44. 
72. Collins MN, Birkinshaw C 2008. Physical properties of crosslinked hyaluronic acid 
hydrogels. Journal of Materials Science: Materials in Medicine  19(11):3335-3343. 
73. Ramamurthi A, Vesely I 2002. Smooth muscle cell adhesion on crosslinked hyaluronan 
gels. Journal of biomedical materials research  60(1):195-205. 
74. Ibrahim S, Kang QK, Ramamurthi A 2010. The impact of hyaluronic acid oligomer 
content on physical, mechanical, and biologic properties of divinyl sulfone-crosslinked 
hyaluronic acid hydrogels. Journal of Biomedical Materials Research Part A  94(2):355-370. 
75. Ramamurthi A, Vesely I 2003. Ultraviolet light-induced modification of crosslinked 
hyaluronan gels. Journal of Biomedical Materials Research Part A  66(2):317-329. 
76. Lai JY 2014. Relationship between structure and cytocompatibility of divinyl sulfone 
cross-linked hyaluronic acid. Carbohydrate Polymers  101:203-212. 
77. Kolb HC, Finn MG, Sharpless KB 2001. Click chemistry: Diverse chemical function 
from a few good reactions. Angew Chem-Int Edit  40(11):2004-+. 
78. Moses JE, Moorhouse AD 2007. The growing applications of click chemistry. Chemical 
Society reviews  36(8):1249-1262. 
	   53 
79. Binder WH, Sachsenhofer R 2007. ‘Click’ Chemistry in Polymer and Materials Science. 
Macromolecular Rapid Communications  28(1):15-54. 
80. Kolb HC, Sharpless KB 2003. The growing impact of click chemistry on drug discovery. 
Drug Discov Today  8(24):1128-1137. 
81. Nandivada H, Jiang XW, Lahann J 2007. Click chemistry: Versatility and control in the 
hands of materials scientists. Adv Mater  19(17):2197-2208. 
82. van Dijk M, Rijkers DTS, Liskamp RMJ, van Nostrum CF, Hennink WE 2009. Synthesis 
and Applications of Biomedical and Pharmaceutical Polymers via Click Chemistry 
Methodologies. Bioconjugate Chem  20(11):2001-2016. 
83. Crescenzi V, Cornelio L, Di Meo C, Nardecchia S, Lamanna R 2007. Novel hydrogels 
via click chemistry: Synthesis and potential biomedical applications. Biomacromolecules  
8(6):1844-1850. 
84. Pahimanolis N, Vesterinen AH, Rich J, Seppala J 2010. Modification of dextran using 
click-chemistry approach in aqueous media. Carbohydr Polym  82(1):78-82. 
85. Chang PV, Prescher JA, Sletten EM, Baskin JM, Miller IA, Agard NJ, Lo A, Bertozzi CR 
2010. Copper-free click chemistry in living animals. Proc Natl Acad Sci U S A  107(5):1821-
1826. 
86. Posner T 1905. Information on unsaturated compounds II The addition of mercaptan to 
unsaturated hydrocarbon. Berichte Der Deutschen Chemischen Gesellschaft  38:646-657. 
87. Hoyle CE, Bowman CN 2010. Thiol–ene click chemistry. Angewandte Chemie 
International Edition  49(9):1540-1573. 
88. Kharasch M, MAY EM, MAYO FR 1938. The peroxide effect in the addition of reagents 
to unsaturated compounds. Xviii. The addition and substitution of bisulfite*. The Journal of 
Organic Chemistry  3(2):175-192. 
89. Lowe AB 2010. Thiol-ene “click” reactions and recent applications in polymer and 
materials synthesis. Polymer Chemistry  1(1):17-36. 
90. Hoyle CE, Lee TY, Roper T 2004. Thiol–enes: chemistry of the past with promise for the 
future. Journal of Polymer Science Part A: Polymer Chemistry  42(21):5301-5338. 
91. Hoyle CE, Lowe AB, Bowman CN 2010. Thiol-click chemistry: a multifaceted toolbox 
for small molecule and polymer synthesis. Chemical Society Reviews  39(4):1355-1387. 
	   54 
92. Roper TM, Guymon C, Jönsson E, Hoyle C 2004. Influence of the alkene structure on the 
mechanism and kinetics of thiol–alkene photopolymerizations with real-time infrared 
spectroscopy. Journal of Polymer Science Part A: Polymer Chemistry  42(24):6283-6298. 
93. Mergy J, Fournier A, Hachet E, Auzely-Velty R 2012. Modification of polysaccharides 
via thiol-ene chemistry: A versatile route to functional biomaterials. J Polym Sci Pol Chem  
50(19):4019-4028. 
94. Gramlich WM, Kim IL, Burdick JA 2013. Synthesis and orthogonal photopatterning of 
hyaluronic acid hydrogels with thiol-norbornene chemistry. Biomaterials  34(38):9803-9811. 
95. Shu XZ, Liu Y, Luo Y, Roberts MC, Prestwich GD 2002. Disulfide cross-linked 
hyaluronan hydrogels. Biomacromolecules  3(6):1304-1311. 
96. Vanderhooft JL, Mann BK, Prestwich GD 2007. Synthesis and characterization of novel 
thiol-reactive poly (ethylene glycol) cross-linkers for extracellular-matrix-mimetic biomaterials. 
Biomacromolecules  8(9):2883-2889. 
97. Shu XZ, Ahmad S, Liu Y, Prestwich GD 2006. Synthesis and evaluation of injectable, in 
situ crosslinkable synthetic extracellular matrices for tissue engineering. Journal of Biomedical 
Materials Research Part A  79(4):902-912. 
98. Peppas NA, Merrill EW 1976. Poly (vinyl alcohol) hydrogels: Reinforcement of 
radiation-crosslinked networks by crystallization. Journal of Polymer Science: Polymer 
Chemistry Edition  14(2):441-457. 
99. Sanabria-DeLong N, Crosby AJ, Tew GN 2008. Photo-cross-linked PLA-PEO-PLA 
hydrogels from self-assembled physical networks: mechanical properties and influence of 
assumed constitutive relationships. Biomacromolecules  9(10):2784-2791. 
100. Urayama K, Takigawa T, Masuda T 1993. POISSON RATIO OF POLY(VINYL 
ALCOHOL) GELS. Macromolecules  26(12):3092-3096. 
101. Horgan CO 2015. The remarkable Gent constitutive model for hyperelastic materials. 
International Journal of Non-Linear Mechanics  68:9-16. 
102. Li J, Suo Z, Vlassak JJ 2014. A model of ideal elastomeric gels for polyelectrolyte gels. 
Soft matter  10(15):2582-2590. 
	   55 
103. Mansur HS, Oréfice RL, Mansur AA 2004. Characterization of poly (vinyl alcohol)/poly 
(ethylene glycol) hydrogels and PVA-derived hybrids by small-angle X-ray scattering and FTIR 
spectroscopy. Polymer  45(21):7193-7202. 
104. Lin-Gibson S, Jones RL, Washburn NR, Horkay F 2005. Structure-property relationships 
of photopolymerizable poly (ethylene glycol) dimethacrylate hydrogels. Macromolecules  
38(7):2897-2902. 
105. Canal T, Peppas N. Proceed Intern Symp Control Rel Bioactiv Mater, 1988, pp 19-20. 
106. Canal T, Peppas NA 1989. Correlation between mesh size and equilibrium degree of 
swelling of polymeric networks. Journal of Biomedical Materials Research  23(10):1183-1193. 
107. De Gennes P-G. 1979. Scaling concepts in polymer physics. ed.: Cornell university press. 
108. Teraoka I. Polymer solutions: An introduction to physical properties 2002. ed.: Wiley-
Interscience. 
109. Liu R, Gao X, Oppermann W 2006. Dynamic light scattering studies on random cross-
linking of polystyrene in semi-dilute solution. Polymer  47(26):8488-8494. 
110. Seiffert S, Oppermann W 2008. Diffusion of linear macromolecules and spherical 
particles in semidilute polymer solutions and polymer networks. Polymer  49(19):4115-4126. 
111. Yu Y, Chau Y 2015. Formulation of In Situ Chemically Cross-Linked Hydrogel Depots 
for Protein Release: From the Blob Model Perspective. Biomacromolecules  16(1):56-65. 
112. Cruise GM, Scharp DS, Hubbell JA 1998. Characterization of permeability and network 
structure of interfacially photopolymerized poly(ethylene glycol) diacrylate hydrogels. 
Biomaterials  19(14):1287-1294. 
113. Ratner B 1989. Biomedical applications of synthetic polymers. Pergamon Press plc, 
Comprehensive Polymer Science  7:201-247. 
114. Okay O 2000. Macroporous copolymer networks. Progress in Polymer Science  
25(6):711-779. 
115. Feil H, Bae YH, Feijen J, Kim SW 1991. MOLECULAR SEPARATION BY 
THERMOSENSITIVE HYDROGEL MEMBRANES. Journal of Membrane Science  64(3):283-
294. 
116. Dai WS, Barbari TA 1999. Hydrogel membranes with mesh size asymmetry based on the 
gradient crosslinking of poly(vinyl alcohol). Journal of Membrane Science  156(1):67-79. 
	   56 
117. Hwang CM, Sant S, Masaeli M, Kachouie NN, Zamanian B, Lee SH, Khademhosseini A 
2010. Fabrication of three-dimensional porous cell-laden hydrogel for tissue engineering. 
Biofabrication  2(3). 
118. Nguyen KT, West JL 2002. Photopolymerizable hydrogels for tissue engineering 
applications. Biomaterials  23(22):4307-4314. 
119. Gehrke SH, Fisher JP, Palasis M, Lund ME 1997. Factors determining hydrogel 
permeability. Annals of the New York Academy of Sciences  831(1):179-184. 
120. Walter H. 2012. Partitioning In Aqueous Two–Phase System: Theory, Methods, Uses, 
And Applications To Biotechnology. ed.: Elsevier. 
121. Amidon GL, Lee PI, Topp EM. 1999. Transport processes in pharmaceutical systems. 
ed.: CRC Press. 
122. Sawhney AS, Jarrett P, Bassett M, Blizzard C. 2013. Drug delivery through hydrogel 
plugs. ed.: Google Patents. 
123. Masket S, Hovanesian JA, Levenson J, Tyson F, Flynn W, Endl M, Majmudar PA, Modi 
S, Chu R, Raizman MB, Lane SS, Kim T 2014. Hydrogel sealant versus sutures to prevent fluid 
egress after cataract surgery. Journal of Cataract and Refractive Surgery  40(12):2057-2066. 
124. Mozurkewich EL, Chilimigras JL, Berman DR, Perni UC, Romero VC, King VJ, Keeton 
KL 2011. Methods of induction of labour: a systematic review. Bmc Pregnancy and Childbirth  
11. 
125. Almomen A, Cho S, Yang C-H, Li Z, Jarboe EA, Peterson CM, Huh KM, Janat-Amsbury 
MM 2015. Thermosensitive Progesterone Hydrogel: A Safe and Effective New Formulation for 
Vaginal Application. Pharmaceutical Research  32(7):2266-2279. 
126. Ewert K, Powers B, Robertson S, Alfirevic Z 2006. Controlled-release misoprostol 
vaginal insert in parous women for labor induction: a randomized controlled trial. Obstetrics & 
Gynecology  108(5):1130-1137. 
127. Halliday JA, Robertson S 2008. Pilocarpine Buccal Insert. DRUGS AND THE 
PHARMACEUTICAL SCIENCES  183:75. 
128. Miller BS, Shukla AR 2010. Sterile Abscess Formation in Response to Two Separate 
Long-Acting Gonadotropin-Releasing Hormone Agonists, Supprelin LA (R) and Lupron Depot-
Ped (R). Endocrine Reviews  31(3). 
	   57 
129. Colombo P 1993. Swelling-controlled release in hydrogel matrices for oral route. 
Advanced Drug Delivery Reviews  11(1):37-57. 
130. Caló E, Khutoryanskiy VV 2015. Biomedical applications of hydrogels: a review of 
patents and commercial products. European Polymer Journal  65:252-267. 
131. Siepmann J, Siepmann F 2012. Modeling of diffusion controlled drug delivery. Journal of 
Controlled Release  161(2):351-362. 
132. Hill-West JL, Dunn RC, Hubbell JA 1995. Local release of fibrinolytic agents for 
adhesion prevention. Journal of Surgical Research  59(6):759-763. 
133. Anseth KS, Metters AT, Bryant SJ, Martens PJ, Elisseeff JH, Bowman CN 2002. In situ 
forming degradable networks and their application in tissue engineering and drug delivery. 
Journal of controlled release  78(1):199-209. 
134. Tyn MT, Gusek TW 1990. Prediction of diffusion coefficients of proteins. Biotechnology 
and bioengineering  35(4):327-338. 
135. White ML, Dorion GH 1961. Diffusion in a crosslinked acrylamide polymer gel. Journal 
of Polymer Science  55(162):731-740. 
136. Siepmann J, Podual K, Sriwongjanya M, Peppas N, Bodmeier R 1999. A new model 
describing the swelling and drug release kinetics from hydroxypropyl methylcellulose tablets. 
Journal of pharmaceutical sciences  88(1):65-72. 
137. Hoffman AS 2012. Hydrogels for biomedical applications. Advanced drug delivery 
reviews  64:18-23. 
138. Jeong B, Bae YH, Kim SW 2000. Drug release from biodegradable injectable 
thermosensitive hydrogel of PEG–PLGA–PEG triblock copolymers. Journal of controlled release  
63(1):155-163. 
139. Franssen O, Vandervennet L, Roders P, Hennink W 1999. Degradable dextran hydrogels: 
controlled release of a model protein from cylinders and microspheres. Journal of controlled 
release  60(2):211-221. 
140. Peppas NA, Khare AR 1993. Preparation, structure and diffusional behavior of hydrogels 
in controlled release. Advanced drug delivery reviews  11(1):1-35. 
	   58 




The diffusion of solutes in hydrogels is an important area of study that is directly relevant 
to a number of research fields, including drug delivery, tissue engineering, and separation 
processes. In drug delivery, understanding the diffusive properties of solutes within a hydrogel is 
crucial for designing controlled release devices that are able to provide the correct release rate 
and profile to be therapeutically effective.1,2  The diffusion of solutes in hydrogels is also critical 
in tissue engineering and in the development of artificial organs, where the survival of 
encapsulated cells requires the diffusion of oxygen, glucose, and nutrients while minimizing the 
diffusion of immunoglobulins and cytokines that might trigger an immune response.3-5  
Hydrogels are also used as membranes in many biological and biomedical applications, such as 
plasmapheresis, where the diffusion of solutes is critical in achieving accurate separations.6,7  In 
all of these applications, a fundamental understanding of the diffusion of solutes through 
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 Given how essential it is to control the release of solutes from a hydrogel, a number of 
theoretical models have been developed that attempt to relate the diffusion coefficient to the key 
parameters of a hydrogel.  The majority of these models compare the relationship between the 




=  f rs,  ϕ      (3.2)  
 
 where Dg is the diffusion coefficient within the hydrogel, D0, the diffusion coefficient of a drug 
in solution at infinite dilution, rs is the size of the drug that is being delivered, and ϕ is the 
polymer volume fraction of the hydrogel. Various models also include more specific parameters 
related to the hydrogel network, including the molecular weight between crosslinks, the 
correlation length, and the fiber radius of the polymer chains. 
In all of the models the normalized diffusion coefficient, Dg/D0, decreases as the radius of the 
solute increases, and as the polymer volume fraction decreases.8-10 
While all of the models share this same trend, the models differ in exactly how or why 
Dg/D0 changes as the radius of the solute changes or hydrogel network changes.  The models can 
be separated into three separate categories that each uses a different phenomenon to describe the 
hindered diffusion of solutes through hydrogels. Free volume theories suggest that the diffusion 
of solutes is restricted in hydrogels due to a reduction in free volume within the polymer space.  
On the other hand, obstruction models suggest that diffusion is restricted due to the polymer 
chains acting as physical obstructions that increase the length the drug has to travel.11  Lastly, 
hydrodynamic models suggest that the tight pores that the solutes must diffuse through increases 
the hydrodynamic drag on the molecule and slows the diffusion.   
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 The majority of these models have been around for over 20 years. The models were first 
reviewed by Muhr and Blanshard in 1981.12  Amsden then expanded upon this work in 1998 
where he reviewed the most recent work and tested the various models against literature data.11  
Since that time, very few models have been developed and the focus in literature has shifted to 
determining which models are best suited to use for a given hydrogel. This has proven to be 
difficult, as the large number of materials and synthesis methods available to form hydrogels has 
led to a wide range of properties and network structures.  
In both of the reviews mentioned earlier, the authors separate hydrogels into two 
distinctive groups depending on their structure.  The first group was classified as homogenous 
hydrogels and is made up of hydrogels whose chains have a high degree of mobility and exhibit 
a more random distribution within the network.  Examples of hydrogels that the authors 
classified as homogenous included poly(ethylene glycol) (PEG), poly(acrylamide), poly(vinyl 
alcohol) (PVA), dextran, and hydroxypropyl methycellulose. The second group, classified as 
heterogeneous hydrogels, involves hydrogels whose chains are often assumed to be completely 
immobile and exhibit a high degree of inter-polymer interactions such as calcium alginate and 
agarose hydrogels.13 One of the assumptions made in the reviews is that the chain mobility of the 
hydrogel determines which models are more suitable in predicting the diffusion coefficient. This 
is due to the fact that in many of the diffusion models, the gel structure is often assumed to have 
some idealized defined geometry such as a series of random impenetrable fibers, or tortuous 
cylindrical rods that connect the two surfaces.    
However, recent research has shown that not only do many hydrogels not fit neatly into 
these two categories, but also that many of the models have proven to be effective at modeling 
the diffusion of solutes in both homogeneous and heterogeneous hydrogels.  For example, Zhang 
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and Amsden have shown that for polymer solutions, the polymer chains can actually be 
considered immobile when the time frame of solute diffusion is considered, an assumption that is 
made into many of the obstruction models.14 Waters and Frank followed up on this work and 
showed that these obstruction models were in fact accurate in modeling the diffusion of solutes 
from PEG/poly(acrylic acid) hydrogels, a network that is believed to contain polymer chains 
with a high degree of mobility.15  Recent modeling work performed by Quesada-Pérez also 
explored how the stiffness of chains affected an obstruction model.  By using Monte Carlo 
simulations, they showed that the model was unaffected by chain stiffness and gave identical 
results for polymer chains that were rigid, semi-rigid, and even flexible.  They concluded that 
even though the model was developed around rigid fibers, the model is suitable for hydrogels 
with flexible polymer chains.16 
Despite this recent work, one area that has received little attention in the literature is how 
the models perform under conditions where the diffusion coefficient in hydrogels is projected to 
be very small, with values below 10-10 cm2/s.  These low values are achieved as the polymer 
volume fraction of the gel increases, or as the size of the solute increases. Under these 
conditions, it is hypothesized that the size of the solute approaches the average mesh size of the 
hydrogel, causing a dramatic reduction in the diffusion coefficient.  In this dissertation, this 
hypothesized reduction is referred to as the screening effect. Unfortunately, there are very few 
studies with hydrogels that display these screening effects.  Figure 3.1 shows the diffusion of 
bovine serum albumin (BSA) within various types of hydrogels that have been reported in 
literature.  Only one study, the release of BSA from dextran hydrogels, includes hydrogels with a 
polymer volume fraction above 0.15.  In all of the other studies, the diffusion was studied in 
hydrogels with polymer volume fractions less than 0.1, and resulted in diffusion coefficients that 
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were all higher than 6.0 x 10-10 cm2/s. The diffusion of IgG, an even larger solute, in hydrogels 




Figure 3.1. The diffusion coefficients of BSA in various hydrogels over a range of polymer volume 
fractions. (Ο) = polyacrylamide hydrogels17, (Δ) = agarose hydrogels18, ( ) = dextran hydrogels (u - 




There are a number of reasons for the limited amount of work seen in literature on solute 
diffusion in hydrogels with low diffusion coefficients.  In order to achieve this hypothesized 
screening effect, either the radius of the solute must be large, the polymer volume fraction must 
be high (which correlates with a smaller mesh size), or some combination of the two.  The larger 
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the solute size decreases, a larger polymer volume fraction is needed to observe the screening 
effect.  Evidence of this is seen in the release of solutes from dextran gels. The screening effects 
of IgG (rs = 5.35 nm21) were observed at polymer volume fractions as low as 0.17, while the 
screening effects in BSA (rs = 3.63 nm22) were seen at 0.20, and lysozyme (rs = 2.05 nm22) was 
as high as 0.29.19  For some small solutes, such as caffeine (rs = 0.52523), screening effects are 
not seen in hydrogels, even with polymer volume fractions as high as 0.48.23  In some cases, the 
solubility of the polymers,15 the polymer’s degree of functionalization,24 or the crosslinking 
method25,26 limits the ability to produce hydrogels with a polymer volume fraction that is high 
enough to observe the screening effect.  Another reason for the limited amount of work seen in 
literature is the difficulty in measuring diffusion coefficients at such low values in hydrogels.  
The small diffusion coefficient lowers the release rates from hydrogels, making measurements 
difficult as concentrations are often below the detection limit27 or take too long to build up to the 
detection limit within the time period studied.19,27  
Despite the limited amount of work in literature, the diffusion of solutes in hydrogels 
with low diffusion coefficients is an important area of study that has major implications in drug 
delivery and tissue engineering. The development of recombinant protein technology has 
introduced a number of large protein and peptide therapeutics that are used in the treatment of 
cancer, autoimmune diseases, and viral infections. There are a number of situations where long 
term, local delivery systems are needed to deliver these therapeutic proteins.  A number of 
researchers have examined the use of hydrogels for sustained delivery of therapeutics to the 
eye,28,29 in the treatment of chronic arthritic pain,30,31 and for delivering chemotherapeutics to 
tumors.32-34  In all of these applications achieving a low diffusion coefficient requires a hydrogel 
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with a low swelling degree. The large size of the therapeutics being delivered will begin to 
approach the mesh size of the hydrogel where the screening effect is hypothesized to occur.   
Developing models for hydrogels that accurately describe the diffusion in this region is 
important not only for making predictions, but also in developing an understanding of how the 
key parameters such as swelling degree, solute size, and crosslink density play a role in diffusion. 
Therefore, because of its importance in this dissertation and the literature, this chapter reviews a 
number of theories that describe the diffusion of solutes within hydrogels, specifically focusing 
on how the models predict the diffusion of large solutes in hydrogels with low swelling degrees.  
 
 
3.2  DIFFUSION MODELS 
  In this section three main categories of diffusion models are reviewed: free volume 
theories, hydrodynamic models, and obstruction models.  While these theories have been 
reviewed extensively before, the focus in those reviews was on hydrogels with a lower polymer 
volume fraction and diffusion coefficients greater than 10-10 cm2/s.  Therefore, this section 
focuses on diffusion of large solutes at low swelling degrees where the screening effect is 
hypothesized to occur.  The models are displayed with data from literature that comes from a 
study by Hennink et al. on the diffusion of BSA in dextran hydrogels.19 This data set was used 
because: 
 
1)  It provided the largest range of polymer volume fractions 
2) It is one of the only papers in literature with values of D < 10-10 cm2/s 
3)  Dextran hydrogels (and similar polysaccharide hydrogels) are used throughout this 
dissertation and the physical properties of the polymer are well known. 
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The goal of this section was not to determine how accurate each of the models are in fitting the 
selected data but rather to examine how these models predict diffusion coefficients at low 






3.2.1 Free Volume Theory 
	  
 The free volume theory used to describe the diffusion in hydrogels is based on the theory 
developed by Cohen and Turnbull to explain the diffusion of molecules in solution.  The theory 
assumes that solutes diffuse by jumping into the voids, or free volume, within the liquid.35 These 
voids are formed at a molecular level due to packing irregularities, excluded volume effects, and 
the movement of neighboring liquid molecules due to Brownian motion. The diffusion can only 
occur if the solute has enough energy to overcome the translational barrier required to jump to 
the new void.  The diffusion also hinges on the probability that there is a space large enough for 
the solute to jump, and the distance needed to jump to this new space.  This can be expressed 
mathematically by the equation: 
D0=  V λ exp - γv
*
vf
    (3.3)  
 
where V is the average thermal velocity, λ is the jump length that is roughly equivalent to the 
diameter of the solute, v* is the required amount of free volume required for the solute to jump 
into a new hole, defined as v* = λπrs2, γ is a geometric correction factor that takes into account 
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the overlap of free volume for multiple solvent molecules, and vf is the average free volume that 
is available in the liquid.11  
 This model was then applied by Yasuda et al. to describe the diffusion of solutes within a 
hydrogel.36 The free volume in the gel is the sum of the free volumes of both the polymer itself, 
and the water within the polymer, given as: 
 
vf  = 1-ϕ  vf,w + φvf,p    (3.4)  
 
in which ϕ is the volume fraction of polymer in the gel (ϕ = 1/Q), vf,w is the free volume per 
molecule of the water, and vf,p is the free volume per molecule of polymer. One of the 
assumptions in developing the model was that the free volume per molecule of polymer was very 
small, leading to: 
 
vf  = 1-ϕ  vf,w     (3.5)  
 
In other words, the diffusion was assumed to occur only within the water-filled regions of the 
hydrogel.  The model also has to take into account the fact that a jump can only be made if there 
is an opening in the polymer network that is large enough for the solute to pass through. When 









   (3.6)  
 
wherein B = γ λ, and a* is the effective cross-sectional area of the solute molecule.  P0 is the 
sieving probability and represents the chances of finding an opening within the polymer chains. 
Essentially, P0 is the way in which the model takes into consideration the screening effect. The 
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sieving probability can range in value from zero to one. When the solute is much smaller than the 
openings in the polymer chains P0 can be taken as unity. Yasuda et al. mentions that, on the other 
hand, in certain cases large molecules might be rejected from the network because there are no 
appropriate sized holes within the network, meaning P0 = 0. In the original paper,36 this sieving 
function is described as: 





where P0(a) is the probability of a solute passing through a given hole in the mesh, and f(a) is the 
hole area distribution function. In other words, the probability of a solute of size a* diffusing into 
the hydrogel is based on how many holes are available in the mesh that are large enough for it to 
pass through. The difficulty in this approach is determining the hole area distribution function, 
f(a), for a given hydrogel. As the polymer volume fraction increases, the average hole size will 
decrease and there will be a smaller number of holes that are large enough to diffuse through. 
Yasuda presented a number of simple distribution functions that might accurately describe f(a) 
for a hydrogel, yet none of them were based on data.   
In Figure 3.2 the Yasuda free volume theory is plotted against data from literature in 
which the diffusion coefficient of BSA was released from dextran hydrogels.19 The dashed line 
represents Equation 3.6 when P0 is equal to one and no sieving effects are taken into 
consideration. Under these conditions the model does an excellent job of correlating the data at 
high swelling degrees.  This is due to the fact that the constant, Ba*/vf,w, was set at a value of 
26.2 that has been shown by Amsden to give the best fit to the data at polymer volume fractions 
below 0.2.11  However, as ϕ approaches 0.2, the data begins to deviate from the model’s 
predictions. The difficulty in using the sieving probability function developed by Yasuda et al. is 
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in determining how to represent f(a). While many simple functions are available it is difficult to 




Figure 2.  The application of the Yasuda free volume theory to literature data on the diffusion of BSA in 
dextran hydrogels.  The dashed line represents the condition in which P0 =1 and  




 A number of variations of the Yasuda free volume theory have been developed.  The 
most commonly used variation is the model developed by Reinhart and Peppas, which is given as: 
Dg
D0




*  exp −  k2rs2
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in which k1 is a fitting parameter that depend on the polymer-solvent system being used, k2 = γ λ 
π/vf,w, rs is the radius of the solute, Mc is the number average molecular weight between the 
polymer crosslinks, Mc
* is the critical molecular weight between crosslinks that occurs at the 
point where the solute is no longer allowed to pass through, and Mn is the number average 
molecular weight of the uncrosslinked polymer.37 
Similar to Yasuda’s original model, the sieving effect is determined by the probability of 
finding holes within the hydrogel mesh that are large enough for a solute to pass through.  This 






*      (3.8)  
 
   
Despite using this model to describe the diffusion within poly(vinyl alcohol)/poly(acrylic acid) 
interpenetrating networks,38 they have also suggested that the sieving term might be more 







                 (3.9)  
 
Unlike Yasuda et al., Reinhart and Peppas relate this probability to physical parameters 
of the hydrogel.  They assume that the cross sectional area of the holes within a hydrogel is 
proportional to the mesh size of an ideal tetrafunctional mesh.37  This area is directly related to 
the number average molecular weight between the polymer crosslinks, Mc, a parameter that can 
be determined from either swelling or mechanical testing. In Equation 3.8, the value of Mc is 
compared to both Mc
* and Mn.  Mn is the number average molecular weight of the uncrosslinked 
polymer and represents the largest mesh size that is possible for a given hydrogel. When Mc = 
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Mn, the sieving function should be equal to 1, as the mesh size of the hydrogel is large and no 
screening effects should be seen.    Mc
* is the critical molecular weight that represents the point at 
which the mesh size is so small that solutes are unable to pass through.  When Mc ≤ Mc
*, the 







Figure 3.3. A schematic representing the range of sizes for Mc, the number average molecular weight 
between crosslinks in a hydrogel that are used to calculate the sieving term in Equations 3.8 and 3.9.  Mn 
is the number average molecular weight of the uncrosslinked polymer and represents the largest mesh size 
that is possible for a given hydrogel.   Mc
* is the critical molecular weight at which point the mesh size is 
so small that solutes are unable to pass through.   
 
 
The Reinhart and Peppas model using Equation 3.7 is shown in Figure 3.4. The constant 
k2 was at 0.017, a value that Amsden determined fit the data best in his review.11  
In that review, Amsden did not use the sieving terms, so the fitting parameter k1 was set at 2.0.  
Varying k1 shifts the data set up or down, and at a k1= 2.0 the normalized diffusion coefficient 
was equal to zero at a polymer volume fraction of zero. In Figure 3.4, Mc
* was varied from 800-
Mc !Mc ! = Mc
*
!Mc ! =Mn!
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2000 g/mol. In each of the curves, at the point when  Mc
* reaches the Mc of the gel, the diffusion 
coefficient is predicted to be to zero.  This is due to the fact that, as Mc drops below Mc
*
, the 
value of Mc−  Mc
*
𝑀n−  Mc
*  becomes negative.  In Equation 3.7, this causes the normalized diffusion 
coefficient to also become negative, a limitation of the model.  The assumption was made that at 
this point the sieving term effectively goes to zero and that solutes are no longer able to diffuse 
into the hydrogel.   
 
 
Figure 3.4.  The application of the Reinhart Peppas model to literature data on the diffusion of BSA in 
dextran hydrogels. The value of  Mc was calculated based on data from ref
19 
 k1 =2, k2 =0.017, Mn =16,700, (        ) Mc
*  = 2000,   (      )  Mc
*  = 1400,   (      )   Mc
















Polymer Volume Fraction (ϕ) 
	   72 
Figure 3.4 shows that the Reinhart and Peppas model is heavily reliant on an accurate 
value of  Mc
*
.  Because of the way the model is set up, as soon as Mc drops below Mc
* the 
diffusion coefficient instantly goes to zero. The value of  Mc
*
 will depend on both the hydrogel 
and the solute being studied, and must be determined experimentally before making any 
predictions. The theory also makes the large assumption that the holes within the mesh of the 
hydrogel are all uniform and have a single relevant length scale.  In reality, there will be a 
distribution of hole sizes and a distribution of values for Mc.  Because of this distribution, sharp 
drops like the one seen in Figure 3.4 are unrealistic. 
The Reinhart and Peppas model using Equation 3.9 is shown in Figure 3.5. By using 
Equation 3.13 the sharp drop-off that is seen in Figure 3.4 is eliminated.  This is due to the fact 
that, as Mc drops below Mc
*
, the value of Mc−  Mc
*
𝑀n−  Mc
*  becomes negative.  Unlike in Equation 3.7, 
in Equation 3.9, this negative term is squared which allows the normalized diffusion coefficient 
to remain positive.  This is a limitation in the model, as the sieving term actually increases once 
the value of Mc drops below Mc
*.  In reality, when Mc drops below Mc
* the theory predicts that 
the sieving term should decrease, yet this is not reflected in the model. 
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Figures 5.  The application of the Reinhart Peppas model (using Equation 3.13 to describe the sieving 
effect) to literature data on the diffusion of BSA in dextran hydrogels.  k1 = 3, k2 =0.017,  
Mn =16,700,  (      )  Mc
*  = 2000,   (      )  Mc
*  = 1400,  (      )   Mc
* = 800. 
  
 
A similar model based on the free volume theory was modified by Lustig and Peppas in which 
the screening effect is again determined by the probability of finding mesh sizes within the 
hydrogel that are large enough for a solute to pass through. The sieving factor was changed to 
take into account the correlation length between crosslinks, ξ.40 This model expresses the sieving 
term as: 
 p(rs) = 1−
r
ξ     (3.12)  
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to describe the sieving term in a number of papers.41,42 The correlation length defines the space 
that is available between network chains in a hydrogel network, and can be defined as the 
distance between two adjacent crosslinks. In Equations 3.12 and 3.13, r represents the size of the 
solute and is defined as the diameter of an equivalent sphere that represents the solute.  The 
equations differ in that Equation 3.12 uses the ratio of the radii to calculate the probability, 
whereas Equation 3.13 uses the ratio of the areas.  The authors concluded that, as Figure 3.6 





Figure 3.6. A schematic showing the diffusion of two different solutes through a crosslinked hydrogel 
network.  The red circle represents the average mesh of the hydrogel network that the solutes must pass 
through.  While the two solutes have the same cross-sectional area, the different shapes and values of r 
make it more probable for solute 1 to pass through the hydrogel mesh. Adapted from ref 43 
 
 
 The Lustig and Peppas model using Equations 3.12 and 3.13 are shown in Figure 3.7.  As 
expected, both models show a dramatic reduction in the diffusion coefficient as soon as the 
diameter of the solute approaches the mesh size. For the given conditions, the two models are 
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very similar through the entire range of the polymer volume fractions, with Equation 3.12 
predicting slightly lower values until the diffusion coefficient begins to drop sharply.  Equations 
3.12 and 3.13 follow the same trend of the Reinhart and Peppas model that is seen in Figure 3.4.  
This was expected, as the model has the same function and only differs in the parameters that are 
used to describe the hydrogel network. The model also shares the same assumption as the 





Figure 3.7.  The application of the Lustig and Peppas model to literature data on the diffusion of BSA in 
dextran hydrogels. ξ is the correlation length of a hydrogel and is calculated according to ref 44.  
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One criticism of these free volume theories is that they rely too much on undefined 
structural parameters.  While they can be accurately fitted to data, these undefined parameters 
make it very difficult to make predictions a priori when only hydrogel characteristics are known. 
Developing a better understanding of these parameters and the ranges in which they are suitable 
are critical in developing accurate models, especially at high polymer volume fractions where the 







3.2.2 Hydrodynamic Theory 
 
 Hydrodynamic theories are based on the idea that as a solute moves through a gel, it will 
experience frictional drag from both the solvent and the polymer chains within the hydrogel.  
The theories were developed from the Stokes-Einstein equation, which describes the diffusion of 
a hard spherical solute through a continuum of much smaller solvent molecules as: 
D = kBTf  =
kBT
6πµrs
     (3.11)  
 
where kB is Boltzmann’s constant, T is the temperature in Kelvin, f is the friction coefficient of 
the solute, and µ is the solvent viscosity.45  
In a hydrogel, the polymer chains are modeled as fixed centers of hydrodynamic 
resistance that slow down the solvent molecules nearest to the polymer chains and increase the 
frictional drag on the solute moving through the hydrogel11. Cukier was one of the first to use 
this thinking in describing the diffusion of solutes through a hydrogel.  He modeled the diffusion 
of spherical solutes through a solution made up of rod-like polymers and a solution made up of 
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=  exp −kcrsϕ0.75      (3.12) 
 
wherein kc is an undefined proportionality constant. The diffusion coefficient within the hydrogel 
decreases exponentially as rs and φ increase, similar to the free volume theory models.  Unlike 
the free volume theory models, there is no sieving factor. While there have been a number of 
diffusion models that have been developed based on hydrodynamic theories, it was demonstrated 
that a majority of them are mathematically equivalent.47  Therefore, we have chosen to focus on 
the Cukier model, as it is one of the most widely cited models in literature for describing the 
diffusion of solutes in hydrogels.11,48-51 
Equation 3.12 has shown to correlate well with data at moderate swelling degrees (ϕ 
<0.15)11, despite the fact that it does not contain any sort of sieving factor. For a given solute 
molecule, any reduction in Dg that is seen is the result of an increase in polymer volume fraction.  
Therefore, significant decreases in the diffusion coefficient due to screening effects are not 
expected based on the model. This is evident in Figure 3.8, which displays the Cukier model to 
the release of BSA from dextran hydrogels.  Changes in kc shift the curve downwards, but do not 
cause the model to predict any noticeable screening effects at high polymer volume fractions. 
Similar to the free volume theory models, the model hinges on an undefined parameter.  Unlike 
the free volume theories, kc is a parameter that is based on solvent-polymer interactions and has 
been shown to be consistent in cases where multiple solutes are studied for a given polymer-








Figure 8.  The application of the Cukier model to literature data on the diffusion of BSA in dextran 
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3.2.2 Obstruction Theory 
A number of models have been developed based on the obstruction theory. This theory 
suggests that the polymer chains of a hydrogel act as a barrier that obstructs the diffusion of 
solutes within the gel and increase the path length that these solutes must travel.  Mackie and 
Meares developed one of the earliest models in which they used a lattice model to express the 







     (3.13)   
 
The model is based on several assumptions including the assumption that the solute molecule is 
equal in size to the polymer segments and that the diffusion can occur only in the spaces that are 
unoccupied by polymer chains.  The model is rather simple, only including the volume fraction 
of polymer in the gel and not including any other properties of the hydrogel or the size of the 
solute. Relative to the other models described in this chapter, Equation 3.13 (shown in Figure 
3.10a) predicts a much higher diffusion coefficient and the normalized diffusion coefficient 
displays very little curvature. 
 Another model based on the obstruction theory was developed by Ogston and assumes 
that the diffusion of solutes occurs through hydrogels that are modeled as a network of straight 
cylindrical fibers (Figure 3.9).53   
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Figure 3.9.  Schematic of the random cylindrical fibers that are used to describe the diffusion of solutes 
through hydrogels in the Ogston model54. 
 
 
These fibers have a given radius, rf, and the diffusion hinges on the probability that a molecule 
with a certain radius can find a space between the fibers large enough to diffuse through. The 




=  exp −
!!!!!
!!
𝜙     (3.14) 
 
The models based on the obstruction theory assume that the polymer chains are straight, 
rigid, and motionless.  Because of these assumptions, the models are mostly used when 
attempting to describe the diffusion of solutes through gels with a very rigid network that has 
well defined pores. Initially it would seem that applying the same models to gels in which the 
polymers are semi-flexible or flexible coils would lead to large errors.  However, as mentioned 
early, when compared to some of the available data, an obstruction-scaling model was shown to 
fit quite well with the diffusion of solutes in flexible hydrogels such as dextran and poly(ethylene 
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oxide),55 and recent modeling showed that the model was unaffected by chain stiffness and gave 
identical results for polymer chains that were rigid, semi-rigid, and even flexible.   
The sieving effect of these obstruction models is directly built in due to the theory and so 
there are no additional terms that need to be added. However, as can be seen in Figure 3.10, the 
obstruction models like the one developed by Mackie and Meares and Ogston do not always 





Figures 3.10a and 3.10b.  The application of the Mackie and Meares model (A) and the Ogston model 
(B) to literature data on the diffusion of BSA in dextran hydrogels. (B) rs =3.63nm,  




 Another obstruction model was developed by Amsden and is based on the Ogston model. 
Similar to the Ogston model, the diffusion is predicted based on the probability of a solute 
finding an opening between polymer chains in the hydrogel network.  However, in the Amsden 
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chains instead of using rigid cylindrical fibers.15 When this is taken into consideration, the 








    (3.15)  
 
where ξ represents the average mesh size within the hydrogel based on the De Gennes’ scaling 
theory, or blob model.  The model can be seen in Figure 3.11, and shows that decreasing the 
fiber radius reduces the curvature of the line.  Similar to the Ogston model, at large fiber radii the 
model predicts higher diffusion coefficients when compared with lower fiber radii.  
 
 
Figure 3.11 The application of the Amsden model  to literature data on the diffusion of BSA in dextran 
hydrogels. rs =3.63nm,  (       ) rf = 1,   (     ) rf = 3, (      ) rf = 5.  The rf of dextran in literature ranges from 
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3.3  CONCLUSIONS  
The goal of this chapter was to review the current state of art on the diffusion of large 
solutes in hydrogels with a focus on low swelling degrees where the screening effect is expected 
to occur. While the models use different approaches for modeling the diffusion of solutes 
through hydrogels, they all depend primarily on water content and solute size, which leads to 
similar predictions for hydrogels with high water contents. Where the models differ, however, is 
at these low swelling degrees. 
A number of free volume theories were reviewed in this chapter. A number of these, such 
as the Lustig and Peppas model and the Reinhart and Peppas model, include a sieving factor that 
under certain circumstances can cause a dramatic drop in the diffusion coefficient.  In these 
models the predictions are highly dependent on the accuracy of calculated parameters such as 
Mc, Mc
*, and ξ that are derived from idealized theory.  These models also rely heavily on 
undefined fitting parameters that need to be defined in order to be predictive.   
The hydrodynamic theory of Cukier was also reviewed this chapter. Unlike the free 
volume theories, the model does not contain any parameters that can account for possible 
screening effects and reductions in Dg are based only on increases in the polymer volume 
fraction of the hydrogel.  The model does contain a parameter that is based on solvent-polymer 
interactions, however it has been shown to be physically consistent in cases in multiple polymer-
solvent systems. 
A few obstruction theories were reviewed in this chapter including the model developed 
by Mackie and Meares and the model developed by Ogston and Amsden.  These models are 
based on the idea that polymer chains in the hydrogel network act as obstructions and increase 
the solute diffusion path length.  Models like the one developed by Mackie and Meares only take 
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into account the volume fraction of polymer in the gel. It does not include any other properties of 
the hydrogel or the size of the solute, and is therefore quite limited in its usefulness for predicting 
the diffusion of solutes in gels. The Ogston and Amsden models take into account the radius of 
the solute and the radius of the polymer chains, which are modeled as either long straight fibers 
or flexible chains. The models were shown to be highly dependent on the radius of the fibers, 
and exhibited the most noticeable declines in the diffusion coefficient at high swelling degrees.  
While this is the opposite of the trend than what would be expected from a hypothesized 
screening effect, the models have been shown to be useful in predicting the diffusion of solutes 
in hydrogels with higher swelling degrees ((ϕ <0.15).15,58 
Overall, the results show that models based on the free volume theory are the only ones 
that contain a specific parameter (the sieving factor) that can cause a dramatic drop in the 
predicted diffusion coefficient.  Despite its limitations, the free volume theory is used in this 
dissertation to predict the diffusion of various solutes through hydrogels due to the fact that they 
provide a number of variable sieving terms that can be used to describe possible screening 
effects. This may be one of the reasons why free volume models are widely used in drug delivery.  
However, the results also highlight the need for additional data in order to rigorously test the 
models and any undefined parameters and see how they perform under a wide range of hydrogels 
and solutes.  All of the models in this chapter were reviewed using a single hydrogel/solute data 
set. Unfortunately, accurately measuring the diffusion coefficients at such low values becomes 
increasingly difficult and time consuming, which has led to a limited amount of data available in 
the literature. With the rise in popularity and usage of therapeutic proteins, obtaining more data 
on the diffusion of these large molecules in hydrogels and how it is impacted by the screening 
effect is critical in developing successful drug delivery devices. 
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The diffusion coefficients of solutes within hydrogels is a central theme throughout this 
dissertation, especially in the region where the size of the solute approaches the mesh size of the 
hydrogel and the screening effect is hypothesized to occur. One of the goals of Chapter 5 is to 
obtain long-term delivery from a hydrogel delivery vehicle.  In order for this to be achieved a 
very low diffusion coefficient is needed.  While this is normally achieved by increasing the 
polymer volume fraction of the hydrogel, there are certain situations where this is either not 
possible or simply undesired due to unwanted side reactions or reductions in biocompatibility.  If 
the screening effect does exist, it would provide a useful way to significantly lower the diffusion 
coefficient while maintaining higher swelling degrees. Additionally, one of the hypotheses of 
Chapter 7 is that the hydrogel synthesis method and resulting network structure could impact the 
diffusion of solutes through the network and under certain conditions cause a screening effect. 
Understanding the diffusion coefficients of solutes within hydrogels and the factors that 
determine when the screening effect is an important area of study that will be discussed 
throughout this dissertation. 
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CHAPTER 4: HIGH EFFICIENCY LOADING OF THERAPEUTIC PROTEINS  
INTO HYDROGEL DELIVERY VEHICLES USING THERMODYNAMICS  
OF AQUEOUS TWO-PHASE POLYMER SYSTEMS 
 
4.1  ABSTRACT 
A versatile and effective method for loading therapeutic proteins and antibodies into 
crosslinked PEG and dextran hydrogels is developed using the thermodynamic principles of 
aqueous two-phase extraction (ATPE) to overcome size exclusion. The partitioning of the model 
protein ovalbumin in a PEG/dextran system corresponded with ATPE heuristics, and the effects 
of salt and pH matched the data trends found in literature.  ATPE heuristics correctly predicted 
the observed trends using a PEG-salt system, and the addition of 0.13 M phosphate caused the 
partition coefficient to double compared to buffer alone. ATPE thermodynamics could even 
overcome size exclusion of proteins as large as antibodies, thus demonstrating the potential of 
the method to load monoclonal antibodies into pre-formed gels. This was demonstrated by 
loading IgG into both PEG and dextran hydrogels by adding a polymer into the solution along 
with the appropriate salt.  Partition coefficients as high as 18 were achieved in a dextran 
hydrogel with the addition of only 6% PEG. These results demonstrate the versatility of a 
method using FDA-GRAS additives to overcome size exclusion of proteins, even as large as 
monoclonal antibodies, into many types of hydrogels, thus opening the door to new delivery 
strategies for therapeutic proteins using hydrogels. 
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4.2  INTRODUCTION 
The release of a therapeutic dose of a drug from a drug delivery system (DDS) over an 
extended period of time is an important topic in drug delivery. The use of hydrogels as a rate-
controlling barrier in such a DDS is a common approach.  Because of their hydrophilic nature, 
they are particularly compatible with protein therapeutics. There are few protein therapeutics that 
have as great a demand and as wide range of use as monoclonal antibodies (mAbs).  Because 
mAbs have such high molecular weights (150 kDa), post-loading into monolithic hydrogels or 
microgels may be impossible due to steric size exclusion of the mAbs from the hydrogel mesh. 
We have previously shown that the thermodynamics of aqueous two-phase polymer systems can 
be used to overcome steric exclusion for proteins on the order of 50,000 Da in dextran gels by 
adding PEG and salts to the loading solution.1-3 This chapter investigates the hypothesis that the 
thermodynamic principles of this method can be generalized to any type of hydrogel and that it 
can work even for proteins as large as mAbs.  It also sets out to prove the versatility of the 
systems and the ability to quickly adapt the systems and theories already developed in literature. 
In the past 25 years the discovery and use of monoclonal antibodies (mAbs) has 
significantly changed the pharmaceutical industry and has increased the need for effective 
methods to incorporate them into drug delivery systems. In 2009 monoclonal antibodies reached 
38 billion dollars in total sales which accounted for almost 40 percent of all biopharmaceutical 
sales worldwide4. In 2009 alone there were 240 mAbs in clinical trials5, and seven new 
monoclonal antibodies were approved to come to market for the first time in the United States 
and Europe.4   Since then, the sale of monoclonal antibodies has shown major growth every year, 
and in 2013 the total global sales of mAbs was nearly 75 billion dollars.6-8 With the surge in 
sales of monoclonal antibodies comes the increased need to effectively and safely deliver them in 
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correct doses to target areas of the body.  Because of their large size and complex structure, 
monoclonal antibodies can often be challenging to incorporate into a drug delivery device.9 
Hydrogels have many suitable properties that would make them a very successful drug delivery 
device if a high concentration of antibodies could be achieved within a hydrogel.10  
Hydrogels are hydrophilic polymer networks that can be designed to exhibit a wide range 
of permeabilities.11  As a result, hydrogels have long been used as drug delivery vehicles for 
controlling and extending the release of therapeutic proteins.   There are many ways to release 
proteins from hydrogels: release due to polymer degradation and swelling, release due to 
hydrogel responses to stimuli such as pH or temperature, and even the hydrolytic or enzymatic 
cleavage of proteins that are either covalently or non-covalently attached.12-14   In drug delivery 
systems, release that occurs primarily through diffusion is one of the most widely used and 
studied release mechanisms.15  In most of these systems the protein is either placed in a hydrogel 
reservoir or loaded evenly throughout a monolithic hydrogel. Monolithic hydrogels, which is the 
approach followed in this chapter, can be loaded in in two ways: by encapsulating the drug 
within the gel during formation, or by synthesizing the gel and then absorbing the drug by 
equilibrating it with a drug solution. The first method is useful for loading a high concentration 
of drug into a hydrogel, yet is generally limited to physically gelling polymers because of the 
possible chemical reactions that can take place between the drug and the hydrogel precursors as 
well as any of the reagents that are used during synthesis. Furthermore, any impurities that might 
accumulate in the hydrogel network during synthesis due to incomplete reaction or side reactions 
will be difficult to leach away without also removing the drug itself.  Loading a gel by soaking it 
in a drug solution eliminates these two obstacles, yet at the same time it introduces new 
difficulties.  Depending on the dimensions of the device and the diffusion rate of the protein, 
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post-loading a gel can be significantly limited by the time it takes for diffusion into the gel. Even 
more significantly, large molecules may be partially excluded based on the entropic size 
exclusion phenomenon and some large molecules, such as antibodies, might even be completely 
excluded from the hydrogel network. 
Overcoming these difficulties is crucial to achieving an effective delivery device with 
high loading and protein that is still functional upon release.  While a lot of research has been 
done to decrease the problems associated with protein encapsulation,16-18 our group described a 
method to overcome the exclusion constraint that plagues most post-loading methods.  In a series 
of papers, it was demonstrated that the protein partitioning in hydrogels closely follows the 
aqueous two-phase extraction (ATPE) heuristics. ATPE is a well-developed technique that uses 
the immiscibility of two aqueous polymer phases to purify proteins.  Proteins selectively 
partition into one of the two polymer phases due to the additional thermodynamic contributions 
that the protein experiences from the polymers in solution. The partitioning is measured using 
the partition coefficient, K, which is defined as the concentration of solute inside the gel divided 




         (4.1) 
The partitioning can be controlled by a number of factors including polymer type and molecular 
weight, salt type and concentration, and pH.19  The same thermodynamics that controls 
partitioning when two polymers are in solution also apply when of the phases is crosslinked to 
form a hydrogel, an advantage that can be manipulated when loading large molecules. Using the 
thermodynamic principles of ATPE, proteins such as ovalbumin, bovine serum albumin (BSA), 
and α-amylase were loaded into hydrogels at significantly higher concentrations when compared 
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with normal equilibration techniques.1-3 Using these loading systems, partition coefficients as 
high as 80 and loadings as high as 450 mg protein per gram of polymer were reported while 
maintaining bioactivity.2 The concept was further exploited to manufacture protein-loaded 
dextran microspheres by using an aqueous two-phase system by Hennink.20 In his initial paper, a 
water-in-water emulsion was prepared with PEG and methacrylated dextran and when an 
initiator was added, dextran microspheres were formed. In later papers, proteins such as IgG 
were also added to the solution, and the use of ATPE principles were exploited to improve the 
partitioning of the protein within the microspheres during gelation.21,22  
 One of the goals of the previous work in the literature was trying to achieve the highest 
possible partition coefficient however, there are two aspects that control the loading of a solute 
into a hydrogel: the partition coefficient and the swelling degree. The total amount of solute that 




=  QKx      (4.2)  
Where Ms is the total mass of solute absorbed by the gel; Mp is the mass of polymer in the gel; Q 
is the gel swelling degree (mass of loaded hydrated mass/mass of dry, unloaded gel); K is the 
partition coefficient of the solute; and x is the mass fraction of solute in the loading solution. 
Equation 4.2 shows that in order to maximize the loading a system should be chosen that 
maximizes both the partitioning and the swelling degree. While a lot of work has focused on how 
the partitioning is affected by the loading solution, very little has been done to explore how the 
loading conditions affect the swelling degree.  The swelling is hypothesized to be indicated by 
the slope of the tie lines of the ternary phase diagram for the given aqueous two-phase system 
(see Figure 4.1).19 In almost every aqueous PEG-dextran systems, the tie lines indicate that the 
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PEG phase will contain a greater percentage of water compared with the dextran phase.  
Therefore, a PEG hydrogel in aqueous dextran is hypothesized to swell much more than a 
dextran gel in aqueous PEG.  If partitioning values are similar, a higher drug loading could 
actually be achieved with a PEG hydrogel if the swelling degree is in fact higher, yet the 
partitioning and swelling of PEG hydrogels in these ATPE loading systems has never been 
investigated.   
 
Figure 4.1 Tertiary phase diagram of a representative PEG-dextran two-phase system.19  A solution 
containing 85% water, 10% dextran, and 5% PEG (Point B) will split into two distinct phases. The 
compositions of these phases are determined by the tie lines (dashed lines).  One phase (Point C) will be 
predominantly PEG, while the other phase (Point D) will be predominantly dextran. 
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The focus of this chapter is on two hypotheses.  The first is that the aqueous two-phase 
driven gel loading phenomenon should be generally applicable to any hydrogel. While there is 
quite a large amount of research that has been done on ATPE using linear polymers in solution, 
in all of the studies on using these principles for drug loading, dextran gel has been used.1-3  If 
alternative systems using hydrogels other than dextran can be shown to follow the ATPE 
heuristics found in literature it would greatly expand the material options for drug delivery.  It 
would allow selection of loading systems and drugs that have been successfully demonstrated in 
literature and quickly extend them to hydrogel drug delivery devices. Systems could be chosen 
that maximize both K and Q and have a polymer that is best suited for a given application in 
terms of biocompatibility, degradability, etc.  The second hypothesis is that the systems that are 
studied in this first section of the chapter can be used to load molecules as large as mAbs into 
hydrogels. While size exclusion can be overcome with ATPE principles, it would seem 
reasonable that at some size this will no longer be possible. And although the literature has 
shown that large molecules such as BSA and ovalbumin can partition into hydrogels, antibodies 
have an even larger hydrodynamic radius (5.3m vs. 3.55 and 2.78nm).23-25  Given the increasing 
demand for monoclonal antibodies and efficient ways to deliver them, if ATP systems are shown 
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4.3  MATERIALS AND METHODS 
 
4.3.1 Hydrogel Synthesis 
Poly(ethylene glycol) diacrylate (PEGDA) hydrogels were synthesized by mixing an 
aqueous solution of 10 w/w% PEGDA polymer 700 MW (Sigma-Aldrich, St. Louis, MO) with 
0.3% wt/wt of the initiator Irgacure 2959 (Ciba, Tarrytown, NY).26  The solution was then stirred 
for 15 minutes and loaded into silicon rubber molds that were 2 mm thick and had precut holes 5 
mm in diameter.  These molds were clamped between two thin glass plates (1 mm thick) and 
irradiated in a Spectronics Spectrolinker XL-1000 (Westbury, NY) at 312 nm for 10 minutes at 
an intensity of 3 mW cm-2.  The gels kept in the molds at room temperature for 24 hours before 
being removed and placed into an excess of D.I. water. The gels were leached in D.I. water 
multiple times a day for three days to remove unreacted monomer and initiator and to allow the 
gels to swell to equilibrium. 
Dextran hydrogels were synthesized by mixing 10 w/w% dextran polymer (40k MW, 
Amersham Bioscience, Uppsala, Sweden) with the crosslinker divinyl sulfone (Sigma Aldrich, St. 
Louis, MO) in an aqueous solution of 0.02 M NaOH 3.  The solution was vigorously stirred and 
then quickly loaded into the molds described previously.  The dextran gels were allowed to react 
for 24 hours and then leached in the same manner as the PEG gels. 
 
4.3.2 Loading Experiments 
The loading solutions were made by mixing a 10 mM sodium citrate buffer at a pH of 
either 3.3 or 5.9 with various partitioning salts and polymers.  The partitioning salts used were 
potassium chloride and tetrabutylammonium fluoride trihydrate at a concentration of 0.22 M and 
were both purchased from Sigma (St. Louis, MO).  The polymers in solution were poly(ethylene 
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glycol) (Sigma, St. Louis, MO) and dextran 40k at a 10 w/w% concentration. The model proteins 
used were ovalbumin (lyophilized powder, ≥ 98%, Sigma, St. Louis, MO) and human IgG 
(lyophilized powder, ≥ 98%, MP Biomedicals, Solon, OH). 
To ensure gel volume was constant, before the gels were placed in loading solutions 
containing protein they were pre-equilibrated in 1 mL of protein-free loading solution and 
allowed to soak for 24 hours. The gels were then added to 1 mL of the same loading solution that 
contained 1 mg/mL of either ovalbumin or IgG.  The gels were equilibrated by placing the vials 
in a shaking incubator (60 rpm) for 24 hours at 4° C.   
 
4.3.3 Protein Recovery and Analysis 
To determine the amount of protein absorbed during the loading step, the protein was 
leached from the gels by soaking them in 1 mL of protein and polymer free buffer in a shaking 
incubator at 4° C for 24 hours.  The protein concentration of the leached solution was then 
determined by using a Bradford assay (Thermo Scientific, Rockford, Illinois) according to the 
procedure provided by the manufacturer. To confirm that all of the protein had been leached 
from the hydrogels they were then soaked in 1 mL of protein and polymer free buffer for an 
additional 48 hours and the protein content was measured once again.  In all of the samples, 
100% recovery occurred in the first 24 hours and no additional protein was detected after that. 
 
 
4.3.4 Release Kinetics 
 
The release study was done using dextran gels synthesized in the same manner as the 
loading experiments except that instead of using a disc-shaped mold, the pre-gel solution was 
injected into a glass capillary tube with an inner diameter of 1.1 mm. The hydrogels were 
removed from the capillary tubes and loaded using the same procedures described earlier, and 
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were then placed in 1 mL of pure buffer.  For each data point the entire release volume was 
removed and a fresh allotment of pure buffer was added.  The sampled volume was then 
analyzed using the Bradford assay.  To obtain the diffusion coefficient of the protein in the gel, 









  exp -­‐Dαn2t                                                (4.3)  
 
where Mt is the mass of the solute that has been released from the cylinder at time t, M∞ is the 
total mass released from the cylinder, a is the radius of the cylinder, D is the diffusion coefficient, 
t is time, and αns are the roots of the equation J0 (aαn) = 0 where J0(x) is the Bessel function of 
the first kind of order zero.27  An assumption was made that the total amount of protein loaded 
was the same as the amount of protein released, based on the assumption that any protein that 
diffuses into the gel should also be able to diffuse out. All the calculations were done on a 
Microsoft Excel spreadsheet and the least squares method was used to determine the best-fit 















4.4.1 Ovalbumin Partitioning in Hydrogel Systems 
 
In this section, the partitioning of the model protein ovalbumin is studied in both PEG 
and dextran hydrogels using aqueous two-phase partitioning.  Using a variety of loading systems, 
the protein loading and gel swelling measurements are compared with trends seen in ATPE 
literature.  The concept is then further extended from gel-soluble polymer two-phase systems to a 
PEG-phosphate two-phase system.   
 
4.4.1.1 Ovalbumin in PEG-Dextran Systems   
PEG-dextran systems are the most widely studied aqueous two-phase systems. While 
previous work by our group focused on the partitioning of proteins in dextran hydrogels, in this 
chapter the partitioning of proteins in PEG hydrogels was studied under similar conditions in 
order to make direct comparisons. There are two main sub-hypotheses to be addressed upon 
looking at the partitioning in PEG hydrogels. The first is that switching from a dextran to a PEG 
gel, should cause opposite trends be seen in protein partitioning. In our previous work, we saw 
that the ovalbumin tended to favor the dextran gels over the PEG in solution as predicted by 
ATPE literature but that the dextran gel deswelled significantly in the PEG solution.  When 
switching to a PEG gel, the hypothesis is that the ovalbumin should now favor the dextran 
solution, and that this effect can be enhanced by adding KCl to the solution and suppressed by 
adding tetrabutylammonium fluoride. The second hypothesis is that the swelling degree of PEG 
hydrogels should be less affected by the addition of dextran to the system than dextran gels are to 
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the addition of PEG into the system, based on the tie lines seen in PEG-dextran aqueous two 
phase systems.  Confirming these hypotheses increases the versatility of the loading method and 
proves that the swelling can successfully be predicted from ternary diagrams in ATPE literature. 
Table 4.1 summarizes the results of the PEG-dextran loading experiments at three 
different conditions in order to compare the swelling degree, partition coefficient, and percent 
loading.  As mentioned earlier, the hypothesis is that for a PEG-dextran system, a PEG hydrogel 
in aqueous dextran will swell more than a dextran gel does in aqueous PEG.  Dextran hydrogels 
have a swelling degree of 7.79 in pure buffer, yet when 10% PEG is added to the system the 
swelling drops sharply to 3.14, a 60% decrease.   PEG hydrogels have a swelling degree of about 
10 in pure buffer, yet the addition of 10% dextran only decreases the swelling degree to 7.5, a 
25% decrease. The swelling results confirm the hypothesis that the slope of the tie lines in the 
ternary diagrams seen in literature for aqueous two-phase systems comprised of PEG and dextran 
directly relate to gel deswelling.28  
Table 4.1.  Swelling Degrees and Ovalbumin Partitioning of PEGDA and Dextran Hydrogels in PEG-
Dextran ATP Systems  
 
           
Hydrogel  Loading Solution        Swelling Degree (g/g)     Partition Coefficient          Percent Loading*  
  Buffer, pH 5.9   7.79 ± 0.16      0.29 ± 0.01  0.23 ± 0.01  
10%  Buffer, pH 5.9, PEG  3.14 ± 0.03      2.37 ± 0.12  0.74 ± 0.04  
Dextran  Buffer, pH 5.9, PEG, KCl  3.28 ± 0.04      5.03 ± 0.89  1.09 ± 0.20  
  Buffer, pH 5.9, PEG, Bu4NF  3.05 ± 0.02      0.80 ± 0.05  0.21 ± 0.01  
         
  Buffer, pH 5.9   9.57 ± 0.16      0.38 ± 0.02  0.30 ± 0.01  
10%  Buffer, pH 5.9, Dextran  7.55 ± 0.08      0.47 ± 0.04  0.28 ± 0.02  
PEGDA  Buffer, pH 5.9, Dextran, KCl  7.71 ± 0.18      0.40 ± 0.02  0.26 ± 0.01  
  Buffer, pH 5.9, Dextran, Bu4NF 7.39 ± 0.15      0.50 ± 0.03  0.25 ± 0.02  
          
  Buffer, pH 3.3   10.45 ± 0.21      0.30 ± 0.02  0.29 ± 0.01  
10%  Buffer, pH 3.3, Dextran  8.09 ± 0.22      0.56 ± 0.04  0.43 ± 0.04  
PEGDA  Buffer, pH 3.3, Dextran, KCl  7.59 ± 0.36      0.59 ± 0.03  0.43 ± 0.02  
  Buffer, pH 3.3, Dextran, Bu4NF 7.65 ± 0.19      0.46 ± 0.04  0.33 ± 0.03  
*Percent Loading = protein loaded (g) / polymer content (g)       
Ovalbumin concentration is 1 mg/mL; Salt concentrations are 0.22 M        
Polymer concentrations are 10% (w/w); PEG = 10 kDa, Dextran = 40 kDa       
Bu4NF = tetrabutylammonium fluoride  	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To clearly demonstrate the trends, the partition coefficients in the dextran gel-PEG 
solution and PEG gel-dextran solution from Table 4.1 have been plotted in Figures 4.2a (dextran 
gels) and 4.2b (PEG gels). The results of the partitioning in dextran hydrogels using PEG as the 
soluble polymer can be seen in Figure 4.2a.  When 10% PEG is added, the partition coefficient is 
increased by a factor of 8 when compared to buffer alone, which is consistent with predictions 
and our prior work.  Additional salts were then added to test the predictions of ATPE regarding 
the ability of salts to increase or decrease the partition coefficient.  Based on heuristics developed 
for ATPE, KCl should amplify the partitioning into the dextran phase while Bu4NF should 
diminish the partition coefficient. KCl and Bu4NF were both used due to their predicted ability to 
substantially impact the partition coefficient in opposite manners.  It should be noted that there 
are a wide range of partitioning salts that have been used in literature.   The results shown in 
Figure 4.2a validate heuristics, as the partition coefficient is doubled when KCl is added, from 
2.37 to 5.03, while the addition of Bu4NF causes the partitioning to drop from 2.37 to 0.80, a 
66% decrease. The partitioning results in dextran hydrogels show that ovalbumin generally 
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Figure 4.2a. Effect of PEG and salt on the partition coefficients of ovalbumin in dextran hydrogels.  The 
data show that soluble PEG increases the partition coefficient, and salts can be used to amplify or 
suppress the effect of PEG, consistent with ATPE heuristics. Buffer: 0.01 M Sodium citrate (pH = 5.9).    
Salt concentrations: 0.22 M.    PEG (10kDa) Concentration: 10% (w/w). All differences were statistically 
significant (p <.007) 
 
 
In switching over to PEG hydrogels, the hypothesis is that the partition coefficients 
would be lower compared to dextran (since ovalbumin favors the dextran phase), yet that the 
partition coefficients can still be manipulated using the different salts in a manner predicted by 
the heuristics.  Specifically, it is expected from theory that the partitioning salts would have the 
opposite effect on ovalbumin partitioning in PEG hydrogels than with dextran hydrogels.2   The 
results at pH 5.9, shown in Figure 4.2b, confirm these hypotheses.  Although the partition 
coefficients in buffer alone are similar, the addition of 10% dextran doesn’t have nearly the 
effect that the addition of 10% PEG had on dextran hydrogels.  The addition of dextran still 
causes the partition coefficient to increase, from 0.38 to 0.47.    The addition of KCl results in a 
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decrease in partitioning, which is what was predicted since KCl causes the ovalbumin to favor 
the dextran phase in this system.  However, the addition of Bu4NF did not result in a statistically 
significant change in partition coefficient. (p > 0.05).  Taken as a whole, the results confirm that 
the while the partitioning in PEG is lower than in dextran, the partitioning still follows the 
predictions of heuristics and can be increased with the addition of a polymer and even further 
with the addition of KCl.  The partitioning with polymer and Bu4NF was inconclusive and 
requires more testing in order to prove a statistically significant increase in partitioning when 
compared to polymer alone. 
 
Figure 4.2b. Partitioning of ovalbumin in PEG hydrogels show the effects of dextran and partitioning 
salts on the partition coefficient. Buffer: 0.01 M Sodium citrate (pH = 5.9).   Salt concentration = 0.22M.   
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The next hypothesis that was tested is the important observation seen in aqueous two-
phase systems where switching from above the isoelectric point to below the isoelectric point 
produces opposite effects in the partitioning. The isoelectric point of ovalbumin is 4.6, and the 
data presented in Figures 4.2a and 4.2b had been conducted at pH 5.9 where the protein had a net 
negative charge.29  The literature heuristics indicate that partitioning salts should affect positively 
and negatively charged proteins in opposite manners, so at a low pH KCl would be expected to 
favor the partitioning of ovalbumin into the PEG phase and Bu4NF to would be expected to favor 
the partitioning into the dextran phase2.  The results, shown in Figure 4.3, are consistent with this 
hypothesis.  Once again, the addition of 10% soluble dextran increased the partition coefficient, 
as the partition coefficient nearly doubles when compared to pure buffer.  The addition of KCl 
did not cause a statistically significant change in partitioning (p > 0.05) however the addition of 
Bu4NF decreased the partitioning from 0.56 to 0.46, a statistically significant drop that matched 
predictions (p=0.04).  The results from these experiments show that the partitioning trends 
exhibited in ATPE systems can be directly applied to a system containing either a dextran 
hydrogel or a PEG hydrogel and that these trends are valid both above and below the isoelectric 
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Figure 4.3. Partitioning of ovalbumin in PEG hydrogels at pH 3.3 show the contrasting effects of 
partitioning salts below the isoelectric point of ovalbumin when compared to Figure 4.1b.   
Buffer: 0.01 M Sodium citrate (pH = 3.3).  Salt concentration = 0.22M.    




4.4.1.2 Ovalbumin in PEG-Phosphate and Dextran-Phosphate Systems 
 Although much of the research in literature on aqueous two-phase systems has been 
focused on polymer-polymer systems there is also a great deal that focuses on polymer-salt 
systems. One of the most common polymer-salt systems used for ATPE is the PEG-phosphate 
system, and it is hypothesized that this same system can be used as a successful loading method 
when, instead of using a soluble PEG phase, PEG hydrogels are used to form the second phase of 
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system as well as a dextran-phosphate system was studied. It is well documented in literature that 
PEG and phosphate form two separate phases, which should provide a suitable system for 
loading ovalbumin into PEG hydrogels.  On the other hand, due to the fact that phosphate does 
not induce a phase separation with dextran in solution, no additional thermodynamic driving 
force from the phosphate is expected. Following this hypothesis, the swelling degrees of PEG 
hydrogels in a salt solution would be expected to decrease based on the PEG-phosphate phase 
diagram tie lines if there is phase separation, as was observed with PEG-dextran systems, while 
the swelling of dextran hydrogels in similar salt solutions would not be affected by the addition 
of salts since the swelling of nonionic gels is not typically significantly affected by salt.30 
 Figure 4.4a shows the swelling degrees of PEG and dextran hydrogels in the polymer-
phosphate system.  In buffer alone the PEG hydrogels swell significantly more (13.2 vs. 8.8) 
than the dextran hydrogels.  The addition of phosphates causes the swelling of PEG to drop from 
13.2 to 7.0, and the addition of sodium chloride caused an additional decrease in swelling to 4.8.  
The same addition of phosphates and sodium chloride had very little effect on the dextran 
hydrogels, which remain at a swelling degree around 10. The partition coefficients of ovalbumin 
in the polymer-phosphate systems can be seen in Figure 4.4b.  In buffer alone, ovalbumin has a 
partition coefficient of about 0.20 in both dextran and PEG hydrogels, reflecting size exclusion 
which is primarily a function of water content.  When the concentration of phosphate in the 
loading system is increased to 0.132 M the partition coefficient doubles to 0.43 for the PEG gels, 
while remaining at 0.20 with the dextran gels. The addition of NaCl further increases the 
partitioning of ovalbumin into the PEG gels, giving a value of 0.52, yet the partitioning in the 
dextran gels remains unchanged at 0.2.   
The overall trend confirms the hypothesis quite well, although the partition coefficients 
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for both hydrogels are small in magnitude. The swelling results and the partitioning of 
ovalbumin in the PEG loading system give clear evidence of two distinct thermodynamic phases 
that causes the ovalbumin to prefer the PEG phase. The partition coefficient increases with the 
addition of NaCl as predicted by ATPE heuristics.  On the other hand, in the dextran loading 
system a change is not observed in partitioning or swelling despite the addition of phosphate or 
NaCl.   This confirms the hypothesis that the protein partitioning effect is only seen in systems 





Figures 4.4a & 4.4b.  Swelling and partitioning of ovalbumin in a PEG-phosphate system and a dextran-
phosphate system. The swelling degrees in Figure 4.3a are consistent with the fact that there is a phase 
separation in the soluble PEG-salt system but not in the dextran-salt system. Figure 4.3b shows that the 
partitioning in PEG increases with the addition of salts, while the partitioning in dextran remains 
unchanged.  Buffer: 0.01 M potassium phosphate (pH = 6.0).   Phosphate concentration = 0.132 M.     
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4.4.1.3 Release Kinetics 
In order to confirm that the protein was distributed throughout the gel and not simply 
adsorbed onto the surface, a release kinetics study was performed.  The results in Figure 4.5 
show an example data set for the release of ovalbumin from dextran hydrogels cylinders loaded 
with a PEG-dextran aqueous two-phase system.  The release profile is initially linear with the 
square root of time, providing visual evidence of Fickian release.  Additionally, the curve fit of 
the release profile based on Equation 4.3 corresponds with the data throughout the entire range 
and provides further evidence of Fickian diffusion. The calculated diffusion coefficient is 8.1 ± 
0.2 x 10-8 cm2/sec (n = 3) which is consistent with values reported in literature for ovalbumin 
diffusion in hydrogels with similar swelling degrees.3 The data confirms that ovalbumin is being 
released in a manner consistent with Fickian diffusion from a uniformly loaded gel. 
 
Figure 4.5. Fickian release of ovalbumin from 10% dextran gels confirms protein is distributed within the 
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4.4.2 IgG Partitioning in Hydrogel Systems  
 
 
 The key motivation for undertaking this research was to determine the feasibility of 
loading mAbs into hydrogels using the aqueous two-phase system loading concept.  With the 
hypothesis that this loading mechanism is applicable to any polymer system with phase 
separation, the demonstration of the potential of the technique was undertaken using the 
partitioning of IgG as the model immunoglobulin for mAbs.  This was done by testing the 
partitioning of IgG in a PEG-phosphate system and the IgG in a PEG-dextran system. 
 
4.4.2.1 IgG in a PEG-Dextran System 
 In ATPE literature, it has been observed that IgG strongly preferred the dextran phase 
over the PEG phase, and thus based on the work presented to this point, it is expected that similar 
trends should be observed with a hydrogel-based aqueous two-phase system comprised of a 
dextran gel and a PEG loading solution.  
 For this experiment, the loading and leaching times were increased, and the experiment 
was run with 50, 100, and 200 hours of loading and leaching times.  Although the diffusion of 
antibodies in hydrogels at very low swelling degrees has not been extensively researched in 
literature, it was estimated using data from literature and the free volume theory described in 
Chapter 331 that the diffusion coefficient of IgG is about 10,000 times slower than ovalbumin in 
a dextran hydrogel under these experimental conditions (D =7x10-12 cm2/s).31 However, due to 
concerns about degradation, the experiments were not carried out to equilibrium given the fact 
that during the length of the entire experiment the IgG would be in solution for a total time of 
100, 200, and 400 hours. The amount of linear PEG in solution was also reduced to 6% due to 
precipitation that occurs at higher concentrations of PEG.32,33 
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 The results were as predicted.  While IgG is completely excluded from the gel in buffer 
alone, the partition coefficient increases substantially with the addition of just 6% PEG, as shown 
in Figure 4.6. The amount of IgG absorbed by the dextran gel increased as the loading time was 
extended from 50, to 100 and then to 200 hours and resulted in partition coefficients of 5.29 ± 
0.16, 8.96 ± 2.71, 17.96 ± 6.40 respectively.   
 
Figure 4.6. Partitioning of IgG into 10% dextran hydrogels show that by adding only 6% PEG to the 
loading solution, size exclusion can be overcome and a partition coefficient of 18 can be achieved. 
Buffer = .01 M Potassium Phosphate (pH = 6.6).   PEG (35kDa) Concentration: 6% (w/w).    *K = 0.06 ± 
0.02  All values were statistically significant (p< 0.05) 
 
 
The large partition coefficients of IgG in a dextran hydrogel illustrate the potential for the 
use of the PEG-dextran system as a mAb hydrogel loading method. While virtually all of the IgG 
was excluded in buffer alone, the loading percentages were at 3.5% after 200 hours. This is 
evidence that large amounts of IgG can be selectively partitioned into a hydrogel using only 
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4.4.2.2 IgG in a PEG-Phosphate System 
 The PEG-phosphate system was examined because the literature predicts a favorable 
partitioning of IgG into the PEG phase, and PEG gels are widely used in drug delivery.  In the 
ATPE literature, a PEG-phosphate system was successfully used to separate IgG from a 
hybridoma cell culture supernatant, and the work was followed up on and optimized using pure 
IgG in a PEG-phosphate system.34,35 With two aqueous phases, a partition coefficient of 10 or 
higher was common and in some cases the partition coefficient was measured at over 100.34,36 
The results from the hydrogel loading system can be seen in Figure 4.7 and show that in buffer 
alone IgG is almost completely excluded (0.06 ± 0.06) from the PEG hydrogel, presumably due 
to entropically-driven steric size exclusion from the gel mesh. When phosphates are added the 
partition coefficient jumps up only slightly to 0.12, and as seen in the literature for ATPE, it isn’t 
until sodium chloride is added that a large jump in partitioning to 0.77 is seen.34 
 
Figure 4.7. Partitioning of IgG into 10% PEGDA hydrogels shows that the addition of phosphates can 
increase partitioning and overcome size exclusion. Buffer = 0.01 M Potassium Phosphate (pH = 6.0).    
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 The identical experiment was also run using various molecular weights of PEGDA, 
ranging from 700 Da to 6000 Da.  By changing the molecular weight of the PEG it was 
hypothesized that the structure of the hydrogel network would change, leading to a change in the 
partitioning. Studies have shown that increasing the molecular weight of the PEG leads to a 




Figure 4.8. Partitioning of IgG into 10% PEGDA hydrogels with varying molecular weights using buffer, 
phosphates, and NaCl as the loading solution. Buffer = 0.01 M Potassium Phosphate (pH = 6.0).    
Phosphate Concentration = .132 M   NaCl Concentration = 1.39 M 
 
 
The partitioning of IgG in PEG can be seen in Figure 4.8 along with the corresponding 
swelling degrees in Figure 4.9.  While the partitioning is almost identical at molecular weights of 
700 and 2000, when 6000 molecular weight PEG is used to form hydrogels IgG is completely 
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results run counter to the predictions, as a larger mesh size should cause an increase in 
partitioning.  However, the mesh size is a bulk property, and PEG hydrogels are known to have a 
heterogeneous structure.  Despite having a smaller predicted average mesh size, the PEG 
hydrogels made with 700 and 2000 molecular weight PEG may be more heterogeneous and 





Figure 4.9. Swelling degrees of 10% PEGDA hydrogels with varying molecular weights in phosphate 
and sodium chloride loading solution. phosphates, and NaCl as the loading solution. Buffer = 0.01 M 
Potassium Phosphate (pH = 6.0).    Phosphate Concentration = .132 M   NaCl Concentration = 1.39 M 
 
 
 To further understand the effects of hydrogel network structure on the partitioning, the 
network structure was altered by changing the solvent in which the polymerization occurred.  
Previous studies have shown that altering the solvent composition by using various ratios of 
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the ethanol content of the solvent, the solvent-polymer interaction becomes less favorable and 
leads to a decrease in the polymer coil’s hydrodynamic volume, an increase in heterogeneity, and 
a decrease in the reaction rate. 39,40 As the ethanol content in the solvent increases, certain PEG 
hydrogels have been shown to exhibit a significant increase (up to 5-fold) in swelling, as well as 
a significant (~ 150 fold) decrease in the shear modulus of the gel.40  However, the swelling 
degrees of 10% PEGDA hydrogels (seen in Figure 4.10) do not display a significant change as 
the ethanol content of the solvent is increased.  In fact, the swelling degrees only range from 8.35 
to 9.86 as the ethanol content in the solvent is changed from 0 to 50% by volume.  While the 
average standard deviation for a given batch is relatively low (0.16), the batch-to-batch variation 
was higher, as three separate batches synthesized using 20% ethanol produced a range of 





Figure 4.10 Swelling degrees of 10% PEGDA hydrogels synthesized in a water-ethanol solvent. The size 
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The partitioning of IgG in 10% PEG hydrogels is also not affected by the amount of 
ethanol present during hydrogel synthesis. The results in Figure 4.10 show that hydrogels 
synthesized with 25% ethanol in the solvent exhibited similar partitioning results to hydrogels 
synthesized in pure water.  Hydrogels synthesized with 25% ethanol in the solvent displayed a 
partitioning of 0.72 ± 0.08, while gels synthesized in pure water had a partitioning of 0.76 ± 0.10. 
While the presence of ethanol in the solvent may result in more heterogeneous PEG hydrogels, 
the results of Figure 4.11 in combination with Figure 4.10, show that it does not affect the 
swelling or partitioning.   
 
 
Figure 4.11. Partitioning of IgG into 10% PEGDA hydrogels synthesized in a water-ethanol solvent. 
Buffer = 0.01 M Potassium Phosphate (pH = 6.0).    Phosphate Concentration = .132 M   
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4.5 DISCUSSION 
The results in the previous section confirm the two hypotheses that this chapter set out to 
test.  The loading method used in this chapter for proteins is thermodynamically general and can 
be extended to a variety of polymer systems where phase separation occurs including both 
polymer-polymer and polymer-salt systems.  In all of the cases the trends match up well with the 
heuristics that are available from ATPE literature, making the selection of promising 
formulations for drug loading quick and efficient.  The results also show that this drug loading 
method works very well for mAbs, removing the size exclusion restraints that tend to plague 
most post loading methods. 
The results also show potential for future drug delivery applications that hope to 
incorporate therapeutic proteins and antibodies into hydrogels.  With the addition of only 6% 
PEG, partition coefficients of up to 18 were reached for IgG in dextran hydrogels, with room for 
potential improvement.  The experiment was not run to equilibrium, no loading salts were used, 
and only two systems and hydrogels were studied.  Future work that focused on maximizing the 
loading of antibodies into the gels, either by increasing the concentration of antibody in solution 
or by changing some of the parameters of the loading solution, would further increase the 
potential of this loading system. A higher partition coefficient leads not only to higher loading 
concentrations, but it also leads to higher amounts of the protein in the loading solution being 
absorbed, something that is commercially important when dealing with antibodies that can be 
incredibly expensive.    
Although the magnitude of the partition coefficient of IgG in PEG hydrogels is lower 
than in the dextran gels the results nevertheless demonstrate the potential of the approach. With 
the addition of only NaCl and phosphates the partitioning can be increased by almost an order of 
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magnitude. Regardless, the partitioning may not be high enough to have useful drug loading 
capabilities in a PEG gel. Looking back at Equation 4.2, in order to effectively use this system 
for loading antibodies in hydrogels, high swelling degrees would be needed along with a large 
concentration of antibodies in the loading solution. Unfortunately, the solubility of IgG is limited 
at high salt concentrations, and precipitation was seen at concentrations above 1 mg/mL.  This, 
combined with the low swelling degrees seen in the loading solution, significantly limits the 
ability to load high amounts of antibodies into the hydrogels, suggesting that for practical 
application the PEG-phosphate system may not be suitable for mAb loading.   
The results also lay out a roadmap for developing a hydrogel mAb loading system.  First, 
a hydrogel of interest is chosen based on the target application and any safety or biocompatibility 
restraints.  Then, the ATPE literature can be used to identify a thermodynamically incompatible 
polymer or salt that will create a phase separation and provide a driving force.  Ideally a system 
would be chosen in which the tie lines slope in a favorable direction and would lead to high 
swelling degrees and a higher loading capacity.  And finally, based on the mAb or protein of 
interest, a loading buffer at a certain pH can be selected along with additional partitioning salts to 
increase the partition coefficient and maximize loading.  The results from this chapter show that 
the ability to use the extensive amounts of ATPE literature available becomes a significant 
advantage in developing an effective hydrogel mAb loading system. 
However, the experiments also illustrate some of the challenges and limitations of the 
method.  As was mentioned earlier, due to concerns about degradation, the experiment was not 
run longer than 200 hours. The diffusion of IgG in dextran is much slower than that of 
ovalbumin in dextran, limiting the practical ability of a drug loading method.  In order to load 
enough IgG into a hydrogel delivery device that is therapeutically useful, a long loading time 
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might be needed which lowers the effectiveness of the method and could also lead to stability 
issues.  One simple way around this disadvantage would be to use a shorter characteristic 
diffusion length. The most practical use for the loading system would be in hydrogels systems 
that could be quickly loaded, such as nanogels and microgels.  The small diffusion length would 
allow for loading times on the order of a few hours, and would help maintain the stability and 
activity of any therapeutic protein that would be loaded. While larger monolithic devices have 
their usefulness in drug delivery, there are a lot of advantages that would make nanogels and 
microgels the preferred route to deliver antibodies and therapeutic proteins.41-43  One of the 
potential drawbacks of using an aqueous two-phase system to load proteins into hydrogels 
previously noted in the literature is the when the system is used to simultaneously crosslink and 
load microspheres at the same time, it is difficult to wash the microspheres without the protein 
also leaching out.44  However, many of the two-phase systems are compromised of common 
excipients used in drug formulations such as buffers, salts, and polymers that are recognized by 
the FDA as GRAS (generally recognized as safe), so rinsing the surface may not be required.  
Additionally, the slow diffusion of antibodies out of the microspheres would allow most of the 
low molecular weight excipients to rinse out without losing too much of the loaded drug product. 
Nevertheless, the main advantage of the loading method is in its ability to overcome size 
exclusion constraints, and this advantage could be used in a number of applications that extend 
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4.6 CONCLUSIONS 
The results from the experiments in this chapter confirm that the loading method for 
proteins is thermodynamically general and can be applied to a number of hydrogels. Systems 
using hydrogels other than dextran were shown to follow the ATPE heuristics found in literature, 
greatly expanding the material options for drug delivery. The results also show that both a 
polymer-polymer and polymer-salt system can be utilized as an effective loading method as long 
as systems are chosen that contain two thermodynamically distinct phases that induce a phase 
separation. And most importantly, the results present clear evidence that the loading method can 
be used to successfully load mAbs into hydrogels. 
The results show the potential utility of the method for drug delivery applications. The 
large amount of ATPE literature available allows a system to be chosen that uses the ATPE 
heuristics to zero in on promising formulations quickly and efficiently. This greatly reduces the 
amount of time and experiments needed to develop a successful loading method. The 
experiments performed in this chapter display how to maximize the loading by increasing the 
partition coefficient, the swelling degree, and the concentration of protein in the loading solution. 
While the work presented here was focused on monolithic, diffusion based drug delivery systems, 
the method can be easily applied to nanogel or microgel based systems.  Additionally, by 
showing that the method works for molecules as large as antibodies, the method provides a much 
needed and beneficial way to load antibodies into a variety of hydrogel delivery systems at a 
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CHAPTER 5: HYALURONIC ACID HYDROGEL IMPLANTS FOR THE  




 A prototype intravitreal implant was developed with the goal of providing 3-6 months 
release of anti-vascular endothelial growth factors to the retina for the treatment of retinal 
diseases such as diabetic macular edema and age-related macular degeneration. The focus of 
chapter was in developing a hollow cylinder made from a hyaluronic acid (HA) hydrogel that 
could be filled with a concentrated drug solution and then capped. The hollow cylinder structure 
was chosen in order to provide the required dosage in a device small enough to be implanted in 
the vitreous.  The device was made from an HA hydrogel due to its similarity in composition to 
the vitreous humor.  However, achieving extended release from a polyelectrolyte gel was 
especially challenging, as it required a hydrogel with a very low swelling degree. In order to 
achieve such low swelling degrees, the cylinders were made from HA hydrogels that were highly 
crosslinked using the difunctional crosslinker divinyl sulfone (DVS). HA-DVS hydrogels with 
swelling degrees as low as 2.7 were achieved using HA concentrations that ranged from 15-30% 
(w/w) and HA:DVS ratios that ranged from 3:1–1:1 (w/w).  The final prototype cylinders were 
capable of successfully releasing an antigen-binding fragment (Fab) for over 4 months at a 
maximum release rate of 4 micrograms a day. 
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5.2 INTRODUCTION 
 
In this work, the use of hyaluronic acid (HA) hydrogels was investigated for the sustained 
release of therapeutic proteins to the eye. While the rise in the number of people affected by 
retinal diseases has lead to the development of a promising new class of drugs, the current 
delivery methods highlight the need for a more effective long-term delivery system. Due to its 
similarity in composition to the vitreous humor, a HA hydrogel is a logical system to deliver 
drugs to the retina.  The goal of this chapter is to develop a prototype HA hydrogel implant that 
is capable of delivering sustained release to the retina.  In order to achieve sustained release from 
such a device, a very low diffusion coefficient is required and it is hypothesized that this is only 
possible with a hydrogel that has a very low swelling degree. Achieving such a low swelling 
degree is particularly challenging using a hydrophilic polyelectrolyte like HA. While there are 
many examples of hyaluronic acid hydrogels in literature1, very few are able to achieve release 
that extends past a few days or even a week.2-6 
 Two of the most frequent causes of blindness and vision loss in the world come from 
retinal diseases: diabetic macular edema and age-related macular degeneration.7-9  Diabetic 
macular edema (DME) is the swelling of the central retina that is caused by the breakdown and 
leakage of plasma from the blood vessels that surround the retina.10  DME affects an estimated 
21 million people worldwide, and being a diabetic complication, that number is expected to rise 
as the amount of people with diabetes is predicted to double by 2030.11,12  Age-related macular 
degeneration (AMD) affects more than 25-30 million people worldwide. It occurs in two forms 
termed “wet” and “dry” AMD. Dry AMD accounts for roughly 80% of all AMD cases, and this 
form is characterized by extracellular depositions called drusen that form under the retina.8  Wet 
AMD, while less prevalent than dry AMD, actually causes more severe and sudden vision loss, 
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and this occurs when blood vessels expand and form directly beneath the retina, leaking fluid and 
blood which damage the photoreceptor cells that are responsible for vision.7  As the prevalence 
of AMD increases with age, incidences of both wet and dry AMD are expected to rise in the next 
decade as the population ages and the average life expectancy reaches continues to increase. 
 While there is no cure for AMD and DME, recent development of anti-vascular 
endothelial growth factor (anti-VEGF) treatments have allowed patients to successfully manage 
the symptoms and vision loss of retinal diseases. These treatments work by binding to the protein 
VEGF and inhibiting its ability to bind to receptors on cells that stimulate angiogenesis and 
vasculogenesis. Anti-VEGF treatments have been shown to stabilize vision in 90% of patients 
with wet AMD, with 30% of patients even seeing a substantial improvement in vision.13  The 
three most common FDA approved medicines used to inhibit VEGF are ranibizumab (Lucentis, 
Genentech, South San Francsicso, CA/Roche, Basel, Switzerland), aflibercept (Eylea, 
Regeneron, Tarrytown, NY), and pegaptanib (Macugen, Valeant Pharmaceuticals, Bridgewater, 
NJ).  Although these three molecules all inhibit VEGF, they are quite different molecules and do 
so in different ways. Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal 
antibody fragment with a molecular weight of 48 kDa.  Aflibercept is a fusion protein of the 
binding domains of human VEGFR1 and VEGF2 combine with a human IgG1 Fc fragment and 
has a molecular weight of 97 kDa.  Pegaptanib is a pegylated aptamer with a molecular weight of 
50 kDa.   
The current delivery method of each of these anti-VEGF treatments is an intravitreal 
injection that are administered to the patient every 4-8 weeks, depending on the drug used and 
the patient’s condition.14  While effective at reducing symptoms, this delivery method is not only 
unpleasant for the patient but it also requires frequent trips to the doctor’s office.  Frequent 
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intravitreal injections drive up the cost of treatment and can also lead to rare but serious 
complications such as infectious endopthalmitis, increased intraocular pressure, and 
cataracts.15,16  In an effort to reduce the number of injections needed per year, much research has 
been done on less frequent dosing schedules.17  The two most widely used dosing schedules are 
the “as needed” and “treat and extend”.  In the “as needed schedule”, three monthly injections 
are given initially and then the patient is monitored and given more injections only when 
evidence of disease reoccurs.18  In the treat and extend schedule, three monthly injections are 
given initially and the patient continues to receive additional injections that are continuously 
extended by two weeks as long as symptoms do not reoccur and there are no signs of increased 
neovascularization.19,20  While these regimens do reduce the number of injections per year (from 
12 to on average 5-821), the overall health benefits and long term impact on the patients are still 
being debated and studied.  It is clear, however, that a long term, sustained delivery device would 
offer a number of advantages including convenience, safety, and financial benefits when 
compared to the current intravitreal dosing regimen. 
There are a number of drug delivery methods that have been developed to deliver long-
term, sustained release to the retina including microspheres, implants, microcatheters, injectable 
depots, and even microneedles.22-24 Of these methods, the one that has had the most clinical and 
regulatory success so far has been implants.25  Early efforts focused on implants that were non-
biodegradable and made from a combination of polymers such as polyvinyl alcohol, ethylene 
vinyl acetate, and silicone.  Vitrasert ® and Retisert ® (Bausch & Lomb, Rochester, NY) were 
two of the first non-biodegradable implants commercially available and can effectively deliver 
the small molecule drugs ganciclovir and fluocinolone acetonide (255 and 452 Da) for eight 
months and three years respectively for the treatment of cytomegalovirus retinitis and chronic 
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uveitis.26,27  While these implants are excellent at controlling the release rate of small 
corticosteroids for an extended period of time they have the downside of having to be surgically 
implanted and removed once the implant is depleted.28 
In an effort to reduce the amount of surgery needed, biodegradable implants were 
developed.  The hydrophobic polymers polylactide (PLA) and poly(lactide-co-glycolide) 
(PLGA) are the most widely used biodegradable materials for ocular implants.29  In 2009 the 
FDA approved Ozurdex® (Allergan, Irvine, CA), a biodegradable PLGA implant that is able to 
deliver 0.7 mg of dexamethasone (392 Da) for up to 6 months for patients who suffer from 
DME.30 Despite the success of these implants for small molecule drugs, the heat, pressure, and 
solvents required to integrate the active substance and form the implant limits the process to 
small, stable molecules. The anti-VEGF treatments needed for wet AMD are less stable and have 
a tendency to aggregate when incorporated into a biodegradable implant.31 Although some recent 
work has been able to limit this aggregation32, more work is needed in order to achieve a 
biodegradable implant that can safely and effectively deliver the anti-VEGF treatments.25  
An alternative option to hydrophobic polymer implants is hydrogels, which have been 
shown to be effective at delivering proteins.33,34  Hydrogels are hydrophilic polymer networks 
that are crosslinked into a permanent three-dimensional network. These networks have the ability 
to swell in aqueous solution and take up a considerable amount of water, making them suitable 
for storing sensitive proteins and antibodies.  Hydrogels can be formed into many different 
shapes and sizes and can be synthesized from a wide variety of biocompatible and biodegradable 
polymers.  Because of their versatility and wide range of properties, hydrogels offer a promising 
potential for ocular delivery, both as injectable implants and as in situ-forming hydrogels.35-37  
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As a natural component of the eye, HA is a logical choice for a hydrogel delivery system 
that would be implanted in the eye for long periods of time, where biocompatibility and low 
toxicity are crucial for success.38 Hyaluronic acid is a negatively charged, linear, unbranched 
polysaccharide that is composed of repeating units of the disaccharide glucoronic acid and N-
acetylglucosamine.39 It has an unusually high viscosity and this coupled with its ability to hold 
and retain water gives HA a number of integral roles in the human body, including providing 
structure in the vitreous of the eye.40,41 The biocompatible and biodegradable nature of HA along 
with its unique properties has led to an increase in its use in biomedical applications over the 
years, including applications in tissue engineering, cardiac repair, valvular engineering, the 
treatment of osteoarthritis, the prevention of post-surgical adhesions, and even as a dermal 
filler.42 HA has also been used extensively in clinical ophthalmology for the treatment of severe 
dry eyes and as a viscoelastic agent in cataract surgery.43-45 HA hydrogels crosslinked with 
adipic acid dihydrazide were tested on retina pigmented epithelium (RPE) cells and were found 
to be non-toxic, and crosslinked HA hydrogels were also seen to be biocompatible when injected 
subconjunctivally. 46,47 
  Unlike the hydrophobic polymers mentioned earlier, hydrogels have high water contents, 
which cause proteins diffusing through them to have relatively high diffusion coefficients (10-7-
10-8 cm2/s). Because of their high water content, these hydrogels often exhibit the rapid release 
of drugs by diffusion. 48,49 HA hydrogels that are chemically or physically crosslinked often 
display release profiles that see complete release in less than a few days, and in limited cases, up 
to a few weeks.50  In order to extend the release rate of drugs, a HA hydrogel with a low water 
content is needed, and it is hypothesized that this can only be achieved with a highly crosslinked 
HA gel.  In this chapter, the feasibility of synthesizing a HA hydrogel with a low water content 
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was investigated using the crosslinker divinyl sulfone (DVS).  While there are a number of ways 
to crosslink HA, using DVS has a number of advantages for this project. Unlike many other 
crosslinking methods, crosslinking with DVS requires no prior modification of HA, as the 
hydroxyls groups of HA react with the vinyl groups of DVS.51  While this reduces the time and 
cost needed to prepare the HA, the ability to react with the hydroxyl groups also provides DVS 
with a large number of possible crosslinking sites.  HA gels formed with DVS have also been 
shown to be bioinert, while polysaccharide gels made with a comparable crosslinker 
gluteraldehyde have shown cytotoxicity when exposed to retinal pigment epithelial cells.52,53 
While the synthesis method has been used before in literature, all of the resulting HA-DVS gels 
had high swelling degrees (q > 20). 52,54-56 
Despite these advantages, one of the limitations in using DVS to crosslink HA is that 
proteins cannot be incorporated into the hydrogel during formation.  Since the reaction is a base 
catalyzed Michael addition, the reaction only occurs under alkaline conditions.  This, along with 
the long reaction time required for crosslinking (24 hrs) can cause DVS to react with proteins 
during hydrogel formation, leading to a potential loss in activity and the possibility of covalently 
attaching the proteins to the hydrogel network. One of the ways around this problem is to 
synthesize the hydrogel and then postload the drug into the gel after formation. 
In this chapter, the release of model protein was studied using hollow cylinders that were 
made of HA-DVS hydrogels. Due to its simple design, hollow cylinders have been used before 
in drug delivery systems, and their principles are well understood.  They can be fabricated 
without the protein, and then subsequently loaded so that degradative conditions are minimized.  
The ability to load a single drug or multiple drugs, as well as slurries or suspensions makes these 
very versatile for drug delivery applications.  Additionally, the inner and outer diameters can be 
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easily adjusted to fine-tune the release profile and the amount of drug that can be delivered and 
the cylindrical shape also makes it very convenient to inject. 
There were a number of scientific goals that this chapter set out to achieve in order to 
develop a prototype HA hydrogel implant that is capable of delivering sustained release to the 
retina.  The first was to determine if hollow mini cylinders could be fabricated using HA 
hydrogels crosslinked with DVS.  The second was to determine if these hydrogels could be made 
with a swelling degree low enough to produce the diffusion coefficients required to achieve 
extended release. Whether or not it is possible to achieve such low diffusion coefficients is 
something that has not been proven in literature to date using HA hydrogels. The final goal of 
this chapter was to demonstrate that a HA-DVS implant could achieve 3-6 months release at a 
rate that would be therapeutically effective if injected or surgically implanted in the back of the 












	   136 
5.3 MATERIALS AND METHODS 
 
5.3.1 Materials 
Hyaluronic acid (51 kDa Mw, pharmaceutical grade from bacterial fermentation)was obtained 
from Lifecore Biomedicals (Chaska, MN). Bovine serum albumin (BSA, lyophilized powder, ≥ 
98%), divinyl sulfone (DVS >98%), ethylene glycol, and vitamin B12 were obtained from Sigma 
Aldrich (St. Louis, MO) along with an albumin–fluorescein isothiocyanate conjugate (FITC-
BSA) and sodium azide (>99.5%). Pierce™ Coomasie Plus Bradford Reagent was obtained from 
Thermo Fisher Scientific (Waltham, MA).  Additionally, an antigen-binding fragment (Fab) with 
an approximate weight of 50 kDa was donated by a pharmaceutical company and used in this 
work. 
 
5.3.2 Hydrogel Synthesis 
Hyaluronic acid hydrogels were synthesized by mixing various concentrations of 
hyaluronic acid and the crosslinker divinyl sulfone in an aqueous solution of 0.02M NaOH.  The 
mixture was stirred vigorously by hand using a glass rod and then centrifuged for one minute to 
remove any air bubbles.  It was then pipetted into molds that were 2 mm thick and had precut 
holes 5 mm in diameter.  These molds were clamped between two thin glass plates (1 mm thick) 
and allowed to react for 24 hours at room temperature.  Once formed, the gels were removed 
from the molds and placed into an excess of D.I. water to remove any unreacted monomer or 
crosslinker. In some cases, the gels were then placed in 30% (v/v) ethylene glycol (0.02 M 
NaOH) solution for 48 hours to cap any singly reacted vinyl sulfone groups that might be 
reactive toward the protein.57 The gels were rinsed by soaking them in excess D.I. water that was 
changed every 12 hours.  
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5.3.3 Swelling Degree 
Fully formed gels were soaked in solutions of D.I. water and 0.01 M phosphate buffer 
saline (PBS, pH =7.4, Sigma Aldrich) until they were fully equilibrated.  The gels were lightly 
blotted to remove excess water and the wet mass was then measured. The gels were then placed 
in a dessicator for 48 hours and allowed to dry.  The gels that were soaked in PBS were first 
soaked in excess D.I. water to remove any salt before being placed in the dessicator.  The dry 
mass was measured and the swelling degree (q) was defined as: 
 
q = Wet MassDry Mass      (5.1)   
 
5.3.4 Mechanical Testing 
The compressive modulus (E) and shear modulus (G), fracture stress, and fracture strain, 
were calculated from stress vs. strain data measured using a RSA-III dynamic mechanical 
analyzer (TA Instruments, New Castle, DE). Cylindrical gels were tested under uniaxial 
compression at a rate of 0.05 mm/s until failure. The compressive modulus was calculated from 
the initial slope of the stress-strain curve. The shear modulus (G) was calculated using the neo-
Hookean model for an ideal elastomer as the slope of the stress (σ) versus the strain 
function   λ −    1
λ2
 as shown below: 
σ  =  G λ−    1
λ2
     (5.2)  
where λ  = L/L0  and L and L0 are the thickness of the deformed and undeformed specimen, 
respectively.  
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The crosslink density was calculated using the swelling degree and the shear modulus 






2/3     (5.3)  
 
Where ρx is the crosslink density, R is the ideal gas law constant, T is the absolute temperature, 
v2 is the polymer volume fraction at the testing conditions, and v2r is the polymer volume 
fraction during hydrogel formation.   




     (5.4)  
 
in which ρ2 is the density of the dry polymer network.  The molecular weight between crosslinks 
was then used in calculating the average mesh size of the gels using the following equation 58: 
 





l     (5.5)  
 
where Cn is the Flory characteristic ratio for HA, Mr is the molecular weight of the repeating 
units, and l is the length of bond along the polymer backbone. 
 
5.3.5 Confocal Microscopy Diffusion Study 
15% (w/v) 2:1 and 3:1 HA hydrogel discs were placed in vials containing 1 mg/mL of 
FITC-BSA in 0.01 M PBS (pH 7.4) with 0.01% NaN3.  The vials were gently stirred at 4° C until 
being tested. At predetermined time points, the samples were removed and 3-dimensional image 
stacks were taken using a Zeiss Meta 510 upright confocal microscope (Carl Zeiss, Thornwood, 
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NY). The slices were 5.9 µm thick and the images taken had 512 x 512 pixels with a pixel size of 
0.5 µm.  FITC-BSA was excited at 488 nm using an argon laser and the fluorescence was 
collected using a 505 nm long pass filter. At each time point, 3 images were taken from each gel 
at different locations in order to remove any effects of photobleaching that could occur. The 
concentration of FITC-BSA was found to have a linear relationship with emission intensity for 
the range of concentrations in this study and the shallow sample thickness that was being 
measured minimized any effects of signal attenuation. The discs had a diameter to thickness 
aspect ratio of 5, which was sufficient to make the assumption that diffusion occurred only in the 
z direction and that radial diffusion was negligible given the size of the sample and the low 
diffusion coefficient being measured. All of the images obtained were analyzed using ImageJ 
software (v1.49), obtained directly from the National Institutes of Health.  
 
5.3.6 Hollow Cylinder Fabrication 
In order to form the gels into hollow cylinders, custom molds were machined using 
polytetrafluoroethylene and stainless steel cylindrical rods of varying diameters.  A small glass 
plate was sealed at the bottom of the base of the mold and the HA-DVS solution was pipetted in.  
The upper cap was then inserted into the mold and clamped into place. After 24, hours the upper 
cap and glass plate were removed and the hollow cylinder was carefully ejected from the mold 
using a custom plunger (shown in Figure 5.1).  The cylinders were then placed into an excess of 
D.I. water to remove any unreacted polymer or crosslinker. All of the cylinders had identical 
outer dimensions with a height of 10 mm and a width 1 mm in diameter.  The inner diameters 
varied from 0.460 mm to 0.635 mm. 
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Figure 5.1. Fabrication method used to create HA-DVS hollow cylinders. (A) HA-DVS solution is 
pipetted into a mold.  A glass plate seals the bottom of the mold. (B) Upper cap is inserted into the mold 
while the crosslinking reaction occurs. (C) Both the upper mold and glass plate are removed and the 
finished hollow cylinders are removed from the mold using a custom plunger. 
 
5.3.7 In Vitro Release from Hollow Cylinders 
Hollow cylinders were loaded with a concentrated solution of either vitamin B12, BSA, or 
the Fab in 0.01 M PBS (pH 7.4) with 0.01% NaN3. The cylinders were then carefully capped 
using cyanoacrylate glue and placed in a vial with 1 mL of buffer.  At predetermined time points 
the buffer was removed and was replaced with fresh buffer in order to maintain sink conditions.  
The concentration of the proteins were then measured using a Bradford assay, while the 
concentration of vitamin B12 was measured by absorption at 550 nm using a Cary 300 UV-Vis 
spectrophotometer (Agilent Technologies, Santa Clara, CA). This process was repeated until all 
of the protein was released.  All of the release studies were performed at room temperature and 
were gently shaken to reduce external mass transfer resistance. The diffusion coefficient was 
calculated using COMSOL Multiphysics© software, a program that uses a finite element method 
to model the release from the hollow cylinders. The release of drugs from a hollow cylinder was 
modeled using Fick’s first law: 
A B C 
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Ni=-Diłci      (5.6)  
 
where Ni is the flux of solute i, Di is the diffusion coefficient, and ∇ci is the concentration 
gradient of species i.  When combined with the continuity equation for mass, 
∂ci
∂t
+ł∘Ni=0      (5.7)  
 
Fick’s second law is obtained and is the main equation used to model the unsteady-state 
diffusion in multiple dimensions: 
∂ci
∂t
=Dił2ci      (5.8)  
 
 
The COMSOL software also includes convection terms into the equations, however these were 
set to zero due to the fact that the release through the walls of the hydrogel implants occurs only 
by diffusion. A boundary condition set the diffusion from the top of the cylinder equal to zero, 
simulating an impermeable cap and the initial concentration outside of the cylinder was set at 
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5.4 RESULTS AND DISCUSSION 
In this section, the goal was to create a prototype hydrogel implant that could deliver 
therapeutic proteins for three to six months. Achieving extended release required a hydrogel with 
a very low swelling degree. A number of concentrations of HA and various ratios of HA:DVS 
were tested in an effort to produce hydrogels with low swelling degrees and high crosslinking 
densities.  The mechanical and swelling properties of HA hydrogels were examined and used to 
estimate the diffusion coefficient of various sized solutes. HA hollow mini cylinders were then 
fabricated and loaded with vitamin B12, BSA, and a model Fab and the release rates were 
measured. In order to confirm that the diffusion coefficient was in the desired range, 1-D 
diffusion was also measured through confocal microscopy by using Fickian diffusion models and 
high molecular weight fluorescent probes. 
 
5.4.1 Designing a Hollow Cylinder 
In order to be successful in delivering therapeutic proteins to the retina, a hollow mini 
cylinder has to meet certain requirements.  These include having the proper release rate and total 
dosage required as well as having the proper diameter, length, and structural integrity to be 
effective.  The most important requirement is to be able to deliver the amount of drug needed to 
be therapeutically effective when implanted into the eye.  The target release rate for this work 
was 2.5 micrograms per day, which when delivered over a period of 3-6 months, gives a total 
dosage target of 225-450 micrograms.  For comparison, intravitreal injections of ranibizumab 
and aflibercept are 0.5 mg and 2.0 mg, respectively.   
Another important design specification is the size of the hollow cylinder.  While the 
smallest cylinder possible would be best, the cylinder has to be able to hold 450 micrograms of 
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drug and at the same time have a wall thick enough to slow the release of drug to achieve the 
extended release needed.  Additionally, the cylinder has to have enough structural integrity to be 
washed, loaded with drug, and inserted in the eye.  Some of the early non-biodegradable 
implants were cylinders that were 0.37 mm in diameter (Iluvien®, Psividia, Watertown, MA) and 
could be injected with a 25-gauge needle.  The biodegradable implants that followed were 
generally larger, as Ozurdex ® has a diameter of 0.45 mm and is injected into the vitreous using a 
22-gauge microinjector.  The largest implant available to date is Renexus® (Neurotech, 
Cumberland, RI), which is currently in Phase II clinical trials59. This polymeric hollow cylinder 
is 6 mm long, has a diameter of 1 mm, and is inserted through a 2 mm incision in the pars plana. 
 The dimensions of the HA cylinders used in this paper have a diameter of 1 mm and a 
length of 10 mm. The thickness of the cylinder walls ranged from 0.183 mm to 0.27 mm. 
Dimensions of this size would certainly require an incision in the pars plana in order to insert the 
cylinder into the eye, an option that is much less convenient than an injection with a small 
needle. While the larger dimensions were suitable for carrying out the release experiments and 
handling the cylinders, the cylinders can theoretically be scaled to any dimension required.  Once 
the diffusion mechanism is well understood, release rates and profiles can be quickly calculated 
and controlled by varying the dimensions of the cylinder, the formulation of HA hydrogel, and 
the drug size and concentration as will be discussed in Chapter 6. 
Given the total dosage needed and the hollow cylinder dimensions, a target diffusion 
coefficient was calculated using COMSOL.  Based on these calculations, in order for the 
cylinder to release 450 micrograms for at least three months within the given geometric 
constraints, a diffusion coefficient of 7 x 10-11 cm2/s is needed. 
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5.4.2 Formulating HA-DVS Hydrogels 
In order to achieve the desired release rate, an HA hydrogel had to be synthesized that 
could achieve this very low diffusion coefficient.  As discussed in Chapter 3, there are several 
factors that influence the diffusion rate of solutes in hydrogels, primarily solute size and swelling 
degree. 60 There are many models used to predict solute diffusion in gels.  They invariably 
include parameters related to solute size and water content, and some even include parameters 
associated with the polymer gel network. The Yasuda et al. free volume theory yields a simple 
but widely used equation that determines the diffusion coefficients of solutes in hydrogels using 
the parameters seen in the equation below: 
 
ln DHD0




H -1      (5.9)  
 
where, Dh is the diffusion of the solute in the hydrogel, D0 is the diffusion of the solute in water, 
k is a constant based on the characteristic of the polymer, rs is the hydrodynamic radius of the 
solvent, and Vf is the free volume unoccupied by the solvent or the polymer chains. H is the 
degree of hydration of the hydrogel and is directly related to the swelling degree q  = 1
1-H
   .  𝛷 is 
a sieving factor that takes into account the screening effect of the network.  While the 
shortcomings of free volume theories were discussed in Chapter 3, this theory and Equation 5.9 
were used due to its widespread use in drug delivery literature and because it provided the best 
fit of the sample data that was available in literature. 
There are a large number of studies in literature that measure the diffusion coefficients of 
solutes of various sizes in highly swollen polysaccharide hydrogels.  While there is little 
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information available on the diffusion in HA hydrogels, work has been done determining the 
diffusion coefficients of IgG, BSA, and Vitamin B12 in dextran hydrogels at a wide range of 
swelling degrees.61  Using the Yasuda et al. free volume theory (Equation 5.9) and the data from 
literature, the slope (krs2/Vf) can be approximated from a plot of ln(Dm/D0) vs. (1/H -1) for each 
solute of radius r (Figure 5.2).  This slope is a characteristic of the polymer/water system for 
dextran hydrogels and, despite differences in the structure of the polysaccharides, it was assumed 





Figure 5.2. The logarithm of the normalized diffusion coefficients of various solutes in dextran 
hydrogels as a function of the inverse of hydrogel hydration.  The data points represent actual diffusion 
coefficients measured in literature and the dashed lines represent the calculated slopes and equal (krs2/Vf). 
Adapted from Hennink et al.62,63 
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With this information, a plot of the diffusion coefficient as a function of swelling degree 
can be created, and the data can be extrapolated down to very low swelling degrees (q<6). This is 
seen in Figure 5.3 for Vitamin B12, BSA, and IgG. The proteins (BSA, IgG) were chosen because 
of their similarity in size to a Fab and mAb. Vitamin B12 was chosen due to its use as a test 
marker when working with the prototype cylinders.  The data points represent the actual 
diffusion coefficients measured in literature for dextran gels, and ranged in swelling degrees 
from 20 to 4. The curve represents the extrapolated projections based on the free volume theory, 
assuming 𝛷 is equal to 1.   In order to reach the target diffusion coefficient of 7 x 10-11 cm2/s, a 
swelling degree of roughly 3.5 is needed for a solute with a similar hydrodynamic radius of BSA.  
If a larger solute is used, such as IgG, a higher swelling degree of 5.8 can achieve the same 
diffusion coefficient.  On the other hand, if a smaller solute is used, such as Vitamin B12, a much 
lower swelling degree of 1.6 is needed to reach the target diffusion coefficient.  
Figure 5.3 illustrates the difficulty in achieving the target diffusion coefficient of 7 x 10-11 
cm2/s. In order to achieve this diffusion coefficient, very low swelling degrees are required, and 
as was discussed in Chapter 3, it is hypothesized that under these conditions the size of the solute 
approaches the average mesh size of the hydrogel and can lead to a dramatic reduction in the 
diffusion coefficient. The free volume theory takes this hypothesized screening effect into 
account by introducing the sieving factor (𝛷) seen in Equation 5.9.  For the calculations in 
Figure 5.3, 𝛷 was set equal to 1, making the initial term go to zero. However, at very low 
swelling degrees is exactly where the solute size would begin to approach the average hydrogel 
mesh size and these hypothesized screening effects would begin to take place.  In fact, one 
method used to get a rough measurement of the average mesh size of hydrogels is to determine at 
what swelling degree the diffusion coefficient begins to stray from the free volume theory61,62. 
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Nevertheless, the free volume theory and the extrapolations made in Figure 5.3 are a useful tool 
to estimate the swelling degree needed to achieve the extended release from a hollow cylinder.  
Given that the sieving factor ranges from 1 to 0, any additional screening effects that occur 
would result in a lower diffusion coefficient than predicted in Figure 5.3, and would allow for a 






Figure 5.3. The predicted diffusion coefficients of hyaluronic acid hydrogels as a function of the swelling 
degree.  The data points represent actual diffusion coefficients measured in literature61,62 and the dashed 
lines represent the extrapolated projections based on the free volume theory, assuming 𝛷 =1. The 
horizontal dashed line represents the target diffusion coefficient of D=7x10-11 cm2/s. The arrows indicate 
that all of the values of D below this line will result in release over 3 months for the cylinder dimensions 



































	   148 
5.4.3 Swelling Ratio and Mechanical Properties 
 HA hydrogels were made using various formulations of HA and DVS.  The goal was to 
not only reach the target swelling degree needed for the desired release profile, but also to 
determine the range of swelling degrees that could be achieved as very little research has been 
done with HA hydrogels at very low swelling degrees63,64.  The concentration of HA ranged from 
15 to 30% (w/v) due to the fact that at concentrations higher than 30% the solution became too 
viscous to work with. The ratio of HA: DVS varied from 3:1 to 1:1. The gels were formed in 
discs, as seen in Figure 5.4, for ease of handling and in order to run the mechanical testing.  
 
Figure 5.4. Representative image of a HA-DVS disc used to carry out swelling and mechanical testing.  
The discs were 5 mm in diameter and had a height of 2 mm. 
 
The swelling degree of the hydrogels in both water and PBS can be seen in Figure 5.5. 
The swelling decreases as the ratio of HA:DVS increases and as the concentration of HA 
increases.  As expected, the highest swelling degree comes from the HA gels at the lowest 
concentration of HA (15%) and the lowest ratio of HA to crosslinker (3:1). Unexpectedly, the 
swelling degree seems to be unaffected by the addition of more DVS at the higher concentrations 
of HA. However, almost all of the gels were below a swelling degree of 5.6, the estimated 
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swelling degree calculated from Figure 5.3 that is needed to reach the desired diffusion 
coefficient for a mAb. Only the 30% HA hydrogels were below the target swelling degree of 3.5 
needed for a Fab.  
Figure 5.5 also shows the swelling degrees of HA-DVS hydrogels in a 0.01 M PBS 
solution. The swelling degree of a polyelectrolyte gel is described by Flory’s classic theory65, 
and is a balance of the osmotic forces from the elastically effective junctions (crosslinking), from 
the polymer-solvent mixing, and from the osmotic pressure of counterions. The swelling of most 
polyelectrolyte hydrogels are affected by the addition of salt, however these HA hydrogels show 
very little change in swelling. 
 
 
Figure 5.5. Swelling degrees of HA-DVS hydrogels in water and 0.01 M PBS. The swelling degrees of 
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The calculated compressive modulus (E), shear modulus (G), E/G ratio, fracture stress 
and fracture strain for the HA gels are reported in Table 5.1.  The compressive modulus and 
shear modulus mirror the same general trend seen in the swelling degree, slowly increasing until 
they reach a plateau at a HA concentration of 30% and a HA:DVS ratio of 2:1.  The E/G ratios 
are close to 3 and validate the assumption that these HA gels are ideal elastomers. While the 
fracture stress increased with higher concentrations of HA and DVS, in all of the formulations 
the gel fracture strain remained between 21 to 26%. 
	  
Table 5.1. Mechanical properties of HA-DVS hydrogels. 
 
 
In an effort to better understand the trends seen in Figure 5.5 and Table 5.1, the sulfur 
content of the hydrogels were measured and can be seen in Table 5.2 along with the crosslink 
density, the molecular weight between crosslinks, and the mesh size. For 15% HA hydrogels, the 
addition of more DVS leads to more DVS reacting with HA and being incorporated into the 
network, as evidenced by the increase in the sulfur content.  Despite the fact that more DVS is 
reacting with HA and being incorporated into the network, the crosslink density of the 15% HA 
gels does not seem to be affected, suggesting that the DVS molecules are reacting only once and 
% HA (wt/v) HA:DVS Ratio E (MPa) G (MPa) E/G Stress (MPa) Strain (%)
15 3:1 2.23 ± 0.16 0.68 ± 0.06 3.2 ± 0.1 0.73 ± 0.23 26.6 ± 6.5
15 2:1 2.57 ± 0.32 0.76 ± 0.10 3.3 ± 0.2 0.76 ± 0.34 23.8 ± 8.5
15 1:1 3.11 ± 0.33 0.84 ± 0.10 3.7± 0.3 0.95 ± 0.24 27.4 ± 4.7
30 3:1 7.45 ± 0.86 2.37 ± 0.28 3.1 ± 0.9 1.93 ± 0.39 22.7 ± 3.1
30 2:1 11.82 ± 2.9 3.71 ± 0.45 3.1 ± 0.8 2.72 ± 0.35 21.0 ± 3.0
30 1:1 9.82 ± 0.93 3.05 ± 0.19 3.2 ± 1.0 2.82 ± 0.63 24.3 ± 3.6
n = 5 for 15% HA and n=6 for 30% HA samples
Gel Formulation Moduli Compressive Failure Properties
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not forming elastically effective crosslinks.  With similar crosslinking densities, the decrease in 
swelling seen in Figure 5.5 can be attributed to an increase in hydrophobicity that occurs from 
the addition of unreacted vinyl groups to the network. 
The results in Table 5.2 also reveal that doubling the amount of HA used to formulate the 
hydrogels from 15% to 30% results in crosslink densities that are twice as high.  For the 30% HA 
gels, the swelling degree and mesh size reach a minimum at a HA: DVS ratio of 2:1. The 
addition of more DVS at a ratio of 1:1 does not decrease the swelling degree any further.  This is 
hypothesized to be a result of phase separation that is seen when adding excessive amounts of 
DVS and is evidenced by a steep drop in reaction efficiency.  Despite the fact that twice as much 




Table 5.2. Network properties and sulfur content of HA-DVS hydrogels 
 
Crosslink Density Molecular Weight
Between Crosslinks
Mesh Size Sulfur Content
% HA (wt/v) HA:DVS Ratio ρx (mol/cm3) Mc (g/mol) ξ (nm) % S (w%)
15 3:1 1.85E-03 783 7.36 5.6 0.87 81%
15 2:1 1.98E-03 732 6.84 7.3 1.29 81%
15 1:1 2.02E-03 719 6.23 10.0 1.91 60%
30 3:1 3.30E-03 440 4.49 6.6 1.15 107%
30 2:1 4.73E-03 306 3.43 8.2 1.45 91%
30 1:1 3.96E-03 366 3.81 8.0 1.5 47%
 NDVS= the number of DVS molecules per HA repeat unit (disaccharide)
* Defined as the percentage of DVS added that reacted with HA
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5.4.4 Diffusion Coefficient Measurement by Confocal Microscopy 
 
 Having formulated hydrogels with the desired swelling degrees, the next step was to 
confirm that the diffusion coefficients of these gels were in fact in the desired range before 
building the prototype.  This was done my measuring the diffusion coefficients of FITC-BSA in 
HA hydrogel discs using confocal microscopy. 15% HA discs with a HA:DVS ratio of 2:1 and 
3:1 were soaked in a 1 mg/mL FITC-BSA solution for 280 hours, and the 1-D diffusion into the 
discs were examined. Image stacks were captured at three different locations on the hydrogel at 
135 and 280 hours and the concentration gradients were calculated from image analysis at each 
penetration depth.  In order to compare the results with theory, the diffusion of FITC-BSA was 
calculated using the solution to Fick’s second law in a semi-infinite slab assuming constant 
concentration at the surface (C = C1, x = 0, t ≥ 0), an initial condition of zero initial concentration 




  = erf
x
2 Dt
     (5.10)  
 
The experimental and theoretical concentration profiles can be seen in Figure 5.6a and 
Figure 5.6b for 15% 2:1 HA hydrogels.  The diffusion coefficient used to calculate the 
theoretical concentration profile was estimated by fitting the experimentally measured data to the 
Fickian profile.  In general, the experimental data fits the theoretical profile, validating the 
expectation that a Fickian diffusion mechanism would be present.  The largest deviation between 
the experimental and theoretical profiles occurs at the larger penetration depths and is even more 
pronounced in Figure 5.6b after 280 hours.  This is believed to be a result of the instability of 
FITC-BSA bond, as has been reported in literature. FITC-BSA incubated in buffer solutions has 
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been shown to degrade and produce smaller fragments after just four days67. Any fragments or 
free FITC that has a much smaller molecular weight would diffuse much faster into the gel than 
FITC-BSA.  This would lead to higher concentration readings at the large penetration depths, 
and would also explain why the error is more pronounced at longer time points. 
  
 
Figure 5.6a.  Concentration profiles of FITC-BSA in 15% HA 2:1 hydrogel discs after 135 hours. The 
dashed lines represent the solution to Fick’s law in a thick slab with varying diffusion coefficients from 
3.0 x 10-12 - 1.0 x 10-11 cm2/s. 
 
Even though the data deviates from the theoretical profile, the experiment is still able to 
provide an estimation of the diffusion coefficient.  The dashed lines in Figures 5.6a and 5.6b help 
provide a range of diffusion coefficients that bracket the data.  The estimated diffusion 
coefficient for a 15% 2:1 hydrogel was 7 x 10-12 cm2/s.  With a swelling degree of 5.75, the 
expected diffusion coefficient was predicted to be around 4.5 x 10-9 cm2/s based on the estimates 
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coefficient for the 15% 3:1 hydrogels (not pictured) was 2 x 10-11 cm2/s. This number was also 
much lower than expected, as a swelling degree of 6.51 would be expected to have a diffusion 
coefficient around 8.8 x 10-9 cm2/s.  The large discrepancy between the diffusion coefficients 
predicted from free volume theory and the diffusion coefficients measured by confocal 
microscopy is possible evidence that screening effect is being observed.  Similar observations 
were seen in literature with BSA in dextran hydrogels. As soon as the swelling degree dropped 
below 5, screening effects caused significant deviations from the free volume theory, with 
diffusion coefficients straying up to three orders of magnitude from predicted values61.  Another 




Figure 5.6b.  Concentration profiles of FITC-BSA in 15% HA 2:1 hydrogel discs after 280 hours. The 
dashed lines represent the solution to Fick’s law in a thick slab with varying diffusion coefficients from 
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5.4.5 Release From Hollow Mini Cylinders 
 While the prior sections helped provide a better understanding of how the swelling 
degree affects the diffusion coefficient in HA-DVS gels, the major goal of this work was to 
fabricate a prototype mini cylinder in order to confirm that extended release of 3-6 months could 
be achieved.  While the main objective of developing a prototype was to show the release of 
larger molecules (48-97 kDa) from HA mini cylinders, the first solute that was tested in the 
hollow cylinders was Vitamin B12.  Due to its smaller size (1355 Da), the diffusion rate of 
Vitamin B12 is much faster than BSA or the Fab, allowing for complete release to occur in less 
than a day.  Vitamin B12 also has the advantage of forming a colored solution when mixed with 
water, which helps in detecting leaks due to cracks in the cylinder or a faulty cap.  The release 
profile of two different cylinders can be seen in Figure 5.7.  The formulation for both cylinders 
was 30% HA 3:1.  
The cylinders exhibit similar release profiles that correspond well with the diffusion 
model, with 90% of the loaded amount released within 200 minutes and 100% release achieved 
by 300 minutes.  The total amount of Vitamin B12 released from cylinder 1 was 0.017 mg, while 
cylinder 2 released 0.014 mg.  The difference is due to an inefficient capping method that can 
occasionally reduce the effective inner volume inside some of the cylinders.  This is taken into 
account when fitting the data with a diffusion coefficient using the modeling software. A 
diffusion coefficient of D = 1.3 ± 0.1 x 10-8 cm2/s was fit to the data.  The diffusion coefficient 
was calculated for both cylinders separately and then averaged together to get the final estimated 
diffusion coefficient.  This diffusion coefficient is about 2 times lower than the 2.4 x 10-7 
diffusion coefficient that was predicted based on free volume theory.  Given its small molecular 
weight and hydrodynamic radius (0.85 nm) any deviations from the theory due to possible 
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screening effects seem improbable, with a more likely explanation being an error in the diffusion 
coefficient estimation due to extrapolation. 
 
 
Figure 5.7.  The release of Vitamin B12 from 30% HA 3:1 hollow mini cylinders.  The release data fits 
the numerical solution to Fick’s law when solved for a hollow cylinder (Eq. 5.8), represented by the 
dashed line with a diffusion coefficient of 1.3 ± 0.1 x 10-7 cm2/s. All of the Vitamin B12 is released within 
300 minutes.   
  
 
Having established a successful method to synthesize, load, and cap HA cylinders using 
Vitamin B12, the focus shifted to the main goal of demonstrating that larger molecules could be 
successfully released at the desired rates.  BSA and a Fab were used as model proteins, and the 
cylinders were loaded with solutions that had a concentration of 160 mg/mL.  Figure 5.8 shows 
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ethylene glycol.  While BSA seemed to be releasing at a normal rate initially, after 15 days the 
release rate significantly dropped.  The experiment was run for 200 days, however the cylinders 
stopped releasing any protein after 50 days. The total amount of BSA released is about 10 mg, 
equating to only 2% of the amount of BSA that was loaded into the cylinders.  Similar results 
were seen in cylinders with formulations of 15% 2:1, 15% 1:1, and 30% 3:1 for both BSA and 
the Fab.   
 
 
Figure 5.8.  Release of BSA from an untreated 15% HA-DVS 3:1 hollow cylinder.  After 55 days only 2% 
of the BSA that was loaded had released from the cylinder. The dashed line represents a Fickian release 
profile with a D = 5.0x 10-12 cm2/sec. N=5 
 
Figure 5.8 highlights the importance of the crosslinking reaction.  While the use of DVS 
provides an easy synthesis method to crosslink HA and achieve the low swelling degrees needed, 
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mechanical testing and sulfur content of the HA-DVS gels prove that there are a large number of 
instances in which only one of the vinyl groups reacts with HA, leaving unreacted vinyl groups 
within the hydrogel networks.  These residual vinyl groups have the ability to react with proteins 
diffusing through the network, covalently attaching them to the hydrogel network and at the 
same time potentially restricting the diffusion. While this reaction generally occurs at higher pH 
values (8-9), the reaction has been shown to occur at a pH of 7 at room temperature57. Given the 
hypothesis that the reaction of protein is affecting the diffusion through the network over time, it 
is difficult to accurately fit the data to a diffusion coefficient.  The dashed line represents the 
Fickian release of BSA from a cylinder with a D= 5.0 x 10-12 cm2/s.  The initial release does, 
however, seem to be in the correct range (slower by a factor of 4) of what was expected from the 
confocal microscopy experiments. 
The release experiments were thus performed using HA-DVS hollow cylinders in which 
the residual vinyl groups had been capped with ethylene glycol.  It should be noted that the 
capping procedure with ethylene glycol did not significantly affect the swelling degrees of HA-
DVS hydrogels (See Appendix A5.4). The release of BSA from 15% HA DVS 3:1 cylinders can 
be seen in Figure 5.9.  The large variance in the data emphasizes the difficulty in performing 
extended release studies with hollow mini cylinders.  The crude capping method, while effective 
initially, began to break down after repeated handling, causing some of the cylinders to leak.  
While these cylinders could easily be recapped, a few cylinders were punctured or cracked 
accidentally during some of the measurements and had to be discarded.  This led to a smaller 
number of cylinders being tested and contributed to the high variability that is seen in Figure 5.9. 
Despite some of the issues with handling and capping the cylinders, the results in Figure 
5.9 show that BSA can be released from a hollow cylinder for over 120 days.  The cylinders 
	   159 
were loaded with a BSA solution with a concentration of 250 mg/mL in order to achieve the high 
release rates.   The maximum release rate is during the first 5 days, when the cylinders are 
releasing an average of 8 micrograms a day.  The release rate stays above the target release rate 
of 2.5 micrograms a day for over 50 days.  While the release rate slowly decreases over time, the 
cylinders continued to slowly release BSA after 120 days.  The cylinders had released 90% of 
the total load after 140 days.  A diffusion coefficient of 7.1 ± 3.1 x 10-11 cm2/s was fit to the data 
using Equation 5.9 and the least squares method.  While the deviation is large, the diffusion 
coefficient is only 3.6 times larger than the measured diffusion coefficient obtained through the 
confocal microscopy experiments. 
 
 
Figure 5.9. Release of BSA from 15% HA-DVS 3:1 hollow cylinders. The release data fits the numerical 
solution to Fick’s law when solved for a hollow cylinder (Eq. 5.8), represented by the dashed line with a 
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 The release of Fab from 15% HA-DVS 3:1 cylinders was also studied and can be seen in 
Figure 5.10.  The results demonstrate that these cylinders are capable of delivering Fabs for 3 
months.  The release is slightly faster when compared to that of BSA, which is to be expected 
given the smaller size of the Fab.  This is reflected in the measured diffusion coefficient of 1.3 ± 
0.5 x 10-10 cm2/s, which is about twice as large as the diffusion coefficient of BSA in the same 
cylinders. The cylinder releases 90% of the total protein loaded at 120 days. Due to limited 
amounts of Fab, these cylinders were loaded with a concentration of 90 mg/mL.  However, the 
maximum release rate observed was 4 micrograms a day, which is still above the target release 
rate.  However, the shape of release curve does not change with concentration, and achieving a 
higher release rate can be easily obtained by simply increasing the concentration. 
 
Figure 5.10. Release of Fab from 15% HA-DVS 3:1 hollow cylinders. The release data fits the numerical 
solution to Fick’s law when solved for a hollow cylinder (Eq. 5.8), represented by the dashed line with a 
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5.5 CONCLUSIONS 
 
 The results of this chapter demonstrate the potential of HA hollow mini cylinders to 
deliver therapeutic proteins to the retina for the desired 3-6 months of time.  They also present a 
drug delivery system that is versatile and can be extended to many other applications where long 
term delivery of proteins is needed. By controlling the concentration of HA and the ratio of HA 
to DVS, the swelling degrees can be altered, and the results proved that this crosslinking method 
was capable of achieving very low swelling degrees.  The low swelling degrees and high 
crosslink densities provide a network for reducing the diffusion of solutes of multiple sizes and 
attaining extended release. The hydrogels exhibited diffusion coefficients that were much lower 
than predicted using the free volume theory, which was hypothesized to be a result of screening 
effects, although more testing is needed to confirm this. Furthermore, hollow cylinders with a 
wide range of dimensions can be easily fabricated with molds.  These cylinders can be filled with 
proteins of any size or molecular weight, demonstrated by the release of Vitamin B12, BSA, and 
a model Fab that showed release profiles consistent with Fickian diffusion.  Release experiments 
with both BSA and the model Fab showed sustained release of at least 16 weeks. The results 
show that these HA-DVS hollow cylinders are suitable implants that can provide extended 
release and could be further investigated for the treatment of retinal diseases.  
At the same time, the work in this chapter revealed some of the shortcomings of an HA-
DVS hollow cylinder.  The hydrogel required a high concentration of DVS in order to get the 
low swelling degrees that were required for extended release.  This led to an excess amount of 
singly-reacted vinyl sulfone groups that were attached to the HA backbone which required 
ethylene glycol capping to eliminate unwanted side reactions with the proteins. It is because of 
these issues that a more efficient crosslinking method is investigated in Chapter 7.  
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CHAPTER 6: MODELING THE RELEASE FROM HOLLOW MINI CYLINDERS  
 
6.1  ABSTRACT 
 
 
The release of therapeutic proteins from hollow cylinders was modeled using the physics 
software COMSOL for the treatment of retinal diseases. The goal of the chapter was to 
determine the range of diffusion coefficients that would produce a therapeutically effective 
ocular delivery device. Hydrogel implants with three different outer diameters were modeled in 
an effort to understand how the diffusion coefficient and cylinder dimensions affect the release 
rate and profile: a 1mm implant that would have to be implanted, a 0.45 mm implant that could 
be injected using a 22-gauge microinjector, and a 0.21 mm implant that could be injected using a 
27-gauge needle. Cylinders with a 1mm outer radius were capable of delivering over 1 mg of 
drug while achieving the target release rate of 2.5 micrograms a day for over 4.5 months. While 
the smaller cylinders make the insertion process faster, safer, and less painful, the 0.45 mm 
cylinders were only capable of releasing at the target rate for a full month, while the 0.21 mm 
cylinders could only achieve the target release rate for one week.  The hollow cylinders were 
most effective at diffusion coefficients between 1.0 x 10-11 and 3.0x 10-11 cm2/s, a rather narrow 
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6.2  INTRODUCTION 
 
 Extended release of therapeutic proteins is an area of study that has received a lot of 
attention of late due to the increasing use of antibodies in treating cancer, autoimmune diseases, 
viral infections, and even asthma.1  While the number of therapeutic proteins in clinical trials 
continues to rise, focus is now being shifted on effective ways to deliver these high value drugs 
for prolonged periods of time.  Due to their large size, complex structure, and sensitivity to 
enzymatic degradation, the majority of proteins cannot be given by the preferred oral route and 
are instead administered via parenteral routes.  While effective, these routes (intravenous, 
subcutaneous, intramuscular) often require large doses to be therapeutically effective and the 
systemic exposure and frequent injections required can often lead to unwanted side effects. 
Alternatively, long term, targeted delivery systems provide local delivery and require lower 
dosages while at the same time improving patient compliance.2 
 There are a number of chronic illnesses that require a constant level of therapeutic 
proteins and would benefit from extended release systems. In oncology, injectable implants are 
able to increase a tumors exposure to chemotherapeutics locally while reducing systemic 
toxicity. Extended release systems can also be used to treat arthritic pain, release needed 
hormones like human growth hormone and insulin, and even deliver growth factors for tissue 
engineering applications.  
 Another area that emphasizes the need for targeted extended release is retinal diseases, 
specifically diabetic macular edema (DME) and age-related macular degeneration (AMD).  
These two diseases affect more than 30 million people worldwide and are the leading cause of 
blindness and vision loss. Both of these diseases stem from issues within the blood vessels in the 
retina.  Due to its location in the posterior segment of the eye, traditional eye drops and 
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intravenous injections are ineffective due to restrictions from the blood-retinal barrier.3 While 
there are a number of effective treatments that have recently been developed, delivering these 
molecules to the retina remains a challenge. The current delivery method is intravitreal injections 
that are administered every 4-8 weeks. These diseases are not curable, and patients have to 
continually receive these injections to manage the symptoms.  These frequent injections are not 
only unpleasant, but are also expensive and increase the risk of complications. The ideal 
intravitreal implant would be able to be injected into the vitreous of the eye and release drugs for 
3-6 months, reducing the amount of times a patient would need to be injected. 
 In the previous chapter, an implantable hydrogel implant was introduced that is capable 
of delivering therapeutic proteins for over three months.  The implants are made of hyaluronic 
acid (HA), a natural component of the eye, and are molded into hollow cylinders. These 
cylinders can be loaded with therapeutic proteins, capped, and implanted into the eye for 
sustained release.  While many implants control the release rate via degradation, diffusion, pH, 
temperature, or a combination of these factors, the release from these cylinders are controlled by 
diffusion alone.  By controlling the HA formulation, wall thickness, and concentration of protein 
within the hollow cylinder, the release profile and rate can be easily controlled.  
 One of the advantages of a hydrogel implant is that it can be molded and shaped into any 
size that is needed for a given application.  In the previous chapter, hollow cylinders were 
synthesized that were 1 mm in diameter and 10 mm in length. This size was chosen for the 
prototype because it is the largest cylinder size known to date that has gone under clinical trials 
for intravitreal drug delivery.4,5 The large size made loading, capping, and handling of the 
cylinders practicable while also providing a large dose that was easy and accurate to measure.  
However, a cylinder of this size would have to be surgically implanted in the vitreous after 
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making a 2mm incision in the pars plana. While this method is feasible, cylinders that could be 
injected using a smaller needle would reduce both time and cost and would be much safer for the 
patient.  One example of a smaller, biodegradable (PLGA) implant that has had clinical success 
delivering small molecules is Ozurdex ®, which has a diameter of 0.45 mm and is injected into 
the vitreous using a 22-gauge microinjector.  Using a 22-gauge microinjector allows for 
intravitreal injections that are much faster and safer when compared to implanting the cylinders 
after incision. However, a 22-gauge needle is still quite large when compared to the needles that 
are currently used for intravitreal injections. 27-gauge needles are currently the standard option 
for delivering substances that are more crystalline in nature (e.g. triamcinolone acetonide 
suspension), while 30 gauge needles or smaller are used to deliver solutions of the anti-vascular 
endothelial growth factors that are the standard treatment for macular degeneration and diabetic 
macular edema.6  In general, both doctors and patients prefer smaller needles, as they have been 
shown to lower the chances of complications and scleral damage while also reducing 
discomfort.7 
The production of smaller hollow cylinders has its fair share of challenges and 
limitations. Smaller cylinders become increasingly difficult to load and cap.  Also, the smaller 
the cylinder, the less volume there is to load with a concentrated drug solution.  This becomes 
even more challenging with intravitreal implants because most of the drugs that are used have a 
high molecular weight and the desired duration of release is 3-6 months.  One way to increase 
the amount of volume inside the cylinder is to reduce the wall thickness.  However, this not only 
makes the cylinders more susceptible to breaking, it also increases the rate of release as there is 
less hydrogel that the drug has to diffuse through. Fabricating such small cylinders and testing all 
of these variables over the time length required for ocular delivery would be very tedious.   
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Fortunately, diffusion in a hollow cylinder is a problem that has been well studied. In 
1959, Carslaw and Jaeger outlined a number of solutions that accounted for the conduction of 
heat through a hollow cylinder under a variety of boundary conditions.8  The mathematical work 
was then applied by Crank to a few select cases of diffusion in hollow cylinders.9 This work was 
extended recently by Huang and Yen to include mathematical solutions that take into account the 
steady state, transient state, and decay transient states of solutes diffusing within a hollow 
cylinder.10  While these mathematical solutions are helpful in understanding the release of drugs 
from hollow cylinders, almost all of the solutions were developed for cases where the boundary 
conditions are constant. Crank has solutions for the steady state release from a hollow cylinder 
where the inner and outer surfaces are kept at a constant concentration.9 Huang and Yen 
developed unsteady state solutions for cases where the inner or outer concentrations are kept 
constant as well as solutions for the case when the walls contain an initial amount of drug and the 
inner and outer surfaces are kept at zero concentration.10  In a hydrogel implant, the 
concentration inside of the hollow cylinder will slowly decline with time, further complicating 
the analysis. When challenging boundary conditions are involved numerical solutions are often 
utilized instead of developing complex analytical solutions. The increase of computing power 
and the large number of software options available has made solving these numerical problems 
easier than ever. 
In this chapter, the diffusion of drugs through intravitreal hollow cylinder hydrogel 
implants are modeled using COMSOL Multiphysics© software in an effort to understand how the 
diffusion coefficient and cylinder dimensions affect the release rate and profile.  This software is 
based on a finite element method and has been used to model many biological systems, including 
transdermal drug delivery, the release of drug from a scleral patch, and even the distribution of 
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heat within the human eye.11-13 Hydrogel implants with three different outer diameters are 
modeled: a 1mm implant that would have to be implanted, a 0.45 mm implant that could be 
injected using a 22-gauge microinjector, and a 0.21 mm implant that could be injected using a 
27-gauge needle.  By using a variety of wall thicknesses and diffusion coefficients, a wide range 
of release rates and profiles can be achieved.  While the focus of this chapter is on ophthalmic 
drug delivery, the delivery devices and release profiles explored in this chapter can be utilized in 
a number of biomedical applications where sustained, local release is required. 
 
 




The release of drugs from a hollow cylinder was modeled using Fick’s first law: 
Ni=-­‐Di∇ci      (6.1)  
 
where Ni is the flux of solute i, Di is the diffusion coefficient, and ∇ci is the concentration 
gradient of species i.  When combined with the continuity equation for mass, 
!!!
!!
+ ∇ ∘ Ni = 0     (6.2)  
 
Fick’s second law is obtained and is the main equation used to model the unsteady-state 
diffusion in multiple dimensions: 
!!!
!!
= Di∇2ci      (6.3)  
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The COMSOL software also includes convection terms into the equations, however these were 




6.3.2 Dimensions and Boundary Conditions 
 
The dimensions of the implants that were modeled can be seen in Figure 6.1. While the 
outer radius (ro) of the cylinders varied, all of the cylinders were 10 mm long and had a 1 mm 
base at the bottom.  The wall thickness and the inner volume of the cylinders was varied by 
changing the inner radius (ri).  The parameter K, defined as the ratio of the outer radius to the 
inner radius (K=ro/ri), ranged from 1.05 to 5.  The volume of the loading cavity ranged from 0.03 
to 6.4 microliters, depending on the inner and outer radius of the cylinder.   
 
Figure 6.1. Dimensions of the hollow cylinder implants.  The outer diameter (ro) was kept constant and 






	   175 
The values of the various simulation parameters used in the model are given in Table 6.1. 
The molecular weight parameter was set at 66 kDa, the molecular weight of bovine serum 
albumin (BSA) which was chosen due to its similarity in size and molecular weight to the 
therapeutic proteins on the market that are currently being used to treat retinal diseases.  The two 
most commonly used drugs are ranibizumab (Lucentis, Genentech, South San Francsicso, 
CA/Roche, Basel, Switzerland) and aflibercept (Eyelea, Regeneron, Tarrytown, NY), and have 
molecular weights of 48 and 97 kDA, respectively.  The initial concentration within the hollow 
cylinder was set at 160 mg/mL in order to keep consistent with Chapter 5, where 160 mg/mL of 
was loaded into hollow cylinder implants and used for release experiments. While the solubility 
limit of BSA is higher than 160 mg/mL, this concentration was chosen to more closely represent 
the concentration that a therapeutic protein would be administered at. In implants of this size, the 
drug formulations often range in concentration from 100 – 500 mg/mL in order to achieve 
extended release.14 In fact, one advantage of a hollow cylinder implant is the ability to load a 
supersaturated solution or slurry in order to increase the total dosage of the device. The solubility 
of therapeutic proteins will vary based on their size, hydrophobicity, and the distribution of 
charges and electrostatics.15,16  The current treatment method for AMD and DME consists of 
intravitreal injections at concentrations that range from 10 mg/mL (ranibizumab) to 40 mg/mL 
(aflibercept).  Given the frequency of the injections, the half-life of these drugs in the vitreous (~ 
9-12 days), and the cost of the drugs, the low concentrations were probably chosen in order to 
achieve the most effective dosage and to limit systemic exposure and do not reflect the solubility 
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The diffusion coefficient of protein within the hydrogel wall was varied systematically 
between 1 x 10-10 and 1 x 10-12 cm2/s.  Diffusion occurred both radially through the cylinder 
walls and through the hydrogel base at the bottom of the cylinder.  A boundary condition set the 
diffusion from the top of the cylinder equal to zero, simulating an impermeable cap.  







    H Height of gel 1 cm
    Ro Outer radius of gel 0.105 - 0.5 mm
    Ri Inner radius of gel 0.035 - 0.476 mm 
    K = Ro/Ri Ratio of outer and inner radii 1 - 5
    Vload* Volume of loading cavity 0.03 - 6.4  uL
    MW Molecular weight of drug 66000 g/mol
    C0 Initial concentration 160 mg/ml
    Mt Mass released at time t 2 - 1026 ug
    M∞ Total mas released 2 - 1026 ug
    Dgel Diffusion coefficient in the gel 1 x 10-10 - 1 x 10-12 cm2/s
    Dinner Diffusion coefficient in the inner volume 1 x 10-7 cm2/s
    Douter Diffusion coefficient outside the implant 1 x 10-7 cm2/s
    L Length of permeable portion of cylinder 0.9 cm
* Calculated using Ro and Ri




Figure 6.2.  Sample concentration profile of a hollow cylinder showing diffusion through the walls and 
base.  The dark red inside the cylinder represents the higher concentration of drug initially loaded, while 
the blue sphere outside of the cylinder represents the release volume that is set at a concentration of 0 
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6.3.3 Finite Element 
 
 A three dimensional free triangular mesh was used to define the computational domain. 
The network was set to be finer in and around the hollow cylinder and broader the further the 
distance away from the implant.  The maximum element size was 0.1 mm and the minimum 




Figure 6.3.  Two dimensional mesh of the hollow cylinder used to define the computational domain.  The 
network is much finer in and around the hollow cylinder and increases in size the further the distance 




	   179 
6.3.4 Release Rate and Profile 
 In evaluating the performance of the hollow cylinders it is helpful to define some of the 
terms that are used to characterize the release rate and profile.  A sample release profile can be 
seen in Figure 6.4.  The release profile is displayed in terms of the cumulative drug released, 
defined as the mass released at t = t (Mt) divided by the mass that is released from the cylinder at 
t = ∞  (M∞).  A distinctive feature of reservoir delivery devices (assuming the wall is unsaturated) 
is the time it takes for the drug to penetrate the wall and begin releasing, defined as tlag. The lag 
time will depend on both the wall thickness and the diffusion coefficient of the drug within the 












t 50% t 90% t lag 
	   180 
Another crucial aspect of any drug delivery device is the rate at which the device releases 
drug to the intended target area.  If the device cannot release drug at a fast enough rate, the 
concentration at the target area will not be high enough to have a therapeutic effect.  If the device 
releases drug too quickly, the concentration at the target area can become too high and may lead 
to potentially toxic side effects.  The concentration range that provides a safe, yet effective, 
therapeutic effect is referred to as the therapeutic window in drug delivery applications and can 
be seen in Figure 6.5. In this chapter, the concept of the therapeutic window is used to describe 
the release rate that can achieve this concentration range at the retina.  The upper and lower 
boundaries for the release rates of this therapeutic window are defined as rt,max and rt,min.  rmax is 
defined as the maximum release rate that is achieved from the delivery device and will vary 




Figure 6.5. The concentration range required for a drug to be effective, yet safe is known as the 











No Therapeutic Effect 
Duration of Action 
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Defining these upper and lower boundaries for an ocular implant is challenging in large 
part due to the difficulty of taking frequent samples from the human vitreous.  Looking at the 
current treatment methods for patients who suffer from AMD and DME can help define the 
target range of concentrations needed for an ocular implant.  The current treatment method is 
intravitreal injections that range in dosage from 0.5 mg (ranibizumab) to 2 mg (aflibercept), 
giving maximum vitreous concentrations of 0.125 mg/mL to 0.5 mg/mL17,18.  Although the 
blood-retinal barrier drastically limits the amount of drug that reaches the serum (approx. 90,000 
times lower than vitreous concentrations), increased levels of these inhibitors in the serum can 
lead to hypertension, and wound complications19.  The maximum amount of drug loaded in the 
cylinders modeled in this paper is just over 1 mg.  Even if the cylinder would crack or break and 
release the entire amount instantaneously, it would lead to a concentration in the vitreous of only 
0.25 mg/mL, similar to that of the intravitreal injections. Therefore the maximum concentrations 
and corresponding release rates described in this paper are all below the ct,max for the intended 
intravitreal application. 
The lower boundary that defines the minimum concentration necessary to achieve a 
therapeutic effect is much harder to define.  Both ranibizumab and aflibercept target a signal 
protein called vascular endothelial growth factor (VEGF).  VEGF plays an important role in the 
development of new blood vessels and elevated levels in the eye can lead to neovascularization 
that occurs behind the retina.20  This can lead to abnormal growth and leakage of the choroidal 
vessels, which leads to macular degeneration and edema.21 Both ranibizumab and aflibercept can 
prevent the signaling between VEGF and endothelial cells. Ranibuzumab was shown in vitro to 
specifically inhibit the proliferation of human umbilical vein endothelial cells that were induced 
by VEGF-A by 50% at concentrations between 11-27 ng/mL.22  Numerous studies have also 
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shown that patients with DME and AMD have elevated levels of VEGF in the vitreous that can 
range from 0.05-2.0 ng/mL.21,23-25  This wide range of VEGF levels makes it difficult to 
accurately calculate the concentration needed.  In this chapter the ct,min was set at 625 ng/mL. 
This concentration within the vitreous of the eye is over 20 times the concentration estimated to 
inhibit cell proliferation and over 300 times the concentration of VEGF in the vitreous. The 
release rate required to achieve this concentration is 2.5 µg/day and was set as the rt,min. 
This value was used to calculate the duration of action, defined as the number of days that the 
release rate of the implant exceeded 2.5 µg/day.  
 
 
6.4  RESULTS AND DISCUSSION 
 In this section hydrogel implants with three different outer diameters are modeled: a 1mm 
implant that would have to be implanted, a 0.45 mm implant that could be injected using a 22-
gauge microinjector, and a 0.21 mm implant that could be injected using a 27-gauge needle.  
Using COMSOL, the release rates and release profiles are plotted for each cylinder (similar to 
Figures 6.4 & 6.5) at varying wall thicknesses. Additionally, the release rates and profiles were 
also plotted using a wide range of diffusion coefficients.  Given the large amount of data 
produced, this section focuses on a reduced set of parameters such as t50%, t90%,  rmax, and the 
duration of action in order to more easily compare the cylinders.  The primary goal of this 
section is to determine the range of diffusion coefficients required for a successful hollow 
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6.4.1. Implantable Hollow Cylinder – 1mm O.D. 
The release of drug from a 1 mm cylinder was modeled with values of K ranging from 
1.05 to 3.  Table 6.2 shows the physical dimensions, wall thicknesses, inner volume, and the total 
mass of drug loaded for the cylinders studied.  Although a delivery device of this size would 
have to be implanted, the large inner volumes and high drug loading that can be achieved at this 
diameter provide the greatest versatility in terms of possible release rates and therapeutic 
durations when compared to the smaller devices.  Using an initial concentration of 160 mg/ml, 
the total drug loaded at K = 1.05 is just over 1 mg of drug.  This is the equivalent dose of two 
standard intravitreal injections of ranibuzumab while offering the advantage of controlled release 
that can be tuned by changing the diffusion coefficient within the wall.  
 
 

















1.05 0.952 0.024 6.41 1026
1.1 0.909 0.045 5.84 935
1.2 0.833 0.083 4.91 785
1.25 0.800 0.100 4.52 724
1.5 0.667 0.167 3.14 503
2 0.500 0.250 1.77 283
5 0.200 0.4 0.28 45
*M∞ was calculated using 160 mg/mL as the initial loading concentration
 and assuming 100% release
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The release profile from a 1mm hollow cylinder can be seen in Figures 6.6 and 6.7.  
Figure 6.6 shows how changes in the wall thickness and diffusion coefficient affect t50%. The 
dashed lines indicate the t50% required for 3-6 months release. As expected, an increase in the 
diffusion coefficient causes a decrease in the time it takes for the implant to release 50% of the 
total load. At the highest diffusion coefficient modeled, D = 1.0 x 10-10 cm2/s, t50% reaches the 
required target in only the cylinders with the thickest walls (K = 2-5).  On the other hand, at the 
lowest diffusion coefficient modeled, D = 1.0 x 10-11 cm2/s, even the thinnest wall thickness at K 
= 1.05, reaches the required target of 45 days (t50% = 47 days).  
 
 
Figure 6.6. The effect of the diffusion coefficient and wall thickness on the release of drugs from a 
hollow cylinder with an outer diameter of 1 mm. Release was measured in terms of t50%, the time it takes 
for 50% of the loaded drug to be released from the device. The labels indicate the value of K, which is the 
ratio of the outer to inner radius of the hollow cylinders. (---) = K = 1.05, (---) = K = 1.1, (---) = K = 1.2,  
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Similar results are seen in Figure 6.7, which shows how changes in the wall thickness and 
diffusion coefficient affect t90%.  At the highest diffusion coefficient modeled, D = 1.0 x 10-10 
cm2/s, t90% reaches the required target in only cylinders in which K > 1.5. At the slowest 
diffusion coefficients, D = 2.5 x 10-11 cm2/s and D = 1.0 x 10-11 cm2/s, small changes in K lead to 
large changes in t90%.  All of the cylinder dimensions reach the required target for 3-6 months 
release and as K reaches values larger than 1.5 the cylinders take over a year to release the entire 
load. At a fixed value of K of 1.05, t90% ranged from as low as 16 days to as high as 156 days 
showing the wide range of release times that can be achieved by changing only the diffusion 
coefficient. 
Figure 6.7. The effect of the diffusion coefficient and wall thickness on the release of drugs from a 
hollow cylinder with an outer diameter of 1 mm. Release was measured in terms of t90%, the time it takes 
for 90% of the loaded drug to be released from the device. The labels indicate the value of K, which is the 
ratio of the outer to inner radius of the hollow cylinders. (---) = K = 1.05, (---) = K = 1.1, (---) = K = 1.2,  
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While the time required to release 50 and 90 percent of the drug loaded is helpful for 
determining the range of diffusion coefficients required, the release rate is necessary in order to 
get a more accurate range. For example, in Figures 6.6 and 6.7 there were no upper boundaries 
set on t50% and t90%.  While many of the cylinders in the figure exceed the required 3-6 months 
release, this extended release may come at the expense of a lower release rate.  If the release rate 
is too low, the concentration at the retina may never reach the ct,min required to be therapeutically 
effective. Therefore, a closer look at the release rates is required. 
The maximum release rate from a 1mm hollow cylinder can be seen in Figure 6.8. It is 
important to note that, unlike the release times (t50% and t90%), the maximum release rate is 
dependent on the initial concentration loaded within the cylinder.  In this chapter, this 
concentration was kept constant at 160 mg/mL. Higher or lower initial concentrations will lead 
to an increase or decrease in the release rates from the values reported in this chapter. In general, 
as the wall thickness (K) increases, the release rate decreases, and as the diffusion coefficient 
increases, the release rate increases.  The largest variations in the release rate occur at values of 
K below 1.2 where the walls are the thinnest.  As expected, the maximum release rate occurs at 
K = 1.05 and ranges from 15 µg/day all the way up to 132 µg/day.  These release rates are 7-50 
times higher than the target rt,min which was set at 2.5 µg/day (dashed line in Figure 6.8). 
Alternatively, cylinders with thick walls in which the value of K is greater than 2 fail to reach the 
target, and at K=2, the cylinder only reaches the target release rate when the diffusion coefficient 
is higher than 4.5 x 10-11 cm2/s.  
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Figure 6.8. The effect of the diffusion coefficient and wall thickness on the maximum release rate of 
drugs from a hollow cylinder with an outer diameter of 1 mm. The labels indicate the value of K, which is 
the ratio of the outer to inner radius of the hollow cylinders. (---) = K = 1.05, (---) = K = 1.1, (---) = K = 
1.2,  (---) = K= 1.25, (---) = K = 2. The dashed line represents the target release rate of 2.5 µg/day that is 




Once again, there is no upper boundary placed on the maximum release rate in Figure 
6.8.  As mentioned earlier, even if the cylinder would crack or break and release the entire dose 
instantaneously the concentration at the retina would still not be high enough to elicit any toxic 
side effects.  However, excessively high release rates (rmax > 20 µg/day) are not desired as they 
quickly reduce the extended release that can be achieved without providing any known 
additional therapeutic benefit. Due to the small size of ocular implants, the drug load is often 
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One way to gauge this efficiency is by measuring the time each implant releases above 
the target release rate, known as the duration of action.  Figure 6.9 displays the duration of action 
that each cylinder can achieve.   The longest duration is 139 days at K = 1.1 and D = 1.0 x 10-11 
cm2/s.  This is just over 4.5 months of release at a rate that is above 2.5 µg/day.  Surprisingly, the 
longest durations do not occur at K = 1.05 for any of the diffusion coefficients. In fact, the 
longest durations occur at larger values of K the faster the diffusion coefficient is, as evidenced 
by the fact that at D = 1.0 x 10-10 cm2/s, the longest duration occurs at a K value of 2.  This 
means that as the diffusion coefficient increases, a longer therapeutic duration can be achieved 
by actually making the walls thicker and decreasing the total volume and load inside the 
cylinder.  This is due to the fact that at the lower values of K, the release rates from the thinner 
walls is initially so high that it quickly depletes the amount of drug inside the cylinder, reducing 
the amount of time the release rate is above rt,min.  Alternatively, at lower diffusion coefficients, 
having too thick of a wall can lower the release rate so much that it never exceeds rt,min.  This can 
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Figure 6.9. The effect of the diffusion coefficient and wall thickness on the duration of action that can be 
achieved from a hollow cylinder with an outer diameter of 1 mm. (☐ ) = D = 1.0 x 10-10 cm2/s, (¢ ) = D = 
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6.4.2. Microinjected Hollow Cylinder – 0.45mm O.D. 
The release of drug from a 0.45 mm cylinder was modeled with values of K ranging from 
1.05 to 5.  Table 6.3 shows the physical dimensions, wall thicknesses, inner volume, and the total 
mass of drug loaded for the cylinders studied.  The main benefit from a delivery device of this 
diameter is that it can be inserted into the vitreous using a microinjector, a much safer and faster 
process than making an incision and implanting the device.  However, even though the device is 
just under half the diameter of the 1 mm cylinders, the inner volume is dramatically reduced.  
This limits the amount of drug that can be loaded. The total drug loaded at K = 1.05 is 208 
micrograms, roughly five times less than the maximum drug that can be loaded in the larger 
1mm cylinders.  Additionally, the wall thicknesses of the 0.45 mm cylinders are much thinner 
than those of the 1.0 mm cylinder at similar values of K. 
 
 
















1.05 0.0013 0.011 1.298 208
1.1 0.409 0.020 1.183 189
1.2 0.375 0.038 0.994 159
1.5 0.300 0.075 0.636 102
2 0.225 0.113 0.358 57
3 0.150 0.150 0.159 25
5 0.090 0.169 0.057 9
*M∞ was calculated using 160 mg/mL as the initial loading concentration
 and assuming 100% release
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The release profile from a 0.45 mm hollow cylinder can be seen in Figures 6.10 and 6.11.  
Figure 6.10 shows how changes in the wall thickness and diffusion coefficient affect t50%.  The 
trend is very similar to that seen in Figure 6.6 for the 1mm cylinders, however the release is 
much faster.  At D = 1.0 x 10-10 cm2/s, t50% never reaches more than 12 days, where as the 1 mm 
cylinders reached a maximum of 56 days. Even though the cylinders are much smaller, the 
devices are still capable of releasing drug for the target period of 3-6 months, as evidenced by the 
t50% of 112 at K = 5 and D = 1.0 x 10-11 cm2/s.  However, given the cylinders smaller dimensions, 
this is only possible with thicker walls (K > 1.5) and at lower diffusion coefficients (D < 3.0 x 
10-10 cm2/s).The release can be extended even further by decreasing the diffusion coefficient to D 
= 1.0 x 10-12 cm2/s. The release profiles of cylinders at this diffusion coefficient are not shown in 
Figure 6.10, yet the values of t50% at K = 1.05 and 1.1 are 95 and 180, respectively. 
Figure 6.10. The effect of the diffusion coefficient and wall thickness on the release of drugs from a hollow 
cylinder with an outer diameter of 0.45 mm. Release was measured in terms of t50%, the time it takes for 50% 
of the loaded drug to be released from the device. The labels indicate the value of K, which is the ratio of the 
outer to inner radius of the hollow cylinders. (---) = K = 1.05, (---) = K = 1.1, (---) = K = 1.2,  (---) = K= 1.25, 
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Figure 6.11 shows how changes in the wall thickness and diffusion coefficient affect t90%.  
At the lower diffusion coefficient values, small changes in K lead to large changes in t90%, 
especially for values of K below 1.5. For all of the diffusion coefficients, as K reaches values 
larger than 1.5, t90% begins to plateau and does not change much as K is increased from 3 to 5. At 
a fixed value of K of 1.2, t90% ranged from as low as 10 days to as high as 100 days showing the 
wide range of release times that can be achieved by changing only the diffusion coefficient.  The 
release is much faster when compared to the 1mm cylinders, which was expected due to the 
thinner walls and smaller loading volumes. At D = 1.0 x 10-10 cm2/s, t90% reaches a maximum at 




Figure 6.11. The effect of the diffusion coefficient and wall thickness on the release of drugs from a 
hollow cylinder with an outer diameter of 0.45 mm. Release was measured in terms of t90%, the time it 
takes for 90% of the loaded drug to be released from the device. The labels indicate the value of K, which 
is the ratio of the outer to inner radius of the hollow cylinders. (---) = K = 1.05, (---) = K = 1.1, (---) = K = 
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The release rate from a 0.45 mm hollow cylinder can be seen in Figure 6.12. The figure 
follows the same trend that is seen in Figure 6.8 for the 1mm cylinders. As the wall thickness and 
K increase, the release rate decreases.  The largest variations in the release rate occur at values of 
K below 2 where the walls are the thinnest.  As expected, the maximum release rate occurs at the 
lowest value of K and ranges from 7.1 µg/day all the way up to 52 µg/day.  These release rates 
are roughly 3-20 times higher than the target rt,min which was set at 2.5 µg/day. 
 
Figure 6.12. The effect of the diffusion coefficient and wall thickness on the maximum release rate of 
drugs from a hollow cylinder with an outer diameter of 0.45 mm. The labels indicate the value of K, 
which is the ratio of the outer to inner radius of the hollow cylinders. (---) = K = 1.1, (---) = K = 1.2,  (---) 
= K= 1.25, (---) = K = 2, (---) = K = 5. The dashed line represents the target release rate of 2.5 µg/day that 
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Figure 6.13 displays the duration of action that each cylinder can achieve.   While the 
figure follows the same trends that are seen in Figure 6.8 for the 1mm cylinders, the durations of 
action are much lower.  The longest duration is 28 days at K = 1.1 and D = 1.0 x 10-11 cm2/s.  
This is less than one full month of release at a rate that is above 2.5 µg/day. In fact, the majority 
of the cylinders have a duration of action under two weeks.  At faster diffusion coefficients  (D = 
1.0 x 10-10 - 5.0 x 10-11 cm2/s) the longest duration does not occur at the lowest values of K and 
instead reaches a maximum at K values of 1.5.  While it may be possible to get a longer duration 
at a lower diffusion coefficient (D <1.0 x 10-11), doing so would require values of K below 1.1.  





Figure 6.13. The effect of the diffusion coefficient and wall thickness on the duration of action that can 
be achieved from a hollow cylinder with an outer diameter of 0.45 mm. (☐ ) = D = 1.0 x 10-10 cm2/s, (¢ ) 
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6.4.3. Injectable Hollow Cylinder – 0.21mm O.D. 
The release of drug from a 0.21 mm cylinder was also modeled.  While the benefits of 
injecting these cylinders using a 27-gauge needle would be enormous, achieving extended 
release in a delivery vehicle that small is hindered by a number of challenges.  The cylinders are 
so small that they have very little interior volume available for loading drugs.  Table 6.4 shows 
the physical dimensions, wall thicknesses, inner volume, and the total mass of drug loaded for 
the cylinders studied.  Even at the thinnest wall thickness (K=1.05), the total mass loaded is just 
over 45 micrograms. Almost five cylinders are needed in order to achieve the same drug loading 
as one 0.45 mm cylinder, and more than twenty cylinders are needed to equal the loading of a 
single 1.0 mm cylinder. 
 


















1.05 0.2 0.005 0.283 45.2
1.1 0.191 0.010 0.258 41.2
1.2 0.175 0.018 0.216 34.6
1.5 0.140 0.035 0.139 22.2
2 0.105 0.053 0.078 12.5
3 0.070 0.070 0.035 5.5
5 0.042 0.084 0.012 2.0
*M∞ was calculated using 160 mg/mL as the initial loading concentration
 and assuming 100% release
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The thin walls of such a small cylinder also limits the release rates and profiles that can 
be achieved. In order to achieve extended release, the diffusion coefficient must be lowered to 
values below D = 1.0 x 10-11 cm2/s.  However, at these values, the release rates are much lower 
than the rt,min which was set at 2.5 µg/day.  The duration of action that cylinders of this size can 
achieve is seen below in Figure 6.14. The longest duration is at K = 1.1 and D = 1.0 x 10-11 cm2/s 
and is only 7 days of release at a rate that is above 2.5 µg/day.  Despite their convenient size, 
cylinders that can be injected using a 27-gauge needle do not seem to be practical for sustained 




Figure 6.14. The effect of the diffusion coefficient and wall thickness on the duration of action that can 
be achieved from a hollow cylinder with an outer diameter of 0.21 mm. (☐ ) = D = 1.0 x 10-10 cm2/s, (¢ ) 
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6.5  ANALYSIS 
The success and implementation of an intravitreal implant will likely depend on a number 
of important considerations that were introduced in this chapter.  The first is the required release 
rate and concentration needed at the retina to provide a therapeutic effect.  In this chapter, the 
target release rate was assumed to be 2.5 micrograms a day. If further studies show that a lower 
concentration is needed at the retina, the duration of action for the implants in this chapter would 
increase.  For example, the microinjected cylinder is capable of releasing for 28 days at a rate of 
2.5 micrograms a day. If the target release rate drops to 1 microgram a day, the duration of action 
increases to 62 days, and if the target release rate drops to 0.5 micrograms a day it increases even 
further to 93 days.  Another consideration is the concentration of the drug that can be achieved in 
the implant.  The concentration used to run the calculations in this chapter was 160 mg/mL.  
Depending on the drug, it might be possible to achieve higher concentrations that would lead to 
higher loads and extended durations of action.  At the same time, certain drugs may have a lower 
solubility limit or may not stable for extended periods of time at such a high concentration. This 
would result in reduced concentrations and would limit the effectiveness of the implant.  
Furthermore, all of the cylinders in this chapter were assumed to be strong enough to be injected 
into the eye.  Depending on the hydrogel formulation, certain wall thicknesses may not have 
enough mechanical integrity to be injected and would need to be tested. 
One of the goals of this chapter was to understand how the diffusion coefficient of the 
intravitreal implant impacted the release rates and profiles of the devices.  Due to the size of the 
device, the range of diffusion coefficients that are effective in controlling the release is 
surprisingly narrow.  The cylinders with the longest duration of action had diffusion coefficients 
between 1.0 x 10-11 – 3.0x 10-11 cm2/s. When the diffusion coefficient is much larger than this the 
	   198 
release rate becomes so fast that it becomes difficult to achieve extended release.  Alternatively, 
when the diffusion coefficient is much smaller than this the release rate is reduced so much that 
the device fails to ever reach the target release rate required for therapeutic effect.  The results 
also show how sensitive the release is to the diffusion coefficient as small changes in the 
diffusion coefficient can lead to drastic changes in both the release rate and the release profile. 
Additionally, as the cylinders decreased in size the release rate and profile became even more 
sensitive to changes in the diffusion coefficient. Controlling the diffusion coefficient is critical in 
developing a successful hydrogel implant and further indicates the importance of understanding 
the diffusion in hydrogels at the low swelling degrees required to achieve such values.  
 
 
6.6 CONCLUSIONS  
 In this chapter, the release of therapeutic proteins from hollow cylinders was modeled 
using the physics software COMSOL for the treatment of retinal diseases. The chapter focused 
on intravitreal implants with varying dimensions and insertion methods that could be used as an 
alternative or replacement to the current standard of care. As expected, the largest size cylinders 
that were studied with a 1mm outer diameter were able to load the largest amount of drug and 
provide the longest duration of action. These implantable cylinders are capable of delivering over 
1 mg of drug and can achieve the target release rate of 2.5 micrograms a day for over 4.5 months. 
However, a cylinder of that size has to be implanted and involves a surgical procedure that is 
time consuming, costly, and has a higher risk of complications when compared to the current 
procedure.  Moving to smaller cylinders makes the insertion process faster, safer, and less 
painful, yet it comes at the expense of smaller drug loading and shorter duration of action. The 
smaller cylinders that can be inserted using a 22-gauge microinjector can be loaded with a 
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maximum of 208 micrograms and are capable of releasing at the target rate for almost a full 
month.  Making an even smaller cylinder that can be injected directly into the vitreous humor 
using a 27-gauge needle severely limits the amount of drug that can be loaded into the device.  
These cylinders are capable of loading only 45 micrograms of drug, and can achieve the target 
release rate for only one week.   
This chapter also shows the importance of the diffusion coefficient in controlling the 
release rate and achieving extended release. The small dimensions required for an intravitreal 
implant leads to a narrow range of diffusion coefficients that are capable of producing an 
effective delivery device.  Creating a hydrogel that can be finely tuned to provide a narrow range 
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CHAPTER 7: CONTROLLING THE NETWORK STRUCTURE OF HYALURONIC ACID HYROGELS 




The excellent physical and biological properties of hyaluronic acid (HA) hydrogels have 
led to an increase in biomedical applications, including the encapsulation of cells and proteins 
for drug delivery and tissue engineering.1,2  While there are a number of reactions that can be 
used to crosslink HA, a number of these reactions have disadvantages, such as complex 
functionalization, inadequate efficiency, and harsh reaction environments that limits the ability to 
encapsulate cells or proteins.  The thiol-ene reaction provides an alternative way to crosslink HA, 
and in this work the many advantages that this reaction provides are investigated.  Hyaluronic 
acid was modified with pentenoic anhydride and crosslinked into hydrogels using the crosslinker 
DTT. Hydrogels made from pentenoate modified HA (PHA) ranged in weight percent from 2-
15%, and in most cases were fully reacted gels in less than 120 seconds, among the fastest that 
have been seen for a thiol-ene hydrogel in literature while using very low initiator concentrations 
(0.1 mM - I2959) and light intensities (3 mW/cm2). The swelling degrees of the PHA hydrogels 
were easily tuned by controlling the degree of substitution as well as the ratio of thiol groups to 
ene groups and the resulting hydrogels showed an 85% increase in fracture strain when 
compared to comparable gels crosslinked using free radical polymerizations, an indication of a 
more uniform network.  Additionally, the model proteins ovalbumin and bovine serum albumin 
(BSA) were encapsulated into the hydrogel and recovered, with the results indicating that the 
percent recovery is related to the amount and location of free cysteine residues on the protein. 
Recovery of up to 78% was seen with ovalbumin. 
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7.2  INTRODUCTION 
 
 
 In the last decade, hyaluronic acid (HA) hydrogels have become increasingly popular in 
biomedical applications due to their excellent physical and biological properties.1,2 HA is a 
naturally occurring polysaccharide that plays a key role in the extracellular matrix of tissues, 
where it provides mechanical structure and acts as a scaffold.3 In tissue engineering applications 
HA hydrogels can be used to encapsulate cells in an effort to mimic this natural scaffold, taking 
advantage of the inherent biological functions of HA.2,4 Drug delivery applications take 
advantage of the nonimmunogenic properties of HA along with the high water content of 
hydrogels to safely encapsulate and deliver biopharmaceuticals including proteins and 
peptides.5,6 In both applications, controlling the reaction conditions and the diffusion of solutes 
through the HA hydrogel is necessary for clinical success.  In this chapter an alternative 
crosslinking reaction, the thiol-ene reaction, is investigated for the synthesis of HA hydrogels.  
This crosslinking reaction is hypothesized to allow for greater control of the hydrogel network 
structure, an important feature that would be useful for hydrogels in drug delivery and tissue 
engineering applications for controlling diffusion, while at the same time providing a way to 
quickly and efficiently tune the mechanical properties of the hydrogel. 
While there are a number of reaction methods available to crosslink HA into hydrogels, a 
number of these reactions have disadvantages, such as complex functionalization, inadequate 
efficiency, and harsh reaction environments that limits the ability to encapsulate cells or proteins.  
HA hydrogels can be crosslinked by two different routes: using unmodified or modified HA. The 
first route is to crosslink unmodified HA directly using difunctional crosslinkers such as divinyl 
sulfone (Figure 7.1b) or bis-epoxides.1 Crosslinking HA directly requires no prior modification 
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of HA, and many of the reactions are straightforward and easy to use.  However, most of the 
reactions are non-specific and will readily react with other labile groups (-COOH, -OH, N-
COCH3) that are available on the backbone of HA.1  As seen in Chapter 5, these reactions often 
lead to undesired reactions with proteins or cells that are being encapsulated, and in many cases 
occur under degradative conditions. The second route is to modify HA with any number of 
chemical groups including bromoacetate7, hydrazides8, tyramines9, thiols10, and methacrylates.11  
These HA derivatives can then be formed into hydrogels by addition reactions, condensation 
reactions, and radical polymerizations. One of the more commonly used methods for creating 
HA hydrogels via chemical modification is the free radical polymerization (Figure 7.1a) of 
methacrylated HA (MHA).1,12  This reaction can be controlled temporally and spatially using 
photoinitiation, and has been used to safely encapsulate cells and proteins.13,14  However, the 
crosslinking in these hydrogels occurs via the formation of polymethacrylate chains.15 These 
dense, hydrophobic chains are known to produce network heterogeneities in hydrogels.16 
One promising reaction that avoids these obstacles is the radically-initiated thiol-ene 
reaction.17-19  The thiol-ene reaction involves the addition of a thiyl radical (RS•) to a carbon-
carbon bond that can be either electron rich or poor18. The mechanism of the reaction was first 
proposed in 193876 and can be seen below in Figure 7.2.20,21 The reaction starts with the initiation 
step in which a thiol is first activated, either with heat or light, to give a thiyl radical.  This thiyl 
radical then propagates across a carbon-carbon double bond (“ene”), resulting in an intermediate 
carbon-centered radical.  This radical is then able to pull a hydrogen electron off of a second 
thiol, which gives the final thiol-ene product and in turn generates a new thiyl radical (known as 
chain transfer) that is able to react with another ene group. 
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Figure 7.1	  The mechanism of the basic thiol-ene reaction including: initiation, propagation, and chain 
transfer. Adapted from Lowe21 and Hoyle, Bowman 17 
 
 
The thiol-ene reaction is often grouped with a number of reactions termed “click 
chemistry” that were introduced in 2001 by K.B. Sharpless.22  Click chemistry is not a single 
specific reaction, but rather a concept that encompasses a number of possible reactions and 
mechanisms that allow for the synthesis of new and useful compounds using simple reaction 
conditions. These reactions proceed to very high yields, are able to be carried out in water and in 
the presence of oxygen, and give products that are easy to collect and purify. In order to achieve 
these qualities in a reaction, a high thermodynamic driving force is be needed, and it is this 
thermodynamic driving force that causes the reaction to be “spring-loaded” and leads to 
reactions that proceed rapidly and with high selectivity. The thiol-ene reaction has many of these 
attractive click attributes: it is extremely fast, proceeds to high yields, can be performed in water 
over a wide range of concentrations, and is insensitive to oxygen.17 The reaction can take place 
with virtually any carbon-carbon double bond, including terminal, internal, conjugated, 
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substituted, and even cyclic alkenes.23  At the same time, there is a wide range of thiols that can 
be used, as any thiol is able to react.  
The use of the thiol-ene reaction to synthesize HA hydrogels is a more recent 
development in literature.  In 2012 Auzély-Velty and her group attached a pentenoate group onto 
the backbone of both HA and dextran by esterification of the hydroxyl groups.24 The motivation 
behind the work was mostly to functionalize the polysaccharides with hydrophobic groups, 
peptides, and oligosaccharides, yet they were also able to form hydrogels using the pentenoate 
modified dextran and a PEG-dithiol.  A year later, Burdick and his group also used the thiol-ene 
reaction to synthesize HA hydrogels, except HA was this time modified with norbornene 
groups.25 They crosslinked the modified HA using dithiothreitiol (DTT), a commonly used 
dithiol molecule, and looked at how the compressive moduli varied with the irradiation time, the 
ratio of thiols to norbornene, and the weight percent of HA in solution.  They were focused on 
photopatterning the hydrogels to either modify the crosslink density or to couple chemical 
ligands.  They did this by choosing conditions in which after gelation there still existed pendent 
norbornenes that could undergo further reactions with a variety of thiol containing molecules. In 
both papers it was evident that the chemistry of the thiol-ene crosslinking reaction provides many 
advantages including high selectivity and reactivity, mild reaction conditions, and fast reaction 
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Another possible advantage that has yet to be investigated in the literature for HA 
hydrogels is the hypothesis that the thiol-ene reaction is able to form more homogeneous 
networks than other reactions, allowing for polymers and gels with very uniform network 
crosslink densities.17,18  When compared to chain growth reactions, the advantage comes from 
the fact that thiyl radicals are highly reactive toward ene groups, and, unlike methacrylated HA, 
the ene groups attached to the HA do not react with one another during the reaction. This results 
in the addition of a single thiol across a single ene group, and avoids the formation of kinetic 
chains that increase the heterogeneity of the hydrogel.  When compared with Michael addition 
type reactions (HA-DVS) in which crosslinking can occur at any hydroxyl group along the 
backbone, the thiol-ene reaction is highly selective and crosslinking can only take place at points 
along the backbone where an ene group exists. This allows for more control over the location 
and number of crosslinks and can result in a more uniform hydrogel network.  A hydrogel with a 
more uniform network has many advantages.  It has been shown in literature that PEG hydrogels 
synthesized using the thiol-ene reaction had significantly improved tensile stress and tensile 
strain when compared to similar hydrogels synthesized by radical chain growth polymerizations 
at similar crosslink densities.26 Additionally, it is hypothesized that hydrogels with a more 
uniform network are able to form hydrogels at lower polymer concentrations.27 
 
  




Figure 7.2	  Three methods of crosslinking HA that are compared throughout this chapter. (A) The free 
radical polymerization of methacrylated HA can be controlled spatially and temporally using 
photoinitiation, however the resulting hydrogel contains kinetic chains that are known to produce network 
heterogeneities. (B) The crosslinking of HA using the bifunctional crosslinker DVS requires no prior 
modification of HA and can react with any hydroxyl group on the HA backbone. However, the non-
specific nature of the reaction makes it difficult to control the network structure of the hydrogel. 
Additionally, the reaction only occurs under elevated pH levels, making it difficult to safely encapsulate 
proteins or cells. (C) The thiol-ene reaction can be controlled spatially and temporally using 
photoinitiation, occurs under physiological conditions, and is highly selective, occurring only at locations 
along the HA backbone that contain an “Ene” group.  This allows for greater control of the hydrogel 
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The major motivation for this study was the hypothesis that a hydrogel with a more 
uniform network would have significant effects not only on the mechanical properties but also on 
the transport of solutes within the hydrogel. While the diffusion models in Chapter 3 focus 
mainly on the swelling degree of the hydrogel and solute size to predict the diffusion coefficient, 
the diffusion also depends on the network structure of the hydrogel. This is especially true as the 
size of the solute approaches the average mesh size of the hydrogel, where the screening effect is 
hypothesized to occur. It is our theory that a more uniform network will produce a screening 
effect and lead to a reduction in the diffusion coefficient at higher swelling degrees when 
compared to hydrogels with more heterogeneous networks.  Being able to better control the 
diffusion of solutes in hydrogels is directly relevant to a number of research fields, including 
drug delivery and tissue engineering. In drug delivery, understanding the diffusive properties of 
solutes within a hydrogel is crucial for designing controlled release devices that are able to 
provide the correct release rate and profile to be therapeutically effective.29,30 In tissue 
engineering, the transport of nutrients, proteins, dissolved gases, waste products, and even cells 
are vital for the successful formation of tissue.31 In both of these cases, the hope is that the thiol-
ene reaction can lead to a more uniform hydrogel in which the diffusion can be better tuned and 
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Another motivation for this study was to compare both the speed and selectivity of HA 
modified with pentenoate to that of HA modified with norbornene. One of the major benefits of 
the thiol-ene chemistry is the fact that the reaction is highly selective, which is only true when 
the reaction proceeds via a pure thiol-ene reaction and there is no homopolymerization that 
occurs. As seen in Figure 7.3, homopolymerization occurs when the carbon centered radical 
reacts with another ene group instead of abstracting a hydrogen from another thiol.  
Homopoylmerization is simply a chain polymerization, reacting the same way in which MHA 




Figure 7.3. The ideal thiol-ene reaction occurs purely via a step crosslinking reaction, and does not 
include any chain polymerization that occurs between the carbon centered radical and another ene group. 
“Mixed mode” happens when both occur, affecting the stoichiometry of the reaction and resulting in an 
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When homopolymerization of enes does occur, it is considered a mixed-mode reaction as 
both the thiol-ene crosslinking reaction and radical chain polymerization are occurring 
simultaneously.  The formation of dense, hydrophobic polyvinyl chains that form during 
homopolymerization increases the heterogeneity of the hydrogel network.  Homopolymerization 
not only affects the network structure of the gels, it also disrupts the stoichiometry of the reaction 
and can leave a number of thiol groups unreacted.  Whether or not the reaction undergoes 
homopolymerization is largely affected by the relative rates of reaction, which is dependent on 
the properties of the ene group. One of the reasons that norbornene is often used in thiol-ene 
reactions is that, due to its bridged cyclic structure, it is unable to undergo chain polymerization 
and proceeds purely via the thiol-ene reaction.  The alleviation of the ring strain of norbornene 
during the propagation step also provides a high driving force and leads to very fast reaction 
times. However, it has also been shown that the speed of the thiol-ene reaction increases with 
increasing electron density of the carbon-carbon double bond18.  This means that a terminal 
alkene, such as the HA modified with a pentenoate group used in this chapter, will react faster 
when compared with the more electron-deficient acrylates and methacrylates, and will lead to 
less chain polymerization. If reactions involving pentenoate modified HA are shown to compare 
favorably to norbornene modified HA both in speed and selectivity it would have important 
implications for future work in this field. The reaction to modify HA with a pentenoate group is 
simpler and faster when compared to norbornene modified HA, and has been shown so to 
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The thiol-ene reaction also has a number of other advantages that would make it useful as 
a crosslinking method to create HA hydrogels for biomedical applications.  In the thiol-ene 
reaction (Figure 7.1c), a single radical species can cause hundreds and even thousands of 
reaction events to occur, which allows the overall reaction to occur with much lower initiator 
when compared with radical chain polymerization, in which radicals are consumed.  This low 
initiator concentration coupled with fast reaction times makes it ideal for in situ gelation and 
protein encapsulation.28,33  The encapsulation of proteins within hydrogels is an important area of 
interest in drug delivery, and was one of the motivations for studying the thiol-ene reaction.  A 
number of hydrogel crosslinking methods cannot be performed in the presence of proteins.  For 
example, in Chapters 4 and 5 divinyl sulfone was used to crosslink HA and dextran hydrogels 
via a Michael addition reaction.  While this crosslinking reaction was effective in achieving very 
low swelling degrees, it only occurs under denaturing conditions and also reacted with proteins 
diffusing into the hydrogel, covalently attaching them to the hydrogel network. Encapsulating a 
protein into a hydrogel network using photoinitiation is especially challenging, as exposure to 
UV light for long periods of time can cause a number of damaging changes to a protein which 
can lead to loss of activity.  Furthermore, the activation of photoinitiators generates free radicals 
that can cause damage to the protein.34  Using a thiol-ene reaction to photoencapsulate proteins 
has two advantages.  First, the speed of the reaction minimizes the amount of exposure that the 
protein has to the UV light.  Second, because the thiyl radical is regenerated in the thiol-ene 
reaction, it requires only small amounts of radical species to complete the reaction, reducing the 
amount of free radicals that can damage the proteins.  Recent research has shown that lysozyme 
maintains 100% bioactivity after being photoencapsulated in PEG gels using the thiol-ene 
reaction.33 Using lithium acylphosphinate (LAP) as an initiator, they showed that this holds true 
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under a range of initiator concentrations and intensities, and that bioactivity was connected to the 
total amount of radicals generated during polymerization.   
 
The work in this chapter hopes to advance the literature and build upon the previous work 
of Burdick and Auzély-Velty by crosslinking pentenoate modified HA using the thiol-ene 
reaction in an effort to determine the key parameters and synthesis conditions that control the 
network structure of the resulting hydrogels. The mechanical properties and swelling degrees of 
these hydrogels will be analyzed in an effort to find evidence of a more uniform hydrogel 
network when compared to alternative crosslinking methods. A more uniform network structure 
would allow for better control of the diffusion of solutes within the hydrogel and could lead to a 
reduction in the diffusion coefficient at higher swelling degrees, both of which would be useful 
in drug delivery and tissue engineering applications for controlling diffusion. The chapter also 
extends the knowledge in literature by investigating the encapsulation of proteins within HA 
hydrogels crosslinked using the thiol-ene reaction, an important area not only for biomedical 
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7.3  MATERIALS AND METHODS 
 
7.3.1 General Materials 
 Hyaluronic acid (51 kDa Mw, pharmaceutical grade from bacterial fermentation) was 
obtained from Lifecore Biomedicals (Chaska, MN). N,N-Dimethylformamide (DMF), 4-
pentenoic anhydride (98%), and DL-dithiothreitol (DTT) were obtained from Sigma-Aldrich (St. 
Louis, MO) along with the proteins bovine serum albumin (BSA, lyophilized powder, ≥ 98%), 
and ovalbumin (lyophilized powder, ≥ 98%). Pierce™ Coomasie Plus Bradford Reagent was 
obtained from Thermo Fisher Scientific (Waltham, MA).   
 
7.3.2 Synthesis of Pentenoate Modified Hyaluronic Acid (PHA) 
 
 The method described here to synthesize PHA is a modified version of a method used 
previously in literature.24 The goal in modifying the previously reported method was to scale up 
the process while at the same time increasing the yield. First, 0.50 grams of HA (40 kDa) was 
dissolved in 25 mL of water and kept at 4 °C overnight while being continuously stirred to 
ensure complete dissolution. 16.66 mL of N,N-Dimethylformamide (DMF) was then added 
dropwise in order to achieve a 3:2 ratio of water:DMF. Pentenoic anhydride was then added to 
the solution in 1, 1.5, 2, or 5 molar equivalents with respect to the repeating unit of HA.  The 
solution was maintained at a pH between 8 and 9 by adding 0.5M NaOH at regular intervals.  
The esterification reaction lasted between 2 and 4 hours, depending on the size of the batch, and 
after the pH had stabilized the reaction was kept at 4 °C overnight to ensure complete reaction. 
At this point NaCl was added to the reaction mixture to achieve a final salt concentration of 0.5 
M and the solution was precipitated into 5 fold excess ethanol.  After removal of the supernatant, 
the precipitate was dissolved in ultrapure water for final purification by diafiltration using 
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cellulose membrane 10k molecular weight cut-off dialysis tubing.  The diafiltration step was 
performed for 48 hours with the water being changed every 8-12 hours. The remaining solution 
was then frozen, lyophilized, and stored frozen until used.   
 
 
Figure 7.4	  Pentenoate groups were added to hyaluronic acid (51 kDa) via an esterification reaction used 
previously in literature.24  The degree of substitution (DS), defined as the amount of pentenoate groups 





7.3.3 NMR Spectroscopy 
 
 In order to determine the degree of substitution (DS), defined as the amount of 
pentenoate groups per repeating units of HA, the final product was analyzed by 1H NMR 
spectroscopy. 7 mg of PHA was first dried for 48 hours in the dessicator and then dissolved in 
600 µL of deuterium oxide and was analyzed at 25 °C using an Avance AVIII spectrometer 
operating at 500 MHz. The DS was calculated by comparing the digital integration of the NMR 
signals that arose from the methylene and double bond protons of the pentenoate group with the 
signals from the methyl protons of HA.  
Esterification 
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7.3.4 Synthesis of PHA Hydrogels 
 PHA hydrogels were synthesized by dissolving PHA and varying amounts of DTT in 
water containing 0.1 mM 2-hydroxy-1-[4-(2-hydroxyethoxy) phenyl]-2-methyl-1-propanone 
(Irgacure 2959 – (I2959)).  Throughout this work, the weight percent PHA (WPHA%) and the 
molar ratio of thiol groups to ene groups (XDTT) were systematically varied.  The solution was 
vigorously stirred using a microspatula and then centrifuged to remove any air bubbles before 
being cast into silicone rubber molds.  The molds were 2 mm thick and had precut holes 5 mm in 
diameter.  These molds were clamped between two thin glass plates (1 mm thick) and the 
hydrogels were irradiated in a Spectrolinker XL-1000 (Spectronics, Westbury, New York) at 312 
nm at 3 mW/cm2 for the desired amount of time.  Once formed, the gels were placed into an 
excess of D.I. water to leach out any unreacted materials.  
 
Figure 7.5	  The crosslinking of pentenoate modified hyaluronic acid occurs via the thiol-ene reaction 





hν (312 nm) 
0.1 mmol 
 Irgacure 2959 
PHA Hydrogel 
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7.3.5 Encapsulation and Recovery of Proteins from PHA Hydrogels 
 The proteins BSA and ovalbumin were encapsulated into the PHA hydrogels using the 
same synthesis method described earlier (7.3.4), except that protein was also dissolved in the 
0.01 M PBS (pH= 7.4) solution at concentrations of 1, 5, and 10 mg/mL.  The concentration of 
I2959 was lowered from 0.1mM to 0.025 mM to prevent the hydrogels from forming before 
being irradiated with UV light, which was occurring at the 0.1 mM concentration for gels 
containing 10 mg/mL protein (discussed in Section 7.4.5). The protein was leached from the gels 
by soaking them in 1 mL of protein free buffer in a shaking incubator at 4° C.  At predetermined 
time points, the gels were placed in 1mL of fresh buffer and the protein content of the leached 
solution was then determined using a Bradford assay.  The predetermined time points were 
chosen in an effort to maintain sink conditions while still obtaining high enough concentrations 
to assay accurately. To solve for the diffusion coefficient the analytical solution of diffusion 
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where Mt is the mass of the solute that has been released from the cylinder at time t, 𝑀! is the 
total mass that has been released from the cylinder at time t = t∞, r is the radius of the disc, and h 
is half the thickness of the disc. D is the diffusion coefficient, t is time, and α and β are defined in 
the above equations, with J0 being a Bessel function of the first kind of order zero.  This equation 
takes into consideration both radial and axial diffusion, and is valid for discs of all h/r ratios. 
 
 
Figure 7.6	  The diffusion of a solute from a disc of radius (r) and half thickness (h) can be solved using 
Equation 7.1 which takes into consideration both the radial and axial diffusion.  The equation is valid for 
discs of all h/r ratios.    
 
 
7.3.6 Swelling and Mechanical Testing 
 Fully formed gels were soaked in solutions of D.I. water or 0.01 M phosphate buffer 
saline (PBS, pH =7.4) until they were swollen to equilibrium and leached of any unreacted 
polymer or initiator.  The wet mass (ms) was then measured and the gels were placed in a 
dessicator for 48 hours at room temperature and allowed to dry.  The gels that were soaked in 
PBS were first soaked in excess D.I. water to remove any salt before being placed in the 
dessicator.  The dry mass (md) was measured and the swelling degree (q) was defined as: 
 
q = msmd
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The compressive modulus (E) and shear modulus (G) were calculated from stress vs. strain data 
collected using a RSA-III dynamic mechanical analyzer (TA Instruments, New Castle, DE). 
Cylindrical gels were tested under uniaxial compression at a rate of 0.05 mm/s and the modulus 
was calculated from the initial slope of the stress-strain curve as shown below: 
σ  =  Eε      (7.5)  
where ε  =   !!!!
!!
 and L and L0 are the thickness of the deformed and undeformed specimen, 
respectively. The compressive modulus was calculated by using the data up to strains of 10%. 
 The shear modulus (G) was calculated using the neo-Hookean model as the slope of the stress 
(σ) versus the strain function   𝜆 −    1
𝜆2
 as shown below: 
σ  =G λ  - 1
λ2
  (7.6)  
 
where 𝜆  = L/L0  and L and L0 are the thickness of the deformed and undeformed specimen, 
respectively. The shear modulus was calculated by using the data up to strain function values of 
3.  The calculation of the shear modulus is based on the assumption that most hydrogels follow 
Gaussian statistics and behave as ideal elastomers.  However certain polyelectrolyte gels, such as 
HA and methacrylated chondroitin sulfate, do not always exhibit a Gaussian distribution36, which 
can lead to errors in the meaningful structural parameters of the hydrogel.37 Although the data 
from compression testing fits Equation 7.6 quite well, the Mooney-Rivlin plot confirmed that the 
hydrogel deviates from neo-Hookean behavior (more detailed analysis can be seen in Appendix 
A7.4). Because of this, calculations for the parameters that are derived from Equation 7.6, such 
as the crosslink density and mesh size, are used only for internal comparisons. 
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 The crosslink density (ρx) of the hydrogels were calculated using the affine model of 





2/3   (7.7) 
 
where R is the ideal gas constant, T is the absolute temperature, v2 is the volume fraction of the 
polymer, and ν2r is the polymer volume fraction during hydrogel formation. ρx was used to 




     (7.8)  
 
in which ρ2 is the density of the dry polymer network.  The molecular weight between crosslinks 
was then used in calculating the average mesh size of the gels using the following equation38: 
 





l     (7.9)  
 
where Cn is the Flory characteristic ratio for HA, Mr is the molecular weight of the repeating 








	   222 
7.4  RESULTS AND DISCUSSION 
 
In this section, HA macromers modified with pentenoic anhydride were crosslinked into 
hydrogels using the crosslinker DTT over a wide range of conditions. The reaction conditions 
were tuned by systematically varying the irradiation time, the weight percent of HA, the degree 
of substitution, and the ratios of thiol groups to ene groups in an effort to determine how each of 
these factors affected the swelling degree and mechanical properties of the hydrogel.  
Additionally, the reaction was carried out in the presence of the model proteins ovalbumin and 
bovine serum albumin (BSA), encapsulating them into the hydrogels. The amount of protein 
recovered was measured in order to determine if any side reactions occur during 





 The goal of this section was to confirm that the formation of pentenoate modified HA 
hydrogels occur from a thiol-ene crosslinking reaction and not the chain polymerization that 
occurs during homopolymerization. To confirm that PHA does not undergo any significant 
homopolymerization, hydrogels were synthesized using the same procedure described earlier 
except without the crosslinker DTT.  By removing the crosslinker, the only way that the 
hydrogels can form is from the chain growth reaction between ene groups. The results in Table 
7.1 show the difference in swelling degrees between 6% PHA hydrogels that have been 
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Table 7.1. Comparison of the swelling degrees of 6% PHA hydrogels synthesized with and without the 
crosslinker DTT.  The timescale at which the thiol-ene reaction occurs is so much faster than that of the 
chain growth reaction between ene groups little to no homopolymerization is expected to occur. All 
hydrogels had a DS=55%, a XDTT =1, and were irradiated at 312 nm (I = 3 mW/cm2). Mean value ± 





When DTT is used as a crosslinker, the solution becomes a gel within 40 seconds, and 
achieves complete gel formation after only 80 seconds. As the crosslinking reaction comes to a 
completion, the swelling degree remained unchanged as no new crosslinks are being formed. 
In comparison, the PHA solution without DTT is unable to form a hydrogel after being irradiated 
for 10 minutes, and only begins to form after being exposed to UV light for 20 minutes. Even 
then, the hydrogels formed are very highly swollen, with swelling degrees ranging from 930 ± 50 
– 1180 ± 150. The results from Table 7.1 give clear evidence that the reaction between the thiols 
and enes is faster than the chain reaction between ene groups. This confirms that there is little to 
no homopolymerization (i.e., chain growth) that occurs during the synthesis of 6% PHA 





0.7 38.5 ± 0.9 No Gel
1.3 31 ± 1.2 No Gel
2 30.6 ± 0.5 No Gel
4 29.3 ± 1.2 No Gel
10 32.5 ± 2.7 No Gel
20 - 1180 ± 150
30 - 1000 ± 55
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It should be noted that while the thiol-ene reaction appears to occur much faster than the chain 
reaction between the ene groups, the results in Table 7.1 are also a result of improved 
crosslinking efficiency that occurs with the thiol-ene reaction. It is possible that some degree of 
chain reaction is occurring between the ene groups, but these reactions may not be forming 
enough elastically effective crosslinks to produce a fully formed gel. For example, MHA 
hydrogels with similar molecular weights that are reacted via chain polymerization usually only 
form at concentrations above 10%.39 This highlights one clear advantage of the thiol-ene reaction: 
the ability to get a well-defined hydrogel at low polymer concentrations where other crosslinking 
methods may not be able to form hydrogels.   
 
7.4.2 Kinetics of Hydrogel Formation 
 The next step in characterizing PHA hydrogels was to determine the time it takes to 
complete the thiol-ene reaction under the synthesis conditions studied in this chapter.  The 
primary objective was not to perform an in depth kinetics study but rather to determine the time 
required for the crosslinking reaction to go to completion.  This was accomplished by measuring 
the swelling degrees of 4, 6, and 8% (w/w) PHA hydrogels that had a DS = 55% and an 
equimolar ratio of thiols to enes after being irradiated with UV light (312 nm) for various 
amounts of time that ranged from 10-300s. The results can be seen in Figure 7.7, which shows 
that as the weight percent of PHA increases, the time it takes to form a fully developed hydrogel 
decreases.  The 8% PHA hydrogels reach a plateau in swelling degree (20.8 ± 1.2) after just 40 
seconds, while the 4% PHA hydrogels take the longest time to reach a plateau in swelling degree, 
achieving a final swelling degree of 55 after being exposed to the UV light for 240 seconds.  
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Figure 7.7 also shows that the swelling degree of PHA hydrogels decreases as the concentration 
of PHA increases. 
 
Figure 7.7.  Swelling degrees of 4%, 6%, and 8% PHA hydrogels as a function of irradiation time. As 
weight percent increases, the time it takes to form a fully developed hydrogel decreases.  All hydrogels 
had a DS=55% and were irradiated at 312 nm (I = 3 mW/cm2). Mean value ± standard deviation, n ≥ 3. 
 
 
While it is difficult to compare the reaction times of hydrogels in literature due to the 
many factors that affect gelation kinetics, the speed at which these PHA gels form is among the 
fastest that have been seen for a thiol-ene hydrogel.  The closest comparison in literature comes 
from hydrogels in which HA was modified with norbornene groups with a DS = 20% and 
crosslinked with DTT.1  These 4% HA hydrogels were formed using 10 mW/cm2 UV light (λ 
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to form in the first 60 seconds, they took 20 minutes to reach fully formed gels.  The results in 
Figure 7.2 show that 4% PHA gels take 4 minutes to fully form, using 22 times less initiator and 
an UV intensity that is 3 times lower. This is direct evidence that HA modified with a pentenoate 
group can form a hydrogel as fast as HA modified with a norbornene group. Another example of 
thiol-ene gels in literature is a PEG 4-arm norbornene that was crosslinked with a PEG dithiol.33  
With a 10 wt % monomer solution, the gels were formed using 10 mW/cm2 UV light (λ = 390 
nm) and the initiator lithium acylphosphinate (LAP) at concentrations of 10, 1, and 0.1 mM.  The 
hydrogels with initiator concentrations of 10 and 1 mM were fully formed in less than 10 
seconds and hydrogels with an intiator concentration of 0.1 mM required 60s to reach fully 
formed gels.  8% PHA gels took less time to gel at identical initiator concentrations and with a 
UV intensity that was 3 times lower.  In comparison, MHA hydrogels are often polymerized for 
10-30 minutes using 3-10 mW/cm2 UV light (λ =312-390 nm) and an I2959 initiator 
concentration of 2.25 mM.11,14,39 
While the results from Figure 7.7 show the speed at which the thiol-ene reaction can take 
place, they also display the ability to control the swelling degree of the hydrogel by simply 
controlling the irradiation time.   One of the advantages of having a reaction that is photoinitiated 
is the ability to control the reaction both spatially and temporally.  By controlling the duration of 
time a gel is irradiated, a hydrogel with a wide range of swelling degrees and mechanical 
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7.4.3 Effect of PHA Concentration 
 Another hypothesized way of controlling the network structure of the hydrogel is by 
changing the PHA macromer concentration.  Increasing the concentration of PHA in solution is 
expected to increase the crosslinking density of the hydrogels, leading to lower swelling degrees 
and higher moduli.  To study the effect of monomer concentration on swelling degree, hydrogels 
with varying weight percent PHA were synthesized. The degree of substitution (55%) and the 
ratio of thiols:enes (1:1) were kept constant throughout the experiment along with the irradiation 
time (320s) and intensity. The swelling degrees of the hydrogels are presented in Figure 7.8 and 
declined continuously as the weight percent of PHA increased. Hydrogels with a 2% PHA 
concentration are not shown, and had a swelling degree of 300 ± 30. The swelling degrees of 
PHA hydrogels ranged from a low of 8.8 at a 15% concentration all the way up to a high of 300 
at a 2% concentration.  
 
Figure 7.8. Swelling degree as a function of the weight percentage of PHA.  As WPHA % increases the 
swelling degree decreases. All hydrogels had a DS=55% and were irradiated at 312 nm (I = 3 mW/cm2) 






















300 ± 30 
2% 
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7.4.4 Effect of Crosslinker Ratios 
In the previous sections it was confirmed that two minutes was an adequate time to fully 
complete the crosslinking reaction and that crosslinking was effective only via the thiol-ene 
reaction under the conditions used.  In this section, the primary goal was to determine how the 
network structure of the hydrogel can be controlled by changing the ratio of thiol groups to ene 
groups (XDTT) and the degree of substitution. To study these changes in network structure, PHA 
hydrogels with a wide range of both XDTT  and degree of substitution (15-55%) were synthesized. 
The weight percent of PHA (6%) was kept constant throughout the experiment along with the 
irradiation time (320s) and intensity.   
The swelling degrees of PHA hydrogels synthesized using varying thiol to ene ratios are 
presented in Figure 7.9a. A more detailed view of the effect of crosslinking ratio on the swelling 
degree of PHA hydrogels can be seen in Figure 7.9b. The results from Figures 7.9a and 7.9b 
indicate that the swelling degree reaches a minimum at XDTT values from 0.6-1.0.  This is 
especially clear for the lower substituted PHA, where a clear minimum range is seen. This is 
consistent with compressive modulus data seen in Burdick’s data on norbornene hydrogels in 
which the DS = 20%.25 However, at the highest degree of substitution (55%), instead of a rather 
sharp change in the swelling, the results indicate that there is no statistically significant change 
from XDTT = 0.6 - 1.4 (p > .05), a result that has never been seen in literature.   
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Figure 7.9a. The effect of crosslinking ratio on the swelling degree of 6% (wt/wt) PHA hydrogels. The 
swelling degrees of the hydrogels are less affected by changes in the XDTT as the degree of substitution 
(DOS) increases.All hydrogels had a PHA weight percent of 6  and were irradiated at 312 nm (I = 3 




As the degree of substitution increases, the swelling degrees of the hydrogels are less 
affected by the changes in the thiol to ene ratio. For example, with a DS =15%, as the value of 
XDTT increases from 0.4 to 0.6 the swelling degree drops sharply from 690 ± 100 to 115 ± 13. 
When the values of XDTT are at 0.6 and1.0, the swelling degrees remain at a value around 120, 
yet as soon as XDTT increases past 1.0, the swelling degree increases sharply again, reaching a 
swelling degree of 355 ± 9 at a XDTT value of only 1.2. Alternatively, PHA hydrogels formed 
with a DS = 55% do not exhibit the same sharp decrease and increase in swelling degrees, and 























  15% 
  20% 
  25% 
  55% 
	   230 
reasoning for this is due to the small amount of functional groups that are on the 15% substituted 
PHA when compared with the 55% substituted HA. At low degree of substitutions, getting the 





Figure 7.9b. The effect of crosslinking ratio on the swelling degree of 6% (wt/wt) PHA hydrogels for 
conditions with Q < 200. The swelling degrees of the hydrogels seem to reach a minimum at values of 
XDTT between 0.6 and 1.0.  All hydrogels had a PHA weight percent of 6  and were irradiated at 312 nm (I 
= 3 mW/cm2) for 320 seconds.  Mean value ± standard deviation, n ≥ 3. The dashed lines serve as a guide 
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Figure 7.10 shows the compressive moduli of 6% PHA gels (DOS=55%) in which the 
value of XDTT ranged from 0.1 to 2.0.  A hydrogel with a higher crosslink density will lead to a 
higher value of E.  The compressive modulus increases as the value of XDTT increases from 0.1 to 
0.4.  When the value of XDTT increases from 0.4 to 1.4, the resulting gels exhibit only a slight 
change in modulus.  It is only when the values of XDTT  increase past 1.4 where the addition of 




Figure 7.10. The effect of crosslinking ratio on the compressive modulus.  The modulus reaches a 
maximum at XDTT  = 0.4-1.4 and decreases as more or less DTT is added. All hydrogels had a DS=55% 
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The calculated compressive modulus, shear modulus, fracture stress, and fracture strain 
can be seen in Table 7.2 for 6% PHA hydrogels (DOS = 55%) along with the crosslink density 
and mesh size.   The moduli data and the corresponding calculations of crosslink density and 
mesh size provide additional evidence that the highest crosslinked gels do not occur precisely at 
XDTT = 1.0 but rather a range between 0.4-1.0.  The shear modulus (G) increases as the value of 
XDTT increases from 0.1 to 0.4 and then plateaus at around 125 when the value of XDTT  ranges 
from 0.4 to 1.4.  A similar trend is seen in both the crosslink density and mesh size of the PHA 
hydrogels.  
 








Gel Formulation Crosslink Density Mesh Size
XDTT q (w/w) E (kPa) G (kPa) Stress (kPa) Strain (%) ρx (mol/m3) ξ (nm)
0.1 164 ± 16.4 23 ± 6.5 8.0 ± 2.7 8.7 ± 4.2 29.1 ± 5.3 117.5 ± 34.1 85.6 ± 11.3
0.2 63.1 ± 2.1 151 ± 39.5 52 ± 5.5 67.7 ± 27.6 27.6 ± 10.6 552.6 ± 54.6 28.6 ± 1.2
0.4 32.6 ± 2.2 368 ± 14.1 124 ± 16.9 172.5 ± 55.9 32.2 ± 4.4 1057.3 ± 116.0 16.6 ± 0.8
0.6 26.2 ± 1.5 387 ± 42.1 134 ± 8.5 240.2 ± 66.8 36.0 ± 4.7 1062.3 ± 45.2 15.4 ± 0.4
0.8 28.2 ± 2.3 353 ± 103.1 121 ± 26.2 256.1 ± 81.6 39.9 ± 3.1 983.0 ± 172.4 16.4 ± 2.0
1 29.0 ± 1.6 347 ± 53.6 121 ± 14.6 270.8 ± 31.9 41.2 ± 2.3 992.3 ± 98.8 16.5 ± 0.9
1.2 32.2 ± 1.4 319 ± 20.5 105 ± 5.9 172.6 ± 37.6 34.2 ± 3.9 891.6 ± 36.5 18.0 ± 0.4
1.4 30.7 ± 2.4 311 ± 59.6 114 ± 9.2 188.9 ± 32.8 38.3 ± 2.8 952.8 ± 48.4 17.1 ± 0.7
1.8 38.5 ± 1.4 244 ± 34.1 83 ± 11.1 171.3 ± 42.2 38.7 ± 3.8 748.1 ± 89.1 20.9 ± 1.2
2 47.7 ± 2.0 219 ± 5.8 76 ± 7.7 155.1 ± 26.7 38.67± 2.3 735.7 ± 63.3 22.6 ± 1.0
Values are mean ± standard deviation with n = 3
Compressive Failure PropertiesModuli
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In an ideal system, the maximum crosslink density would occur at XDTT = 1.0, the ratio at 
which every thiol has an ene to react with, and each dithiol that reacts would form an effective 
crosslink between two different chains.  Therefore, hydrogels synthesized at XDTT = 1.0 should 
have the lowest swelling degree and the highest moduli. As Figure 7.11 shows, at XDTT values 
lower than 1, there are not enough thiol groups to react with the surplus of ene groups, and even 
though each reaction is expected to form an effective crosslink, the hydrogel will have a lower 
crosslink density compared to the gels synthesized at XDTT = 1.0. At XDTT values greater than 1 
there are excess amounts of thiol groups, which saturate the ene groups. Even though all of the 
ene groups are able to react, the excess amount of thiol groups combined with the speed of the 
reaction limit the amount of effective crosslinks that can form, which is hypothesized to lead to 
lower crosslink densities. Additionally, under these conditions, there is expected to be a number 





Figure 7.11. Idealized schematic showing how the thiol-ene crosslinking reaction of PHA is affected by 
the ratios of thiol groups to ene groups (XDTT). The green dots represent the ene groups attached to the 
HA backbone and the red semicircles represent a thiol. 
 
 
XDTT = 1 XDTT > 1 XDTT < 1 
PHA 
Dithiol 
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The results in Figures 9, 10 and Table 7.2 show that hydrogels synthesized at XDTT = 1.0 
have the lowest swelling degree and the highest moduli. The results indicate that the highest 
crosslinking density occurs at values XDTT between 0.6 and 1.0.  There are a number of possible 
explanations as to why this is, and they all relate to the potential reactions that can occur that 
limit the efficiency of the reaction (Figure 7.12). Despite the fact that at XDTT = 1.0 there is one 
thiol for every ene, this does not mean that every thiol will react with an ene to form an effective 
crosslink.  In some cases, thiols can react with two enes that are on the same HA chain, forming 
an intramolecular loop.  This may lead to instances in which only one of the thiols of a DTT 
molecule reacts with an ene group, leaving a free thiol attached to the HA backbone.  This can 
also be affected by steric constraints as well as structural limitations due to the chain 
conformations of the HA polymer.  
 
 
Figure 7.12. Idealized schematic showing potential reactions that can occur at a ratio of thiol groups to 
ene groups (XDTT) equal to one. (A) Ideal reaction in which each ene group (green dots) reacts with a thiol 
group (red semicircles), forming an elastically effective crosslink between two separate chains. (B) Two 
thiols react with enes that are on the same chain, forming an intramolecular loop.  (C) Only one thiol is 
able to react with an ene group, leaving a free thiol group attached to the HA backbone. (D) A chain 
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Additionally, there is a possibility that some degree of homopolymerization is occurring, which 
would reduce the amount of enes that are available to form crosslinks and lead to a shift in the 
minimum away from XDTT = 1 that is seen in Figures 7.9a and 7.9b.  However, this shift was also 
seen in thiol-ene hydrogels in which norbornene was attached to HA, and norbornene is unable 
to participate in chain reactions.  
 
 
One of the hypotheses this chapter set out to prove was the idea that thiol-ene reactions 
are believed to form much more homogeneous networks than its chain growth counterparts, 
which allows for polymers and gels with very uniform network crosslink densities. One of the 
advantages of a more uniform hydrogel network is improved mechanical properties, especially 
the fracture stress and strain.  As gels are placed under strain, the energy is distributed among the 
elastically effective chains. In heterogeneous hydrogels, there will be regions within the gel that 
contain a less concentrated amount of chains.  Under strain these weaker regions will undergo 
failure first, which causes multiple fracture events and leads to macroscopic rupture.  In a more 
uniform network, the strain is more evenly spread out across the chains, which results in 
increased fracture strains.  This was demonstrated by Sakai and Shibayama in 2008 through the 
use of highly uniform tetra-PEG hydrogels.41   
While it may be difficult to distinguish the differences in network uniformity between the 
PHA hydrogels listed in Table 7.2 which were all synthesized using the thiol-ene reaction, a 
comparison of HA hydrogels synthesized using three different crosslinking methods provides 
clearer evidence.  This comparison can be seen in Table 7.3, which displays the fracture stress 
and strain of 13% (w/w) HA hydrogels synthesized using the thiol-ene reaction, the radical chain 
polymerization of methacrylated HA15, and the crosslinking of HA using the bifunctional 
crosslinker DVS (Chapter 5).  While the compressive modulus and fracture stress differs 
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between the three crosslinking methods, this can be attributed to wide range in swelling degrees 
that are seen between the three types of hydrogels due to the varying crosslinking densities.  In 
general, as the swelling degree of an HA gel decreases, both the compressive modulus and the 
fracture stress increase.  However, the fracture strain of a HA gel has been shown to not be 
strongly dependent on the swelling degree and crosslinking density, as can be seen in Table 7.2, 
Table 5.1, and in work with MHA hydrogels.15  The fracture strains of PHA hydrogels are on 
average 85% higher than the fracture strains of MHA hydrogels. For MHA hydrogels, the low 
fracture strain was hypothesized to be a result of the stiff chain conformation of HA which could 
possibly lead to network deformations.  The fracture strains of PHA are still relatively low, most 
likely due to the chain conformation of HA, yet they are much higher than MHA hydrogels.  
This suggests that the PHA networks are less heterogeneous and provides evidence that the 
hydrogel networks of HA hydrogels crosslinked via the thiol-ene reaction are more uniform than 
the networks of MHA hydrogels. Additionally, these trends can be observed over a wide range of 
formulations, as 6% PHA hydrogels also had very high fracture strains of 36 ± 4%.  PHA 
hydrogels were synthesized at the same concentration and with similar degrees of 
functionalization as the MHA hydrogels, yet the MHA gels have swelling degrees that are almost 
three times higher and have compressive moduli that are more than half that of PHA hydrogels.  
While this does not provide further evidence of a more uniform network, it does provide 
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The fracture strains between the PHA and HA-DVS hydrogels were not statistically 
significant (p=0.338), and therefore no conclusions could be made about differences in network 
structure between the gels.  The benefit of the thiol-ene reaction is that crosslinking can only 
occur on the HA backbone where ene groups are present, which allows for more control of the 
network structure. Further work is needed to investigate the hypothesis that PHA hydrogels 




















13% PHA* Thiol-ene 10.5 ± 0.5 1090.6 ± 76 523.4 ± 91 30.1 ± 1.9
13% MHA# Chain growth 27.5 ± 0.22 476 ± 63 75.1 ± 9.7 16.28 ± 0.61
13%  HA-DVSa Michael addition 6.6 ± 0.19 2230 ± 160 730 ± 230 26.6 ± 6.5
Values are mean ± standard deviation
*Degree of substitution = 55%, XDTT = 1.0,  n=4
# Degree of methacrylation = 47%, n =5
a HA:DVS ratio = 3:1,  n=5
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7.4.5 Encapsulation of Proteins into a PHA Hydrogel 
  
The results of the previous sections investigated a number of variables that can be used to 
control the network structure of the hydrogel including the irradiation time, the polymer 
concentration, the degree of substitution, and the ratio of thiols to enes.  The results also 
provided evidence of a more uniform network structure. The major motivation behind this work 
was to test the hypothesis that a hydrogel with a more uniform network could have significant 
effects on the transport of solutes within the hydrogel.  Another motivation for using the thiol-
ene reaction was to encapsulate proteins within hydrogels, taking advantage of the speed and 
selectivity of the thiol-ene reaction, along with the mild reaction conditions.  If proteins could be 
successfully encapsulated, it would represent a major improvement when compared to the 
Michael addition reaction used in Chapters 4 and 5 in which divinyl sulfone was used to 
crosslink HA and dextran hydrogels.  Not only did this reaction occur under denaturing 
conditions, it also reacted with proteins diffusing into the hydrogel and covalently attached them 
to the hydrogel network. 
To study the photoencapsulation and release of proteins in PHA hydrogels, the model 
proteins BSA and ovalbumin were encapsulated into PHA hydrogels with the concentration of 
protein in the hydrogels ranging from 1 mg/mL to 10 mg/mL. These proteins were chosen due to 
the fact that they have similar sizes yet differed in the amount of free thiols that might participate 
in the reaction during encapsulation. BSA is known to have a free cysteine residue that is on the 
surface of the protein, and this thiol can react with the ene groups on the HA backbone.42  On the 
other hand, while ovalbumin has 4 total cysteine residues, 2 are in a dithiol bond and the other 
two have been shown to be buried in the hydrophobic regions of the deeply folded protein, and 
only accessible after denaturation.43 These buried free thiols are not expected to react with the 
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ene groups on the HA backbone, which should lead to much higher recoveries when compared to 
BSA.  
To test this hypothesis, ovalbumin and BSA were encapsulated under identical conditions.  
The weight percent of the PHA hydrogels was increased to 13% and XDTT was set equal to 1.0 in 
order to lower the swelling degree and the diffusion coefficient in an effort to extend the release. 
The release of ovalbumin from 13% PHA hydrogels can be seen in Figure 7.13. After 700 
minutes, 90% of the ovalbumin had diffused of the gel.  The release profile follows Fickian 
diffusion, as seen by the dashed line that represents the analytical solution described in Equation 
7.1. The discs released 71.5 ± 10.9% of the total protein that was loaded.  Using the dimensions 
of the discs and Equation 7.1, a diffusion coefficient was fit to each curve (n=3) by minimizing 
the sum of squared residuals. The three values were then averaged together to give a final 
diffusion coefficient of 8.70 ± 1.1 x 10-8 cm2/s.  Unfortunately, the high swelling degrees (q=10.5) 
of these PHA hydrogels makes it difficult to compare diffusion coefficients with the HA-DVS 
hydrogels (q<6) studied in Chapter 5.  However, using the projections based on the free volume 
theory presented in Figure 5.3 for BSA, a HA hydrogel with a swelling degree of 10.5 is 
predicted to have a diffusion coefficient of 8.30 x 10-8 cm2/s.  This is noteworthy because the 
similarity in the predicted and measured diffusion coefficients signifies that, despite some 
evidence of a more uniform network structure in PHA hydrogels found in the previous section, 
there is no dramatic change in the diffusion coefficient.  However, it may be that the swelling 
degree is too high to notice any impacts the network structure might have on the diffusion 
coefficient due to the hypothesized screening effect, and any possible deviations from the 
predictions may only occur at lower swelling degrees or with larger solutes.  
 
	   240 
 
Figure 7.13. The release of ovalbumin from 13% PHA hydrogels exhibits Fickian release.  Dashed line 
represents a D = 8.70 ± 1.1 x 10-8 cm2/s.  Gels were loaded with 10 mg/mL ovalbumin and released 71.5 ± 
10.9% of the total protein loaded. All hydrogels had a DS=55% and were irradiated at 312 nm (I = 3 




One unexpected observation of the encapsulation study was that the addition of 10 
mg/mL BSA caused the solution to gel before being irradiated with UV light.  This prevented 
them from being formed into discs, making it difficult to accurately measure the release.  The 
early gelation also resulted in an increase in swelling degree when compared with the PHA 
hydrogels encapsulated with 10 mg/mL ovalbumin.  To further investigate the effects of protein 
concentration on the swelling, equilibrium experiments were performed.   
For these equilibrium experiments, the release of protein from PHA discs was only 
measured after 24, 48, and 72 hours to confirm complete release. The swelling degrees and the 
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amount of protein recovered after release are presented in Table 7.4.  Hydrogels synthesized 
without encapsulated proteins had an equilibrium swelling degree of 10.50 ± 0.03. When 
proteins were encapsulated during hydrogel formation at concentrations below 5 mg/mL the 
swelling degree remained unchanged and stayed at 10.5 for all of the formulations, evidence that 
protein is not interfering is not altering the network structure of the PHA hydrogels 
 
Table 7.4. Swelling degree and protein recovery from 13% PHA hydrogels. The swelling degree of the 
PHA hydrogels remains unchanged for all formulations except 10mg/mL BSA.  Ovalbumin has a higher % 
recovery when compared to BSA. All hydrogels had a DS = 55% and were irradiated at 312 nm (I = 3 
mW/cm2). Mean value ± standard deviation, n ≥ 3. (n=2 for 10mg/ml BSA hydrogels) *Data taken from 




However, when the concentration of protein was increased to 10 mg/mL, the protein 
began to have an effect on the thiol-ene reaction. Hydrogels containing both BSA and ovalbumin 
were synthesized at 10 mg/mL concentrations and began to gel in minutes, even before being 
placed into molds and exposed to UV light. The solution containing 10 mg/mL ovalbumin 












No Protein 0 10.50 ± 0.03 0 -
1 10.49 ± 0.16 0.031 29.9 ± 3.7%
5 10.58 ± 0.14 0.157 49.7 ± 1.3%
10 13.24 ± 0.44 0.314 66.8 ± 4.0%
Ovalbumin 5 10.58 ± 0.31 0.157 77.8 ± 1.6%
10* 10.56 ± 0.82 0.314 71.5 ± 10.9%
BSA
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7.4.  This contradicts the results seen in the previous release studies (shown in Figure 7.13) in 
which 10 mg/mL ovalbumin was successfully encapsulated and released from PHA hydrogels 
and had no effect on the swelling degree. The solution containing 10 mg/mL BSA only partially 
gelled, and the remaining solution was able to be placed into molds and irradiated. The swelling 
degree of these hydrogels encapsulated with 10 mg/mL BSA increased to 13.24 ± 0.44.  
The reason these solutions gelled before being exposed to UV light is unknown.  Perhaps 
an impurity in the lyophilized protein introduced a free radical into the solution that started the 
reaction at high concentrations. Another possibility is that the protein itself is absorbing light and 
causes the thiol-ene reaction to start.  Tryptophan, tyrosine, and phenylalanine are known to 
absorb light in the near UV range, which could lead to an excitation followed by a relaxation that 
could produce a radical species44. It has already been mentioned earlier that in the thiol-ene 
reaction a single radical species can cause hundreds and even thousands of reaction events to 
occur due to the regeneration of the thiyl radical. The fact that these gels partially formed before 
being exposed to UV light could explain the increase in swelling degree.  Another theory for the 
change in swelling degree is that the high concentration of proteins in the solution affects the 
thiol-ene reaction.  If BSA prevents DTT from reacting with PHA or if BSA reacts itself with the 
PHA it would reduce the amount of effective crosslinks and increase the swelling degree. 
 Table 7.4 also displays the percentage of protein released from PHA hydrogels.  When 1 
mg/mL of BSA is encapsulated, 30% of the protein is recovered.  When the concentration of 
BSA is increased to 5 mg/mL, 50% of the protein is recovered. While there are a number of 
possible explanations for this, the most likely is that a finite amount of BSA, which is known to 
have a free cysteine residue, has reacted with ene groups on the HA backbone and are covalently 
attached to the network.  One piece of evidence that supports this theory is the fact that almost 80% 
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of the ovalbumin, whose free cysteines are buried in the folded protein, is recovered from PHA 
hydrogels. More experiments are needed to fully understand how the proteins are being affected 
by the thiol-ene reactions and to investigate the effects that encapsulated proteins have on the 
swelling degree and initiation kinetics of PHA hydrogels. This is especially important for drug 
delivery applications where expensive drugs such as antibodies need to be delivered and a high 
recovery is necessary in order to reduce costs.  More importantly, many antibodies rely on  
internal disulfide bridges to maintain their structure and any reactions that alter or affect this 
structure may reduce the binding capability and effectiveness of the antibody.  
  
7.5 CONCLUSIONS 
 Overall, the results in this chapter illustrate a simple yet versatile way to synthesize HA 
hydrogels and take advantage of the benefits offered by the thiol-ene reaction.  Using this 
reaction, PHA gels are able to form complete gels in less than 120 seconds, among the fastest 
that have been seen for a thiol-ene hydrogel in literature at very low initiator concentrations (0.1 
mM - I2959) and light intensities (3 mW/cm2).  Not only does the speed of this reaction compare 
favorably with reactions seen in literature that use norbornene, the results also confirmed that 
there is little to no homopolymerization that occured during the synthesis of PHA hydrogels, 
evidence of the high selectivity of the reaction. The results also expand the literature knowledge 
of the effects of XDTT on the swelling and mechanical properties of HA hydrogels. The results 
indicate that the highest crosslinking density occurs at values XDTT between 0.6 and 1.0, while 
also showing for the first time that a low degree of substitution increases the sensitivity of this 
effect.  The results also provided evidence of a more uniform network structure when compared 
to similar MHA hydrogels crosslinked via radical chain polymerization, as evidenced by an 
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increase in fracture strain of 85%.  Lastly, it was shown that proteins could be encapsulated into 
PHA gels and released.  The amount of protein released was revealed to be influenced by the 
amount and location of free cysteine residues on the protein, and recovery of up to 78% was seen 
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CHAPTER 8: CONCLUDING REMARKS AND FUTURE WORK 
	  
 
In the last decade the use of antibodies to treat cancer, autoimmune diseases, viral 
infections, and even asthma has increased, causing an increase in the study of ways to extend the 
release of therapeutic proteins. Parenteral delivery routes often lead to an increase in systemic 
exposure while requiring frequent injections, and in many cases, long term, local delivery 
systems are preferred. In ocular drug delivery this is particularly true, due to retinal diseases such 
as age related macular degeneration and diabetic macular edema that require frequent injections 
into the vitreous in order to deliver drugs to the retina and prevent major vision loss.   While 
there are a number of drug delivery methods and materials that are being developed in an effort 
to provide long-term, sustained release to the retina, for this application hydrogels have received 
very little attention. Hydrogels can exhibit a wide range of permeabilities while also having the 
ability to be synthesized using a variety of biocompatible materials, making them a favorable 
option for ocular delivery vehicles. The difficulty in developing an effective ocular delivery 
device is in controlling the diffusion of proteins within a hydrogel in order to provide the correct 
release rate and profile.  The objective of this dissertation, therefore, was to investigate the 
permeability of therapeutic proteins in hydrogels to aid the development of long-term drug 
delivery vehicles.  
While one of the aims addressed in this dissertation was the development of a hydrogel 
implant that can be used specifically for treating ocular delivery, the major aim was to develop a 
better understanding of how solutes diffuse through hydrogels when the diffusion coefficient is 
very small.   The review in Chapter 3 highlighted the need for this, and showed that even though 
there is a large amount of work in literature that has advanced the understanding of the important 
variables that govern diffusion in hydrogels, very little has been done at diffusion coefficients 
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below 10-10 cm2/s. These low values are achieved as the polymer volume fraction of the gel 
increases or as the size of the solute increases, and under these conditions it has been 
hypothesized in literature that a dramatic reduction in the diffusion coefficient will be seen, 
which is referred to as the screening effect.  However, there is very little evidence in literature 
that supports the hypothesis that such a phenomenon exists due to the difficulty in measuring 
diffusion coefficients at such low values in hydrogels. The majority of the work in the chapter 
was concentrated on a number of the established theories that describe the diffusion of solutes 
within hydrogels, specifically focusing on how models based on these theories predict the 
diffusion of large solutes in hydrogels with low swelling degrees where the screening effect is 
hypothesized to occur.  Of these models, those based on the free volume theory are the only ones 
that contain a specific parameter (the sieving factor) that can cause a dramatic drop in the 
predicted diffusion coefficient.  However, these models rely heavily on the accuracy of measured 
gel parameters such as the molecular weight between crosslinks (Mc), the network mesh size (ξ), 
and on undefined fitting parameters. The other models based on the obstruction theory and the 
hydrodynamic theory do not predict a dramatic reduction in the diffusion coefficient at low 
swelling degrees.  Overall this analysis showed the need for additional research and data in order 
to rigorously test the models and see how they perform under a wide range of hydrogels and 
solutes. 
The permeability of solutes within hydrogels was a central theme throughout this 
dissertation, and played a large role in Chapter 4, where a method for loading therapeutic 
proteins into hydrogels using the thermodynamic principles of aqueous two-phase extraction was 
developed.  While the loading method was first developed by Gehrke et al.1 with proteins on the 
order of 50 kDa in dextran hydrogels, it was hypothesized that the thermodynamic principles of 
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this method could be generalized to any type of hydrogel and that it could work even for proteins 
as large as monoclonal antibodies. The results in Chapter 4 supported this hypothesis.  The 
model protein ovalbumin was shown to diffuse into both PEG and dextran hydrogels, and the 
partition coefficients were manipulated by using salts in a manner that was predicted by 
heuristics both above and below the isoelectric point.  The partition coefficient of ovalbumin was 
even shown to increase with PEG hydrogels by using a polymer-salt loading system, something 
that has never been shown in literature before and further demonstrated the generality of the 
concept.  The results expand the options for hydrogel drug delivery and allow for systems that 
can be chosen that maximize both the partition coefficient and the swelling degree and have a 
polymer that is best suited for a given application. The second hypothesis was also confirmed, as 
the antibody IgG was successfully loaded into both PEG and dextran hydrogels. Partition 
coefficients of up to 18 were reached for IgG in dextran hydrogels with the addition of only 6% 
PEG after being almost completely excluded when loaded in buffer alone.  The results showed 
promise as a drug loading method, but also brought the importance of the diffusion of solutes 
within hydrogels to light.  The diffusion of IgG was significantly slower than ovalbumin and 
required extended loading times, which limits the practical ability of the method to load 
monoclonal antibodies into hydrogels with dimensions other than microgels. 
The diffusion time was also a consideration in developing a prototype ocular implant using 
a hydrogel that could provide 3-6 months release of anti-vascular endothelial growth factors to 
the retina, the main objective in Chapter 5.  Postloading a monolithic implant using diffusion 
(similar to the loading method used in Chapter 4) would not only take 3-6 months, it would also 
require either very large partition coefficients or a very high loading concentration (most likely 
above the solubility limit) in order to provide the dosage required in a device small enough to be 
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implanted in the vitreous.  Since this was not feasible, the focus on the chapter was in developing 
a hollow cylinder made from a hyaluronic acid (HA) hydrogel that could be filled with a 
concentrated drug solution and then capped.  The main challenge was in producing a HA 
hydrogel that had a diffusion coefficient low enough to achieve extend release. Using the 
cylinder dimensions and Fick’s law, a target diffusion coefficient was calculated.  Using the 
models in Chapter 3, the swelling degree needed to achieve this target diffusion coefficient was 
predicted to be between 3.5 and 5.8. In order to achieve such low swelling degrees, the cylinders 
were made from (HA) hydrogels that were highly crosslinked using the difunctional crosslinker 
divinyl sulfone (DVS).  The resulting hydrogels had swelling degrees as low as 2.7 using HA 
concentrations that ranged from 15-30% (w/w) and HA:DVS ratios that ranged from 3:1–1:1.  
Using a custom machined mold, a prototype hollow cylinder was successfully fabricated, loaded 
with drug, and capped. The model protein bovine serum albumin (BSA) exhibited steady release 
from the hollow cylinders for over 140 days.  While the release slowed over time, the release rate 
stayed at or above 2.5 micrograms per day for over 50 days when loaded with a 250 mg/mL 
solution.  Additionally, the cylinders exhibited a much lower diffusion coefficient than predicted 
(3 x 10-11 vs. 9 x 10-9 cm2/s) for a hydrogel with a swelling degree of 6.5, which suggests the 
possibility of screening effects playing a role in the diffusion. The release of an antigen-binding 
fragment (Fab) was also examined and the results demonstrated that these cylinders are capable 
of delivering Fabs for 3 months.  The release was slightly faster when compared to that of BSA, 
which is to be expected given the smaller size of the Fab and was reflected in the measured 
diffusion coefficient of 5.5 ± 1.5 x 10-11 cm2/s, about twice as large as the diffusion coefficient of 
BSA in the same cylinders. The results demonstrated that these HA-DVS hollow cylinders are 
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suitable implants that can provide extended release and could be further investigated for the 
treatment of retinal diseases.  
However, the results also revealed some of the difficulties in developing injectable hollow 
cylinders from an HA-DVS hydrogel. The small size of the cylinders and the crude capping 
method led to a few punctures, cracks, and leaks after repeated handling during measurements 
and led to a smaller number of cylinders being tested.  This contributed to the high variability 
that was seen in the data.  Furthermore, due to poor crosslinking efficiency, the hydrogel 
required a high concentration of DVS in order to get the low swelling degrees that were required 
for extended release.  This led to an excess amount of vinyl sulfone groups that were attached to 
the HA backbone which required ethylene glycol capping to eliminate unwanted side reactions 
with the solutes.  This, along with the high functionalization required to reduce the swelling 
degree, may lead to a decrease in biocompatibility. 
One of the advantages of a hydrogel implant is that it can be molded and shaped into any 
size and therefore, for any given application, the release profile and rate can be controlled by 
tuning the wall thickness, hydrogel formulation, and concentration of protein within the hollow 
cylinder. In Chapter 6, the diffusion of drugs through intravitreal hollow cylinder hydrogel 
implants were modeled using COMSOL Multiphysics© software in order to determine the range 
of diffusion coefficients and cylinder dimensions that would produce a therapeutically effective 
ocular delivery device. Once this range in diffusion coefficients was determined, a corresponding 
gel formulation could be developed. Hydrogel implants with three different outer diameters were 
modeled in order to compare devices that would need to be implanted, inserted using a 
microinjector, or injected using a 27-gauge needle.  Implantable cylinders with 1mm outer 
diameters were shown to be capable of delivering over 1 mg of drug and achieving a release of 
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2.5 micrograms per day for 4.5 months. While these larger cylinders are able to provide the 
longest duration of action, their size requires them to be surgically implanted in a procedure that 
is time consuming, costly, and can lead to complications.  While a smaller cylinder makes the 
insertion process safer, less painful, and faster, the results showed that these smaller cylinders are 
limited in their ability to deliver high loads and achieve extended release.  Cylinders with outer 
diameters of 0.45 mm were found to be capable of delivering only 208 micrograms of drug and 
could achieve a release of 2.5 micrograms a day for only 28 days, roughly five times shorter than 
the larger cylinders. The cylinders with an outer diameter of 0.21 mm, while able to be injected 
directly using a 27-gauge needle, was severely limited in the amount of drug that could be loaded 
and released.  The cylinders achieved a release of 2.5 micrograms a day for only one week. 
The results showed just how challenging it can be to develop an effective intravitreal 
implant. The size dimensions that are required for ocular delivery leads to a narrow range of 
diffusion coefficients that are capable of producing an effective delivery device.  The hollow 
cylinders were most effective at diffusion coefficients between 1.0 x 10-11 and 3.0x 10-11 cm2/s, a 
very narrow range that highlights the importance of being able to tune the diffusion coefficient of 
hydrogels.  The results also show that hollow cylinders are a viable option for ocular drug 
delivery.  While the dimensions for an intravitreal implant will always be limited to the sizes in 
Chapter 6, the target release rate and initial concentration within the cylinder may vary 
depending on the desired application.  This could result in cylinders that are capable of longer 
release times, and might shift the range of diffusion coefficients that is most effective in 
achieving both the release rate and duration.  Regardless, given the size requirements for ocular 
delivery, any application will require tight control of the diffusion coefficient in order to be 
therapeutically effective. 
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Creating a hydrogel that can be finely tuned to provide a narrow range of diffusion 
coefficients was one of the main focuses of Chapter 7. In this chapter, HA was modified with 
pentenoic anhydride and crosslinked into hydrogels via the thiol-ene reaction.  The thiol-ene 
reaction was hypothesized to produce hydrogels that not only consisted of a more homogeneous 
network structure, but could also be easily tuned by controlling the ratio of thiols to enes.  The 
thiol-ene reaction was also investigated due to its many advantages, which include fast reaction 
times, high efficiency, insensitivity to oxygen, and a wide range of possible crosslinkers. Using 
this reaction, PHA gels were able to form fully crosslinked gels in less than 120 seconds while 
using very low initiator concentrations (0.1 mM - I2959) and light intensities (3 mW/cm2).  This 
was among the fastest that have been seen for a thiol-ene hydrogel in literature. The results also 
confirmed that there is little to no unwanted side reactions that occur between the ene groups 
during the synthesis of PHA hydrogels, evidence of the high selectivity of the reaction.  The 
results also expand the literature knowledge of the effects of XDTT on the swelling and 
mechanical properties of HA hydrogels. The results indicate that the highest crosslinking density 
occurs at values XDTT between 0.6 and 1.0, while also showing for the first time that a low 
degree of substitution increases the sensitivity of this effect.   Evidence of a more uniform 
network structure was also observed when compared to similar MHA hydrogels crosslinked via 
radical chain polymerization, as the fracture strain of PHA hydrogels were approximately double 
that of MHA.   
The results also showed that proteins could be encapsulated into PHA gels and released. 
Studies comparing the release of BSA and ovalbumin revealed that the percent recovery of 
encapsulated proteins was affected by the amount and location of free cysteine residues on the 
protein.  Recovery of up to 78% was seen with ovalbumin, while the recovery of BSA ranged 
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from 30-50%, providing evidence of a possible reaction between the PHA and free thiols on 
BSA. One of the benefits of being able to encapsulate proteins is the ability to measure the 
release from PHA hydrogels. The release of ovalbumin from PHA hydrogels (q=10.5) exhibited 
Fickian release with a calculated diffusion coefficient of 8.7 x 10-8 cm2/s. Based on the free 
volume theory presented in Figure 5.3 for BSA, a HA hydrogel with a swelling degree of 10.5 is 
predicted to have a diffusion coefficient of 8.30 x 10-8 cm2/s.  This is significant because it 
signifies that, despite some evidence of a more uniform network structure in PHA hydrogels, 
there was no dramatic change in the diffusion coefficient when compared with predictions. 
Possible deviations from the predictions may only occur at lower swelling degrees or with larger 
solutes.  More work is required in order to determine if the network structure of PHA hydrogels 
can actually lead to differences in the diffusion coefficients when compared to gels with similar 
swelling degrees crosslinked via other reactions. This is discussed in the future work section later 
in this chapter. 
As a whole, this dissertation advances the current knowledge on the permeability of 
proteins in hydrogels for drug delivery applications.  The work presented demonstrates that 
hydrogel delivery vehicles are capable of achieving extended release of therapeutic proteins. The 
work also highlights the need in literature for more data at very low diffusion coefficients where 
the diffusion models were demonstrated not to work.  The dissertation also introduced the 
development of a hydrogel system that may not only be suitable for practical applications such as 









RECOMMENDATIONS FOR FUTURE WORK 
	  
	  
1. Further investigation of the screening effect in hydrogels 
 One of the main goals of this dissertation was to investigate the diffusion of solutes in 
hydrogels where the diffusion coefficient is very small, with values below 10-10 cm2/s.  It was 
hypothesized that as the size of the solute approaches the average mesh size of the hydrogel, a 
dramatic reduction in the diffusion coefficient would occur due to a screening effect, and that 
these low values can be achieved achieved as the polymer volume fraction of the gel increases or 
as the size of the solute increases. While the diffusion of BSA in HA-DVS hydrogels provided 
some evidence of this screening effect in Chapter 5, more work is needed to confirm that the 
experimental diffusion coefficients strayed significantly from the values predicted by a number 
of the diffusion models because of this screening effect and not due to errors in the models’ 
prediction due to extrapolation. 
The work in Chapter 7 set the foundation for answering this question by developing a 
hydrogel that has a more uniform network.  It is hypothesized that a more uniform network will 
produce a screening effect and lead to a reduction in the diffusion coefficient at lower polymer 
volume fractions when compared to hydrogels with more heterogeneous networks. For example, 
a 10% PHA hydrogel would be expected to have more of a screening effect when compared with 
a 10% methacrylated HA hydrogel or a 10% hydrogel synthesized using the crosslinker DVS. 
Despite evidence of a more uniform network structure, the results in Chapter 7 revealed that 
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diffusion of BSA in PHA hydrogels with a swelling degree of 10.6 were not significantly 
different than the predictions based on the free volume theory presented in Chapter 5. However, 
it may be that the swelling degree was too high to notice any impacts the network structure might 
have had on the diffusion coefficient, and any possible deviations from the predictions may only 
occur at lower swelling degrees or with larger solutes. 
 Future work that focused on the diffusion of large solutes such as IgG or BSA in PHA, 
MHA, and HA-DVS hydrogels of similar swelling degree would provide greater insight into the 
role that the network structure plays on the diffusion coefficient and would be helpful in 
determining whether or not the screening effect is real. If it can be shown that the diffusion in 
PHA hydrogels is significantly slower than that of MHA and HA-DVS hydrogels it would 
impact the way we think about diffusion.  Most of the diffusion models focus mainly on the 
swelling degree and solute size to predict the diffusion coefficient.  While many of the models 
include parameters that try to take into account differences in network structure, they all vary in 
how the diffusion is predicted at very low diffusion coefficient values. The results would provide 
actual evidence that the crosslinking method and network structure need to be considered when 
determining the diffusion of a solute within a gel and would also provide the much needed data 
needed to evaluate the accuracy of the models. If the results showed significantly different 
diffusion coefficients at similar swelling degrees, it would also have an immediate impact on 
drug delivery applications.  A specific example is the need for extended release from an ocular 
delivery system that has been the focus of chapters 5 and 6 in this dissertation.  The screening 
effect and dramatic decrease in the diffusion coefficient can be used as an advantage, giving the 
desired release rate and profile at higher swelling degrees. This would require less polymer 
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modification and could lead to increased biocompatibility and a reduction in interactions 
between the crosslinker and the diffusing solute. 
While the results would have a significant impact, the research in this dissertation 
highlights some of the reasons why there are very few studies with hydrogels that display these 
screening effects: the experiments are very long and present many challenges. These challenges 
include the inability to produce hydrogels with a polymer volume fraction that is high enough to 
observe the screening effect, and the difficulty in actually measuring the diffusion coefficients at 
such low values in hydrogels due to concentrations that are often below the detection limit2 or 
take too long to build up to the detection limit within the time period studied.  A successful 
experiment would have to overcome both of these challenges. A PHA hydrogel would have to be 
made with a low enough swelling degree (which correlates with a smaller average mesh size) in 
order to observe any hypothesized screening effect.  If that can be achieved and MHA and HA-
DVS hydrogels can be made with similar swelling degrees, the diffusion coefficient also has to 
be accurately measured.  While there are some issues that would need to be resolved, an 
experiment using fluorescently labeled proteins measured with confocal microscopy is still a 
promising option.  Despite the limited amount of results presented in Chapter 5, a large amount 
of work and effort went in to developing the confocal microscopy methods needed to measure 
diffusion coefficients. The time and energy spent establishing the procedures and protocols will 
help speed up future progress and will help provide more immediate returns. 
While the results of this study rely heavily on the assumption that the PHA hydrogels do 
in fact have a highly uniform network structure, there are alternative hydrogels that could be 
used to test the overall theory.  While the synthesis method is different (polymerization of 
monomers vs. crosslinking of polymers) there are a number of PEG based hydrogels that have 
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been synthesized using thiol-ene chemistry which have been shown to have very well defined 
network structures and would be an excellent substitute to PHA3-6. Additionally, PEG hydrogels 
are cheap, readily available, and easy to work with and would provide an alternative to the costly 
HA.  
 
2. Synthesizing HA hydrogels via the thiol-yne reaction 
Chapter 7 showed the many advantages the thiol-ene reaction offers when used to make HA 
hydrogels. If there is one downside to radical initiated thiol-ene reactions it is that the gels are 
more limited in terms of crosslink density when compared to some of the more common HA 
polymerization methods, especially the crosslinking of unmodified HA directly using bifunctional 
crosslinkers such as divinyl sulfone or bisepoxides. The difficulty is that the crosslink densities of 
a thiol-ene gel are ultimately determined by the degree of substitution.  In Chapter 7, the degree of 
substitution of HA with ene groups plateaued at around 60%, and further attempts to add more 
functional groups were unsuccessful due to the inaccessibility of the remaining hydroxyl groups. 
One possible way around this is to replace the “ene” groups with “yne” groups, changing the 
reaction to a thiol-yne reaction.7,8 
Thiol-yne reactions have been around since the middle of the 1900’s, 9-11 yet it wasn’t until 
the last couple of years that researchers have started to use the reaction to create and modify 
polymer networks 7,12,13.  The reaction is shown in Figure 8.1 and proceeds similarly to a thiol-ene 
reaction.  First a thiyl radical reacts with the alkyne to produce a carbon-centered radical.  This 
carbon-centered radical then abstracts a hydrogen from a nearby thiol, forming a vinyl sulfide and 
generating another thiyl radical.  This vinyl sulfide is then capable of reacting with another thiyl 
radical, eventually forming a dithioether.  The benefit of this reaction is that each yne moiety can 
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Figure 8.1	  The mechanism of the thiol-yne reaction. Reproduced from Fairbanks et al.7 
 
 
To the best of our knowledge, the use of the thiol-yne reaction to crosslink HA would 
demonstrate for the first time the use of radical thiol-yne chemistry to form hydrogels from 
disaccharides.  In fact, the only other instance in literature on hydrogels and thiol-yne chemistry 
is when poly-(diethylacrylamide) was modified with alkynes and reacted with a multithiol to 
form thermoresponsive hydrogels8. The alkyne group can be attached to HA using the same 
esterification chemistry described in Chapter 7 except propiolic anhydride is used instead of 
pentenoic anhydride, virtually the same molecule except instead of an alkene group it contains an 
alkyne group.  If for some reason the esterification reaction does not work, an alternative method 
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developed by Crescenzi et al. can be used in which an amine group is reacted with the carboxyl 
group.14  
When added to the HA backbone, the additional functionality of the alkyne will provide a 
number of advantages not only in increasing the crosslink density, but also for postmodification. 
Since two thiols are able to react with each yne group, it is possible to form an HA hydrogel with 
double the amount of crosslinks when compared to an HA gel that has been functionalized with 
the same amount of ene groups.  However, this does assume that the addition of a second thiol 
group would produce an effective crosslink.  As Figure 8.2 shows, it is very possible that the 
second thiol would react with the same yne group that the first thiol group did, forming 
essentially one large crosslink that would not significantly affect the mechanical properties or the 
diffusion of solutes within the hydrogel.   
 
Figure 8.1	  The addition of two dithiol groups to the same yne groups would not significantly affect the 
mechanical properties or the diffusion of solutes within the hydrogel when compared to the thiol-ene gels 
produced in Chapter 7. 
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This would have to be tested, and could be further influenced by the molecular weight of 
the dithiol crosslinker.  For example, a larger dithiol such as a PEG-dithiol could be used initially 
to form the hydrogel using a 1:1 thiol:yne ratio, which would form a hydrogel while at the same 
time leaving ene groups on the backbone.  Then, the hydrogel could be soaked in a solution 
containing a smaller dithiol, such as DTT and reacted again.  This would reduce the probability 
of two dithiols reacting with the same yne groups.  
The other added benefit is that unreacted ene groups can undergo secondary 
modifications, which can be used to introduce chemical groups other than crosslinkers. These 
modifications can be performed with any chemical that has a terminal thiol, making it useful for 
a wide variety of applications from tissue engineering to drug delivery. Burdick and his group 
have demonstrated this use of secondary modification and photopatterning using the norbornene 
modified HA described earlier.15 However, they use a thiol-ene gel, and in order to perform 
secondary reactions they had to leave unreacted vinyl groups attached to HA which reduced the 
compressive modulus of the gel relative to a fully crosslinked hydrogel. By using thol-yne 
chemistry, highly crosslinked gels can be obtained while still leaving functional groups available 
to perform secondary reactions. 
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APPENDIX FOR CHAPTER 5 




The inner diameter can be varied to control the inner volume as well as the wall thickness 
 
We currently have molds with an inner diameter of : 
0.460 mm   =  Wall thickness of  0.27 mm  
0.635 mm   =  Wall thickness of  0.183 mm 
 
Inner Diameter of .460 mm = .00150 mL  volume 
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A5.2 HA-DVS Hollow Cylinder Pictures 
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#	  of	  DVS	  on	  HA
Repeating	  Unit
Carbon Hydrogen Oxygen Nitrogen Sulfur Total	  Weight
0 14 21 11 1 0 379.318
1 18 27 13 1 1 497.473
2 22 33 15 1 2 615.628
3 26 39 17 1 3 733.783
4 30 45 19 1 4 851.938
5 34 51 21 1 5 970.093
1.5 20 36 14 1 1.5 562.5985
#	  of	  DVS	  on	  HA
Repeating	  Unit
Carbon Hydrogen Oxygen Nitrogen Sulfur Ratio	  S/N
0 44.3% 5.6% 46.4% 3.69% 0.00% 0.00
1 43.5% 5.5% 41.8% 2.82% 6.45% 2.29
2 42.9% 5.4% 39.0% 2.28% 10.42% 4.58
3 42.6% 5.4% 37.1% 1.91% 13.11% 6.87
4 42.3% 5.3% 35.7% 1.64% 15.06% 9.16
5 42.1% 5.3% 34.6% 1.44% 16.53% 11.45
1.5 42.7% 6.5% 39.8% 2.49% 8.55% 3.43






Hyaluronic Acid (MW = 379.32) :     Divinyl Sulfone (MW = 118.15) 
C14H20O11N1        C4H6O2S1   
Carbon = 44.3%        Carbon = 40.7% 
Hydrogen = 5.6%        Hydrogen = 5.1% 
Oxygen = 46.4%        Oxygen = 27.1% 





































15%	  HA	  3:1 6.6 681.4 0.001852 647.9 7.36
15%	  HA	  2:1 5.86 758.7 0.001982 605.42 6.84
15%	  HA	  1:1 4.54 841.2 0.002018 594.53 6.23
30%	  HA	  3:1 3.55 2367.2 0.003296 364.03 4.49
30%	  HA	  2:1 2.73 3710.9 0.004734 253.46 3.43
30%	  HA	  1:1 2.87 3054.9 0.003963 302.8 3.81
Hydrogel Synthesis and Characterization: 
 
30% HA-DVS  1:1 Ratio = 3.2 Molecules of DVS for every repeat unit of HA 
30% HA-DVS  2:1 Ratio = 1.6 Molecules of DVS for every repeat unit of HA 





















30%$HA'DVS$1:1 38.98 5.65 45.04 2.33 8.0 3.43 1.5 47%
30%$HA'DVS$2:1 39.08 5.9 44.36 2.46 8.2 3.33 1.45 91%
30%$HA'DVS$3:1 39.1 5.98 45.87 2.49 6.56 2.63 1.15 107%
15%HA'DVS$1:1 39.73 5.16 42.78 2.29 10.04 4.38 1.91 60%
15%HA'DVS$2:1 39.21 5.79 45.17 2.49 7.34 2.95 1.29 81%
15%HA'DVS$3:1 39.29 5.59 46.77 2.78 5.57 2.00 0.87 81%
	   271 
A5.4 HA-DVS Ethylene Glycol Capping 
 
 
***Special thanks to Dr. Berkland and Jian Kian for their help in producing these figures*** 
 
Protein diffusing through the hydrogel network would be able to react with any DVS groups that 
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SDS-PAGE indicates no protein aggregation in cylinders up to 64 days; Fab missing after 32 days: 
BSA Controls = Fresh 0.5 mg/ml solution + 0.5 mg/ml solution that has been stored in fridge for 64 days 
 
Cylinder D = BSA from 30% HA 3:1 (64 days in cylinder) 
Cylinder G = BSA from 15% HA 1:1 (46 days in cylinder) 
mAb controls = Fresh 0.5 mg/ml solution + 0.5 mg/mL solution that was stored in fridge for 32 days 
Cylinder mC =  mAb from 15% HA 1:1 (32 days in cylinder) 
Cylinder  
Fab loaded into 15% HA 1:1 Cylinder 
(32 Days) 
15% HA 1:1 Cylinder 
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In order to eliminate any unwanted side reactions that might occur between the DVS and the 
proteins diffusion through the hydrogel network, the cylinders were treated with ethylene glycol to 
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APPENDIX FOR CHAPTER 7 
 
 
A7.1 Pentenoate Modified Hyaluronic Acid (PHA) Synthesis 
 
 
Purpose:  To make a pentenoate modified HA that can be used to make gels via thiol-ene click 
chemistry. The synthesis is relatively simple, and the most difficult part is the 
precipitation/purification step.  Each batch takes about 2-3 days to make, however the total work 
time required is about 4-6 hours.  The batch size has been successfully increased from 0.3 g to 
0.5 g to 1.0 g.  The degree of substitution (DOS) of PHA can range from about 6% to 60% 
depending on the ratio of pentenoic anhydride to HA during synthesis. The DOS is calculated by 
spectral integration of the 1H NMR (accuracy ~10%) and is defined as the amount of ene groups 




-­‐ Hyaluronic Acid (51 kDa) 
-­‐ DIUF Water 
-­‐ Pentenoic Anhydride 
-­‐ 0.5M or 1.0M NaOH 
-­‐ DMF 
-­‐ NaCl 




1.) HA (0.50 g, 0.75 mmol) is dissolved in ultrapure water (25 mL) at 4C, and the resulting 
mixture is kept at 4C under continuous stirring overnight for complete dissolution.   Can be 
scaled up.  Ratio = 5 mL of water for every 0.1 g of HA. 
 
2.) DMF (16.66 mL) is then added dropwise in order to have a water/DMF ratio of 3/2 (v/v). 
 
3.) Pentenoic anhydride (1.2g) is added (= 5 molar equivalents with respect to the repeating unit 
of HA) while maintaining the pH between 8 and 9 (by adding 0.5M or 1.0 M NaOH) for 3-6 
h.  Reaction is carried out in the fume hood and hooked up to a pH meter to read continuously 
at room temperature.  At first, NaOH is added about every 5 minutes, but by the end of the 
reaction it slows down to every 20-30 minutes.  The pentenoic anhydride will look like small 
brown immiscible droplets, and they should slowly disappear as the reaction proceeds. 
 
4.) When the pH stabilizes, the reaction is kept at 4C overnight under continuous stirring to 
ensure complete reaction. 
 
5.) After this time, NaCl isadded to the reaction mixture to have a NaCl concentration of 0.5M 
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6.) The polymer is precipitated by addition of cold ethanol (with a water/EtOH (v/v) ratio of at 
least 1/5).  
 
7.) The solution is then centrifuged and the supernatant is removed, the precipitate is redissolved 
in ultrapure water for a final purification by diafiltration with ultrapure water (10k MWCO). 
Diafiltration lasts for 48 hours, changing the water every 8-12 hours. 
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A7.2 Pentenoate Modified Hyaluronic Acid (PHA) Hydrogel Synthesis 
	  
 





-­‐ Pentenoate modified Hyaluronic Acid (PHA) 
-­‐ DIUF Water 
-­‐ Dithiothreitol (DTT) 
-­‐ Irgacure 2959 




1.) A solution of 0.1 mmol Irgacure 2959 is made. This is a very low initiator concentration, so it 
is best to make in large quantities.  Due to the sensitivity of the reaction to free radicals, a 
fresh Irgacure 2959 solution should be made with each batch of PHA gels. 
2.) In one vial, the amount of PHA needed for hydrogel synthesis is measured out.  PHA 
hydrogels have been made with the concentration of PHA ranging from 2-16%. 
3.) In another vial, the amount of crosslinker needed is measure out.  While the majority of the 
PHA hydrogels in this dissertation were crosslinked with DDT, the advantage of the thiol-ene 
chemistry is that any soluble difunctional thiol will work as a crosslinker. 
The key here is how many thiol groups are added relative to the amoung of ene groups that 
are functionalized on the HA.  Depending on the application, the ratio of thiol groups to ene 
groups (XDTT) can be varied. In most cases, the hydrogels are synthesized with a 1:1 ratio.   
4.) Then amount of Irgacure solution needed to make your gels (2% to 16% PHA) is then 
calculated.  This solution is then pipetted into the vial with the crosslinker and stirred to make 
sure it is fully dissolved.  This solution is then pipetted into the vial that contains the PHA. 
5.) The final solution is stirred thoroughly, centrifuged to remove any bubbles (40-60s), and 
pipetted into molds. 
6.) The molds are then irradiated at 312 nm.  The time required for complete hydrogel formation 
is dependent on the concentration of PHA. 
7.) After 5-10 minutes the hydrogels are removed from the molds and placed into an excess of 
D.I. water to remove any unreacted materials. 
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-­‐ The most commonly used Type 1 photoinitiator (cleavage type) 
-­‐ Among the most water soluble of the commercially available Type 1 photoinitators 
- Solubility limit in water at ambient conditions is less than 2% 
- However, even 0.5 % (w/w) solutions require substantial agitation/heating to     dissolve 
 -  The bigger drawback is the low molar extinction coefficient at 365 nm.  (4 M-1 cm-1) 





-­‐ Water solubility is much better (up to 8.5 wt%) 
-­‐ Molar extinction coefficient at 365 is substantially higher (218 M-1 cm-1) 
-­‐ Major benefit comes from the fact that when the LAP is photoinitiated and cleaved, there is a 
significant reduction in light absorption 
 
-Can play a significant role in cases where the gel is not optically thin. As initiator on the surface is 
consumed, the light is able to reach greater depths and increase the cure depths that can be achieved. 
 
 
Impact on our Thiol-Ene Research: 
 
 - If we were initiating at 365 nm it would have a huge impact, but as the graphs on the next page 





if we use I2959 vs LAP  at 312, both H,v, Na, f, ϕ and I will all be roughly the same.  The only difference 
could be ε (which we already said was high for both at 312) and the concentration.  
Also, at 312 nm we have to worry about light attenuation since both LAP and I2959 absorb a ton of light 
at 312 nm even after initiation.  
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 (a) Cleavage of I2959 and LAP into substituent radicals following photon absorption. (b) Molar 
absorptivities of the I2959 (solid line)and cleavage products (dashed line). (c) Molar absorptivities of 
LAP (solid line) and cleavage products (dashed line). 
	  
Cost to Produce LAP: 
	  
-­‐ Dimethyl	  phenylphosphonite	  	  (5g	  -­‐	  $60)	  
-­‐ 2,4,6-­‐trimethylbenzoyl	  chloride	  	  (5g	  -­‐	  $205)	  
-­‐ lithium	  bromide	  (100	  g	  -­‐	  $53)	  
-­‐ 2-­‐butanone	  	  (500	  mL	  -­‐	  $48)	  
	  
TOTAL	  =	  $366	  	  to	  produce	  roughly	  2	  x	  5g.	  	  Which	  given	  how	  little	  we	  need	  to	  use	  (0.03	  wt%	  to	  .3	  
wt%)	  would	  probably	  last	  for	  quite	  some	  time.	  
	  





	   279 
A7.4 Pentenoate Modified Hyaluronic Acid (PHA) Mechanical Testing and Mooney Rivlin 
 
 
6% PHA Hydrogels – Thiol:Ene Ratio =1.0 
Summary of 6% PHA 1.0 (last data preceding break, E, G, and E/G)
Stress(kPa) Strain(%) Strain Fcn E G E/G
280.7 41.9 2.4 349.2 121.4 2.9
296.5 41.2 2.3 399.7 135.8 2.9
229.7 41.0 2.3 292.6 107.1 2.7
Average 269.0 41.36 2.322 347.2 121.5 2.9
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~[f*]=2C1+2C2*(1/lambda)
Intercept (G) Slope C1 C2 R-Squared Best Fit Start (x-value) Best Fit End (x-value)
-100.6 133.370 -50.3 66.7 0.995 1.044 1.695
-85.3 134.668 -42.7 67.3 0.989 1.042 1.663
-129.5 144.500 -64.8 72.2 0.996 1.040 1.673
Average -105.1 137.51258 -52.57025 68.8
StDev 22.4 6.1 11.2 3.0
Summary of 6% PHA 1.0 Mooney Rivlin Data(between specified data points)
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Stress(kPa) Strain(%) Strain Fcn E G E/G
450.0 29.5 1.3 1017.2 355.1 2.9
516.4 29.6 1.3 1165.0 432.2 2.7
473.9 28.4 1.2 1033.1 384.9 2.7
653.5 32.8 1.5 1147.3 445.2 2.6
Average 523.4 30.1 1.4 1090.6 404.3 2.7
StDev 90.9 1.9 33.2 76.3 41.8 0.1











































Summary of 13% PHA In Water Mooney Rivlin Data(between specified data points)
~[f*]=2C1+2C2*(1/lambda)
Intercept (G) Slope C1 C2 R-Squared Best Fit Start (x-value)Best Fit End (x-value)
49.2 205.74 24.6 102.9 0.673 1.034 1.454
-118.3 408.15 -59.1 204.1 0.971 1.028 1.369
-137.7 376.82 -68.9 188.4 0.942 1.025 1.349
-181.7 438.28 -90.8 219.1 0.943 1.034 1.416
Average -97.12 357.25 -48.56 178.6
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0 13.9&±&0.5 1090.6&±&76.3 523.4&±&90.9 30.1&±&1.9
0.033 9.94&±&1.45 545.1&±&56.4 711.2&±&78.9 47.5&±&0.6
0.1 8.57&±&0.83 506.1&±&37.1 801.0&±&104.8 48.6&±&1.1
0.3 7.00&±&0.55 284.8&±&122.1 833.61&±&377.4 56.3&±&2.1
0.5 6.41&±&0.17 206.2&±&125.3 845.5&±&347.3 59.7&±&4.6










0 13.9&±&0.5 1090.6&±&76.3 523.4&±&90.9 30.1&±&1.9
0.1 12.08&±&1.3 627.7&±&61.5 769.4&±&187 44.5&±&3.5
0.3 9.01&±&0.6 523.5&±&135 592&±&85.7 44.9&±&1.2
1 7.41&±&0.5 316.9&±&41.7 544.8&±&90.7 49.1&±&2.6
1.5 6.17&±&0.4 467&±&50.2 1049.6&±&211.8 53.2&±&3.3
3 4.32&±&0.2 434.5&±&56.0 960.4&±&231.3 52.3&±&3.2
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A7.6 Synthesizing PHA Hydrogels using EDTT instead of DTT 
 
Hydrogels were orginally made using the crosslinker 2,2′-(Ethylenedioxy)diethanethiol (EDTT).  
This is a very cheap dithiol that is in liquid form and was used to make the Dextran gels in the Mergy/ 
Auzely Velty paper.  
 
 
Figure A7.6.1.  Structure of 2,2′-(Ethylenedioxy)diethanethiol (EDTT) 
 
Early obersvations indicated that when adding the crosslinker the solution was always cloudy.  After 
testing the solubility, it was found that EDTT was mostly immiscible in water, causing cloudiness in the 
solutions. However, we were still able to get hydrogels after irradiating for only 20 seconds (10s on both 
sides of the molds = 20 seconds total).  From this point on the crosslinker used was dithiothreitol (DTT) 
which is very soluble. The swelling degrees of the hydrogels made with the two different crosslinkers 
were very similar. 
	  
	  
 
